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‘‘In these several sessions we heard exciting new data which indicate the critical role of induced IDO activity 
in several important areas. The activation of dendritic cells (macrophages, astrocytes, etc.) results in IDO 
induction with the depletion of tryptophan levels locally or systemically. This seems to be the mechanism by 
which interferon inhibits the growth of certain bacteria, intracellular parasites, and viruses. Most exciting were 
the reports that tryptophan depletion also inhibits T lymphocyte replication which results in 
immunosuppression and tolerogenicity. This has far reaching implications in many fields of medicine, 
including fetal rejection, and organ transplant survival. However, in some cases the effects of the IDO activity 
may be the result of elevated kynurenine pathway metabolites rather than the depletion of tryptophan. For 
example, many studies have described the excitatory and toxic effects of quinolinic acid on neuronal activity. 
Furthermore, the depletion of tryptophan leads to decreased levels of serotonin which may produce a wide range 
of effects. In closing, I would like to ask us all to recognize Professor Osamu Hayaishi for his brilliant, 
pioneering work in elucidating the tryptophan metabolism, particularly for his important finding of 
indoleamine dioxygenase (IDO) and for induction by interferon-c. These findings now allow us to reinterpret 
many older empirical observations of the tryptophan metabolism in animals and man, which has now opened 
up a whole new era of better understanding the role of tryptophan in the fields of immunology, AIDS, organ 
transplant, autoimmune diseases, cancer, and mental functions. The next few years will, I am sure, see 
unbelievable advances in these areas of biology and medicine.’’ 
Prof. Raymond Brown’s closing remarks in the 10th meeting of the 
International Study Group for Tryptophan Research (ISTRY) held at Padova in Italy in 2002 





This chapter is based on the publication: 
Neuroinflammation in Alzheimer's disease and major 
depression 
Comment on Biol Psychiatry, 2010, Mar 15;67(6):550-7. 
Nikoletta Dobos1, Jakob Korf1, Paul G. M. Luiten1, Ulrich L. M. Eisel1 
1Department of Molecular Neurobiology, University of Groningen, Groningen, The Netherlands 
Biological Psychiatry. 2010 Mar 15;67(6):503-4. 
1. INDOLEAMINE 2,3-DIOXYGENASE (IDO) 
The history of indoleamine 2,3-dioxygenase (IDO), the key enzyme of the kynurenine 
pathway and tryptophan catabolism began in 1967 when Professor Hayaishi and his 
colleagues described an enzyme, which converted D-tryptophan to D-kynurenine (Higuchi 
and Hayaishi 1967; Yamamoto and Hayaishi 1967). Since then, especially in the last decade, 
extensive research focuses on the role of IDO in many approaches. 
Tryptophan is an abundant essential amino acid, a key molecule for proteins and also for the 
neurotransmitter, serotonin. Approximately 95% of the tryptophan is metabolized via the 
kynurenine pathway, only about 1% is converted into serotonin. Along the kynurenine 
pathway, several biologically active compounds are generated until it ends in complete 
oxidation of tryptophan or in the production of nicotinamide adenine dinucleotide (NAD) 
(Takikawa 2005). 
Figure 1. The kynurenine pathway. Adapted from Löb et al. 2009. (Lob, Konigsrainer et 
al. 2009) 
The first and the rate-limiting step of the kynurenine pathway is catabolized by indoleamine 
2,3-dioxygenase (IDO) or tryptophan 2,3-dioxygenase (TDO). TDO is explicitly expressed 
in the liver, whereas IDO is an ubiquitously expressed enzyme, it can be found in the lung, 
intestines, spleen, kidney, brain, and interestingly, the highest expression was measured in the 
placenta (Yamazaki, Kuroiwa et al. 1985; Takikawa 2005). 
10 
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Among others, pro-inflammatory cytokines, e.g. Tumor Necrosis Factor alpha (TNFơ), 
interferon gamma (IFNƣ), or interleukin 6 (IL-6) can induce IDO expression and/or activity 
(Leonard 2007; Dantzer, O'Connor et al. 2008). 
IDO has been described to be involved and play a crucial role in the defense mechanism 
against bacterial and viral infections. Antimicrobial, antiviral activity is explained by 
interferon gamma (IFNƣ) induced, IDO mediated tryptohan depletion in the host cells, 
which results in the inhibition of the growth of the pathogens (Pfefferkorn 1984; Shemer 
and Sarov 1985; Byrne, Lehmann et al. 1986). IDO has been implicated in 
immunsuppression as well. IDO is responsible for immunological paradoxes, like maternal 
tolerance and fetal survival, tumor growth or persistent infections, like Acquired Immune 
Deficiency Syndrome (AIDS) (Mellor, Munn et al. 2003). High placental IDO levels inhibit 
T-cell mediated immune responses, therefore fetus-rejection is prevented (Munn, Zhou et al. 
1998; Suzuki, Tone et al. 2001). It has been shown that tumor cells express IDO, which 
leads to local tryptophan depletion and subsequent T-cell inhibition and tumor persistance 
(Uyttenhove, Pilotte et al. 2003; Godin-Ethier, Hanafi et al. 2011). Human 
immunodeficiency virus (HIV) patients show increased IFNƣ and therefore increased IDO 
levels as well. Chronic induction of IDO in HIV patients results in chronic T-cell inhibition 
and probably in immunsuppression and immunodeficiency (Brown, Ozaki et al. 1991). 
In addition, IDO is also induced under several neuroinflammatory conditions, including 
Alzheimer’s disease (AD) (Guillemin, Brew et al. 2005). 
2. NEUROINFLAMMATION 
Although inflammation per se is a protective reaction of the body against intruding parasites, 
bacteria, or viruses, inflammation is also a major component of chronic degenerative 
diseases. In fact, investigating immune responses in brain diseases is a relatively young 
science, mainly because the brain was considered an “immune privileged site.” Today, we 
know that almost all components of the immune system are also present within the brain 
(Mrass and Weninger 2006). Microglia are the macrophages of the brain and comprise 10-
12% of the total cell number of the brain (Kannan, Balakrishnan et al. 2009). Within the 
brain, microglia strongly interact with astrocytes, neurons and blood vessels. After injury or 
stress, microglia get activated, their morphology is changed and they start to secrete 
proinflammatory cytokines. Proinflammatory cytokines, such as interleukin (IL-1), TNFơ 
and IFNƣ coordinate the local and systemic inflammatory response to pathogens (Banks 
2005). 
The innate immune response is paramount in maintaining tissue homeostasis. Therefore, not 
all immune responses should be considered per se as damaging. This is especially clear for 
the cytokine TNFơ and its receptors. Upon local challenges such as ischemia (in stroke) or 
amyloid precipitations (in Alzheimer’s disease), TNFơ and its receptors become strongly 
expressed. TNFơ not necessarily damages brain tissue via activating TNF Receptor 1 
(TNFR1). Stimulation of TNF Receptor 2 (TNFR2) by TNFơ antagonizes TNFR1 death 
signals by inducing a neuroprotective signaling cascade that requires the activation of protein 
kinase B/Akt and Nuclear Factor kappa B (NF-NB) (Marchetti, Klein et al. 2004). 
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3. TNFơ SIGNALING PATHWAY 
The cytokine, TNFơ was discovered about 30 years ago, as a tumor necrotizing serum 
production (Kiger, Khalil et al. 1980). Kiger et al. observed in Bacillus-Calmette-Guerin 
(BCG)-pretreated mice a delayed fibrosarcoma development without toxic side effects. Since 
then, the role of TNFơ and its receptors have an enormous scientific and clinical interest and 
TNFơ-related research has been expanded. TNFơ is a 26 kDa type II transmembrane 
protein, which is cleaved by the metalloprotease TNFơ-converting enzyme, that results in 
the 17 kDa monomer, and after trimerization it becomes active as a soluble 51 kDa protein 
(Black, Rauch et al. 1997; Naude, den Boer et al. 2011). TNFơ exerts its biological functions 
via the two TNF-receptors: TNFR1 and TNFR2. 
Under normal physiological conditions TNFR1 is ubiquitously expressed on almost every 
cell types, and gets activated rapidly, whereas TNFR2 is expressed typically at low levels in 
immune cells and its activation takes longer (Loetscher, Pan et al. 1990; Schall, Lewis et al. 
1990; Tartaglia and Goeddel 1992; Naude, den Boer et al. 2011). TNFR1 can be activated by 
both, membrane-bound and soluble TNFơ (Grell, Douni et al. 1995) and mainly involved in 
apoptosis (Eisel 2006). The TNFR1 contains a death domain, which becomes - after ligand 
binding to the receptor and dissociation of the silencer of death domains (SODD) – 
available for the adapter protein TNF receptor-associated death domain (TRADD) 
(Tartaglia, Ayres et al. 1993; Jiang, Woronicz et al. 1999; McCoy and Tansey 2008; Naude, 
den Boer et al. 2011). TRADD binding subsequently recruits other proteins that are involved 
in downstream signaling, for example, TNF receptor associated factor-2 (TRAF2) or 
receptor interacting protein (RIP) (McCoy and Tansey 2008; Naude, den Boer et al. 2011). 
Of note, RIP can be also recruited to TNFR1 independent of TRADD (Chen, Chio et al. 
2008). RIP-dependent activation of NF-NB signaling initiates then pro-survival signaling, 
cellular proliferation, or cytokine production (McCoy and Tansey 2008). This complex 
recruits the cellular inhibitor of apoptosis proteins 1 and 2 (cIAP 1,2) which leads to the 
activation of ERK, JNK, p38 MAP kinase, and ceramide/sphingomyelinase pathways 
(Winston, Lange-Carter et al. 1995; Shu, Takeuchi et al. 1996; Lee, Huang et al. 2003). The 
kinetics of the JNK activation determines the effect of TNFơ. A rapid, acute JNK activation 
is cytoprotective, whereas a sustained JNK activation results in a caspase-dependent 
apoptosis (McCoy and Tansey 2008). Furthermore, internalization of TNFR1 after activation 
results in the dissociation of the TRADD/TRAF2/RIP complex and association of Fas-
associated death domain (FADD), recruitment of pro-caspase 8. Caspase-8 is responsible for 
extrinsic as well as intrinsic apoptosis pathway (McCoy and Tansey 2008). In conclusion, 
TNFR1 mediated signaling pathway can contribute to several outcomes, e.g. proliferation, 
cell survival or apoptosis. 
Additionally, the involvement of TNFR2 makes the signaling pathway more complex. 
TNFR2 is expressed in certain types of cells, e.g. neuronal subtypes, oligodendrocytes, 
microglia and astrocytes, endothelial cells, and certain T-cell subpopulations, including 
lymphocytes (CD4+ and CD8+ T cells), cardiac myocytes, thymocytes and human 
mesenchymal stem cells (Choi, Lee et al. 2005; Faustman and Davis 2010; Naude, den Boer 
et al. 2011) and gets activated by the membrane-bound form of TNFơ (McCoy and Tansey 
2008). The restricted expression of TNFR2 is coupled with restricted biological functions. 
TNFR2 lacks the death domain, and induces long-term activation of NF-NB, resulting in 
pro-inflammatory and pro-survival signaling pathways (McCoy and Tansey 2008; Naude, den 
Boer et al. 2011). TNFR2 can also activate the phosphatidylinositol 3-kinase/protein kinase 
BȬserine-threonine kinase pathway dependent signaling to promote neuron survival 
(Marchetti, Klein et al. 2004). 
Overall, TNFR2 mediated pathways are believed to be protective, by initiating pro-
inflammatory and pro-survival signaling pathways. 
TNF signaling has been shown to play a very important role within the central nervous 
system (CNS). TNFơ is crucial for instance in microglia and astrocyte activation, in the 
regulation of the blood brain barrier permeability, in glutamatergic transmission or in 
synaptic plasticity (Selmaj, Farooq et al. 1990; Merrill 1991; Beattie, Stellwagen et al. 2002; 
Pickering, Cumiskey et al. 2005). Elevated TNFơ levels have been found in several 
neurological and psychiatric disorders, e.g. ischemia (Liu, Clark et al. 1994), traumatic brain 
injury (Goodman, Robertson et al. 1990), multiple sclerosis (Hofman, Hinton et al. 1989), 
Alzheimer's disease (Fillit, Ding et al. 1991), and Parkinson's disease (Nagatsu, Mogi et al. 
2000) or major depression (Tuglu, Kara et al. 2003) as well. Therefore, the idea of targeting 
TNFơ and its receptors to treat disorders or at least modify disease development turned on 
the spotlight. Several studies have been done to elucidate or ameliorate diseases by inhibiting 
TNFơ or selectively its receptors (Tobinick 2007; Griffin 2008; Tobinick and Gross 2008; 
Tobinick 2009; Frankola, Greig et al. 2011). Interestingly, it was recently shown, in a mouse 
model of AD that imipramine, a tricyclic antidepressant (Chavant, Deguil et al. 2010) can 
prevent cognitive decline and amyloid beta accumulation by TNFơ inhibition. Of note, 
TNFơ is a potent inducer of IDO (Dobos, de Vries et al. 2011). 
Figure 2. TNFR crosstalk. Adapted from Naude et al. 2011. (Naude, den Boer et al. 2011) 
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The involvement of TNFơ and its receptors in cognitive and physical functions during the 
aging process will be further discussed in Chapter 3. 
4. NEUROINFLAMMATION AND MAJOR DEPRESSION 
Depression, in the clinic called major depressive disorder (MD), clinical depression, unipolar 
depression, is the most common mood disorder worldwide. Lifetime prevalence of 
depression in the general population is 10-25% for women and 5-12% for men. The 
diagnosis of the disease is not easy; there are few other diseases, which might show 
completely opposite symptoms, like depression. For instance, weight loss or weight gain, 
insomnia or hypersomnia, both might represent a symptom of major depression. However, 
in general, MD can be characterized by depressed or irritable mood, lethargy, diminished 
interest or pleasure in all, psychomotor agitation or retardation, fatigue or loss of energy, 
feelings of helplessness, worthlessness or guilt, concentration problems, indecisiveness, 
recurrent thoughts of death or suicide. The diagnosis of major depression can be made, 
when five or more of these symptoms last for at least a 2-week period of time, and 
depressed mood or anhedonia is a mandatory symptom (Association 2000). 
There have been several hypotheses (the monoamine hypothesis, the glucocorticoid 
hypothesis, neuroplasticity hypothesis, cytokine hypothesis) proposed for major depression, 
however, to date, none of them can meet all criteria to explain the pathogenesis of this 
disorder. There is little doubt that MD should be defined as a multifactorial disease in which 
various mechanisms are involved, dependent on individual differences and vulnerability, and 
disease history. In this thesis, the cytokine hypothesis of depression will be the focus of 
study. 
Since 1991, when Smith proposed the macrophage theory of depression (cytokine 
hypothesis), the knowledge on the relations between inflammation and depression has 
enormously expanded (Smith 1991). The basic idea of the cytokine-immune model of 
depression came from the fact, that upon the activation of the immune system, cytokines are 
produced which alter brain function and behavior. In the last two decades, many researchers 
provided direct evidence for increased cytokine levels in major depression to confirm the 
theory (Capuron, Ravaud et al. 2001; Banks 2005; Goeb, Even et al. 2006; Su, Huang et al. 
2010). Both experimental (O'Connor, Andre et al. 2009) as well as clinical studies point to a 
role of IL-2, IFNơ, or IFNƢ in major depressive disorders (Capuron, Ravaud et al. 2001; 
Goeb, Even et al. 2006). Furthermore, meta analysis have been done and showed a positive 
correlation between elevated TNFơ, TNF-Ƣ1, IL-1, IL-6, C-reactive protein (CRP) and the 
symptoms of major depression (Howren, Lamkin et al. 2009; Dowlati, Herrmann et al. 
2010). 
Cytokine-induced inflammation might be responsible also for altered serotonin synthesis. 
Reduction of the availability of serotonin is believed to be one of the causes of major 
depression. Reduction of tryptophan levels by cytokine-upregulated IDO activity affects 
serotonin (5-HT) synthesis, which is implicated in a variety of psychiatric disorders, but also 
affects cerebral plasticity, because 5-HT can increase production of neurotrophic peptides, 
such as brain derived neurotrophic factor (BDNF). Finally, the end product of the 
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kynurenine pathway, is a neurotoxic activator of the N-methyl-D-aspartate receptor, called 
quinolinic acid (QUIN). This factor can also contribute to excitotoxic effects in 
neurodegenerative diseases. These observations suggest that the tone of cerebral 5-HT 
should be kept within a narrow range, because deranged 5-HT levels compromise various 
brain functions. There is mounting evidence that IDO is a prominent player in the relation 
between chronic inflammation and depression, as we know from the effects on IDO of 
toxins like lipopolysaccharide (LPS) or pro-inflammatory cytokines, such as TNFơ and 
IFNƣ. 
5. IMAGING NEUROINFLAMMATION 
Aging is not only a simple physical phenomenon, but also a more complex social, cultural 
and economical issue. Currently, there is no cure for neurodegenerative diseases, like 
Alzheimer’s disease. The biggest problem is with such diseases, that the diagnosis is very 
difficult. Symptoms overlapping with other diseases, one disorder is accompanied by the 
other one. Another problem is, like it has been shown in Alzheimer’s disease, that the 
pathological changes, for instance amyloid beta accumulation and neuronal loss are present 
some decades before the clinical symptoms appear (Perrin, Fagan et al. 2009). Therefore, 
extensive research has been focusing on the development of novel non-invasive techniques 
and methods to investigate pathological structures and functions within the central nervous 
system or to diagnose neurodegenerative diseases at a very early stage, preferably at the time, 
when it does not show any clinical signs yet. 
One of the solutions could be the use of neuroimaging techniques, like positron emission 
tomography (PET), magnetic resonance imaging (MRI), single-photon emission computed 
tomography (SPECT), near-infrared fluorescence imaging (NIRF), bioluminescence imaging 
(BLI) etc (Klohs and Rudin 2011). 
Positron emission tomography is an in vivo nuclear imaging technique which measures the 
distribution of radiotracers in tissue (Klohs and Rudin 2011). Radiotracers are molecules 
labeled with a radionuclide which first undergoes positron emission decay resulting in the 
emission of a positron. The next step is called annihilation, when the positron captures an 
electron. Annihilation generates a pair of ƣ photons, emitted in opposite direction by 180°. 
The scintillation detector of the PET scanner detects ƣ photons. Two- or three-dimensional 
pictures are constructed by computer analysis (Venneti, Wiley et al. 2009; Klohs and Rudin 
2011). 
One of the main characteristics of neurodegenerative diseases is neuroinflammation. As 
mentioned before, during neuroinflammation, microglia, the most important immune cells 
of the brain get activated. Activation of microglia manifests in morphological changes as well 
as production of cytokines and expression of receptors, like the peripheral benzodiazepine 
receptors (PBRs) on the outer membrane of the mitochondria (Cagnin, Kassiou et al. 2007; 
Doorduin, de Vries et al. 2008). 
 
Figure 3. Microglia activation. Adapted from Venneti et al.(Venneti, Lopresti et al. 2006) 
It has been shown, that microglia are the main source of PBRs in the CNS (Banati, Myers et 
al. 1997), but also astrocytes and infiltrating macrophages express them (Doorduin, de Vries 
et al. 2008). The exact fraction of PBRs expressed by activated microglia and other cells can 
not be determined, and this should be taken into account. However, PBRs are a good target 
to visualize inflammation in the brain by PET. There have been several PET tracers 
developed for PBR imaging. The first and for a long time the only one in the human 
application was the carbon-11 labeled PK11195 (1-[2-chlorophenyl]-N-methyl-N-[1-
methylpropyl]-3-isoquinoline carboxamide) (Doorduin, de Vries et al. 2008). The [11C]-
PK11195 has been successfully used to visualize neuroinflammation by detecting activated 
microglia in various neurological diseases, e.g. Alzheimer’s disease (Groom, Junck et al. 
1995), HIV-associated dementia (Hammoud, Endres et al. 2005), Multiple sclerosis (Banati, 
Newcombe et al. 2000). 
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Figure 4. In vivo imaging of PBRs on the outer membrane of activated microglia. 
Adapted from Venneti et al. 2009.(Venneti, Wiley et al. 2009) 
6. ALZHEIMER’S DISEASE 
Alzheimer's disease is an irreversible progressive neurodegenerative disorder and the major 
cause of dementia. The disease symptoms in sporadic cases usually start after the age of 60. 
Time between the first expression of behavioral disease symptoms and death might be up to 
10 years. Thirty-five million people worldwide are estimated to suffer from AD, and in the 
United States alone 5.3 million people are diagnosed with the disease. According to the 
World Health Organization, AD is the fifth leading killer, and presently there is no cure for 
the disease. 
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The core symptom of AD is impaired cognitive function. AD brain pathology is 
characterized by extracellular depositions of amyloid Ƣ, intracellular aggregates of the protein 
tau, and loss of cholinergic forebrain innervation. These neuropathological hallmarks of AD 
are mainly present in brain regions involved in cognition like cortex, hippocampus and 
amygdala. However, it is still uncertain whether the amyloid Ƣ plaques and neurofibrillary 
tangles are causative in AD. It has been shown, that burden of amyloid Ƣ plaques poorly 
correlates with the cognitive decline in AD (Villemagne, Pike et al. 2011). Also, mouse 
models of AD with abnormal plaque development, do not show the cognitive deficits (Davis 
and Laroche 2003). Instead, amyloid Ƣ oligomers are more toxic and responsible for 
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neuronal death (Larson and Lesne 2012). Besides neuronal loss and protein deposits in the 
brain, inflammatory processes also play an important role in AD. Astrogliosis, activation of 
microglia due to plaque depositions, toxic oligomers, tau-aggregations leads to widespread 
neuroinflammation. Microglia-driven inflammatory response includes cytokine production 
(TNFơ, IFNƣ, IL-6) and induction of inflammatory enzyme systems, like inducible nitric 
oxide synthase (iNOS) and the prostanoid generating cyclooxygenase-2 (COX-2), reactive 
oxygen species or free radicals which additionally triggers neuronal dysfunction and death 
(Heneka, O'Banion et al. 2010). 
As mentioned before, neuroinflammation plays an important role not only in 
neurodegenerative diseases but in major depression as well. AD is often accompanied by 
symptoms of depression, anxiety, irritability and mood instability. In many cases patients 
have undergone long time treatments against these psychiatric symptoms before being 
clinically diagnosed for AD. In those cases anxiety or depression is not just a side effect of 
AD but rather an integral part of the typical behavioral symptoms. Interestingly, the affective 
status may even be of predictive value for disease development (Jost and Grossberg 1996). 
7. MULTIPLE SCLEROSIS 
Multiple Sclerosis (MS) is an inflammatory disorder of the central nervous system (CNS). 
Mostly young and middle aged adults are affected by MS (Feinstein 2000). Damaged myelin 
sheaths are the most important hallmark of the disease and demyelination is responsible for 
physical and cognitive disability. 
During the disease, abnormal B and T cell response against antigens, e.g. myelin basic 
protein (MBP), proteolipid protein (PLP), myelin oligodendrocyte glycoprotein (MOG) and 
myelin-associated glycoprotein (MAG) are observed. B cell activity is located only in the 
CNS-cerebrospinal fluid, whereas myelin antigen-reactive T cells have been found in patients 
blood as well (Link 1998). Besides autoreactive B and T cells, damaged blood brain barrier, 
infiltration of macrophages into the CNS and activated glial cells are also detectable in MS. 
The general inflammation in the body leads to abnormal cytokine production, and an overall 
elevated cytokine profile (Link 1998; Trenova, Manova et al. 2011). There is no cure for the 
disease, only relapse remitting therapies can help patients with MS. Interferon beta (IFNƢ) is 
the first-line, successful and safe therapy in MS. IFNƢ is able to slow the progression of 
brain atrophy in MS and reduces the relapse rate by approximately 30% (Farrell and 
Giovannoni 2010; Rudick and Goelz 2011). 
It is known that IFNƢ inhibits T cell activation by down regulation of major 
histocompatibility complex (MHC) class II expression on antigen-presenting cells therefore 
IFNƢ is able to alter the inflammatory response. It reduces Th1 pro-inflammatory cytokines 
and directs a shift towards the Th2 cytokine-profile (Markowitz 2007). The mechanism of 
action of IFNƢ starts with its binding to the interferon ơ/Ƣ receptor, which consists of a 
signaling chain (IFNAR1) and a binding chain (IFNAR2). After creation of this complex, the 
intracellular part of the receptor interacts with Janus kinase 1 (JAK1) and Tyrosine kinase 2 
(Tyk2). The interaction results in a phosphorylation cascade and finally activates Signal 
Transducer and Activator of Transcription (STATs). Activated STATs translocate into the 
nucleus and bind ISRE elements and subsequently induce gene transcriptions (Farrell and 
Giovannoni 2010). 
 
Figure 5. Mechanisms of type I and type II interferon mediated signaling. Adapted 
from Platanias 2005. (Platanias 2005) 
The therapeutic effect of IFNƢ can be direct, if IFNƢ binds to its receptors and induces gene 
transcriptions, or indirect when gene transcription alters other cells involved in pathogenic 
mechanisms in MS. Although IFNƢ is a safe and effective therapy, it has serious side effects, 
like major depression (Feinstein 2006; Fragoso, Frota et al. 2010). Interestingly, it is known, 
that besides pro-inflammatory cytokines, IFNƢ is also a potential inducer of the depression-
associated enzyme, IDO. Stimulation of ISRE by IFNƢ has been shown to induce IDO 
expression (Suh, Zhao et al. 2007). 
The link between IFNƢ-induced IDO expression and behavioral changes in mice will be 
further discussed in Chapter 5. 
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8. AIM AND OUTLINE OF THE THESIS 
In summary, there is growing evidence that inflammatory processes play a key role in major 
depression as well as in neurodegenerative diseases like AD and might be partly responsible 
for the depression symptoms in AD patients. The overall aim of this project was to 
investigate the role of neuroinflammation in depression and neurodegenerative diseases. In 
the present thesis we paid special attention to an ubiquitously expressed enzyme, 
indoleamine 2,3-dioxygenase (IDO), which is induced by inflammatory stimuli and might be 
responsible for the depressive symptoms in neurodegenerative diseases. 
Chapter 1 provides a general insight into the field of neurodegeneration, neuroinflammation 
and depression. The role of IDO, the possible link between neuroinflammation and 
depression under neurodegenerative circumstances has been pointed out. 
Chapter 2 has been published in NeuroImmune Biology – The Brain and host defense and 
reviews Tumor Necrosis Factor ơ as a neuroinflammatory mediator in Alzheimer's Disease 
and stroke. This book chapter focuses on molecular mechanisms and neuroinflammatory 
imaging. 
Chapter 3 describes the role of TNFR1 and TNFR2 on behavioral changes in the aging 
process. Therefore, behavioral studies - to investigate cognitive and physical functions - were 
conducted in young (3 months) and aged (22 months) wildtype, TNFR1 knock out (TNFR1-
/-) and TNFR2 knock out (TNFR2-/-) C57BL/6 mice. We showed that TNFR2 plays a key 
role in hippocampus-dependent memory formation and neuromuscular function. 
Furthermore, the results suggest, that the absence of TNFR1 or TNFR2 does not influence 
the aging process. 
In Chapter 4, evidence for the role of IDO has been given in a mouse model of 
neuroinflammation induced depression. We showed, that glial activation - reflecting 
neuroinflammation - culminated 3 days after LPS injection. LPS injected animals displayed a 
significant increase of depressive-like behavior in the forced swim test (FST), a significant 
increase of IDO in the brainstem, and increased kynurenine/tryptophan ratio in the serum 
compared to vehicle injected animals. We also investigated the effect of a competitive IDO-
inhibitor, 1-methyl-tryptophan (1-MT) in centrally induced neuroinflammation, and we 
reported, that in experimental conditions, IDO inhibition can prevent the development of 
depressive-like behavior. 
Chapter 5 presents interferon Ƣ (IFNƢ) induced IDO expression and activity with 
subsequent depressive-like behavior using a wildtype and an interferon ơ/Ƣ receptor knock 
out mouse strain. The results obtained in this study give evidence that IFNƢ-induced IDO 
increase and the subsequent behavioral changes are through the interferon ơ/Ƣ receptors. 
Finally, Chapter 6 summaries this thesis, contains general discussion and ends in future 
applications of the results presented here. 
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ABSTRACT 
Neuroinflammatory responses in neurodegenerative diseases have been extensively 
investigated over the past decade. Although still far from being fully understood, 
neuroinflammatory responses are now considered to be part of the physiological response 
repertoire of the brain to traumatic and chronic neurodegeneration and to exhibit both 
neurotoxic and neuroprotective functions. Recent findings in neuroinflammatory research of 
neurodegenerative brain diseases suggest that inflammatory responses should also be 
considered as opportunities to fight the disease. We discuss the possibilities of using 
neuroinflammatory responses for neuroimaging and diagnosis and also for developing future 
therapeutic strategies. Among the pro-inflammatory cytokines involved in all of the 
degenerative diseases of the brain tumor necrosis factor alpha (TNF) plays a role of prime 
importance. We discuss this role of TNF with emphasis on the mechanisms of TNF 
receptor-mediated intracellular processes, and the molecular pathways that underly 
neuroprotective signaling through TNF receptor 2. Neuroinflammatory mechanisms while 
associated with direct damage of or protection of nervous tissue, have multiple additional 
impacts on the affected brain. Other aspects of the link between neuroinflammation and 
neurodegeneration include activation of enzymatic processes such as indoleamine 2,3-
dioxygenase, the consequences of which on neuronal function and excitability we discuss in 
the context of neurodegenerative disorders like Alzheimer’s disease. 




Stroke and neurodegenerative diseases are among the leading causes of permanent 
disabilities and death in western societies. With an increasingly aged population both 
conditions pose a constant challenge to the individual and to society. Although in recent 
decades considerable advances have been made in the treatment of symptoms, for example 
in certain aspects of degenerative disorders like Parkinsonism, virtually no treatments are 
available as yet that interfere with the causal mechanisms underlying these brain diseases. 
This is particularly the case for treatment of cognitive failure in dementing illnesses including 
Alzheimer’s disease and Parkinson’s disease with dementia (AD; PD) as well as CVA. 
With respect to the role that inflammation plays in brain diseases, our understanding of the 
central nervous system has evolved over the past decade from one of an immune-privileged 
organ, to one where inflammation is pathognomonic for some of the most prevalent 
neurodegenerative diseases. Inflammation, whether in the brain or periphery, is almost 
always a secondary response to a primary pathogen or pathophysiological process. In 
Alzheimer’s disease, inflammation is considered as a secondary response that follows 
impaired processing and precipitation of amyloid oligomers, but one that likely causes 
additional neuronal damage and cell loss. It is now established that inflammatory mediators 
not only play predisposing roles in the development of atherosclerotic stroke but also in 
what happens to damaged post-ischemic or post-hemorrhagic tissue. This role is certainly 
not limited to cerebrovascular brain disease. If one compares the inflammatory responses 
that follow upon ischemia to the responses observed in diseases like AD or PD remarkable 
similarities are observed. In ischemic stroke it is accepted that in a substantial number of 
patients progression of neural injury continues beyond 24 hours after stroke onset (Dirnagl 
2004). The mechanisms thought to be involved in lesion progression and in delayed 
neuronal cell death are: increasing and spreading vascular occlusions, excitotoxicity, deranged 
calcium homeostasis, necrosis, apoptosis and inflammation. Except for vascular occlusion, 
excitotoxicity, calcium accumulation, apoptosis and inflammation are also hallmarks of 
chronic neurodegenerative diseases (Mattson 2004). 
On the other hand there is growing evidence that also for AD and PD vascular pathology 
and a reduced supply of oxygen and nutrients that may come into play as major risk factors 
that can promote neurodegenerative processes (Farkas and Luiten 2001; Kalaria 2003; de la 
Torre 2004; Liebetrau, Steen et al. 2004). Necrosis is believed to be the result of a short-
lasting insult leading to a “non-organized” cell death. Cell necroses can be initiated by a 
physical insult, energy depletion or other stress factors with a fatal result characterized by 
release of intracellular contents, including high concentrations of glutamate, into the 
extracellular space. Apoptosis, or programmed cell death, on the other hand, is induced by 
intra- cellular mediators such as mitochondrial pathways or increases of intracellular calcium 
or by external cytokine ligands exemplified by members of the TNF receptor superfamily 
such as TNF itself, FasL or TRAIL in the absence of trophic factors and/or anti-apoptotic 
signals. The apoptotic program generally activates a cascade of caspases which trigger other 
signaling molecules and enzymes that finally lead to degradation of DNA and proteins. The 
cell becomes fragmented and these fragments are enveloped as small packages to be digested 
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by macrophages and microglia. As a result no further inflammation is triggered and no 
cytotoxic components come to be released into the surrounding extracellular space. The 
extracellular factors that induce, apoptosis are part of the innate immune response that is 
mediated in part by immune cells and can be considered as a tissue-mediated stress response. 
Protection of the whole organism by the immune system therefore includes the conversion 
of an unregulated necrotic into a regulated and controlled apoptotic cell death in order to 
prevent increased tissue damage. 
From the basic neuroinflammatory mechanisms and their biochemical characteristics, the 
role of putative mediators that could play a key role in neurodegenerative disorders has been 
explored, with Alzheimer's disease serving as a prototypic disorder. Although in 
experimental cellular models the various biochemical aspects and processes of inflammation 
can be well characterized, assessment of cerebral inflammatory processes in vivo is still in its 
infancy. Whereas structural imaging shows merely late and robust anatomical consequences 
of an inflammatory event, functional imaging is a strong potential candidate to bridge this 
mechanistic gap between in vitro and in vivo knowledge. Although peripheral immune-
associated cells (e.g. lymphocytes) do occasionally cross the intact blood-brain-barrier - often 
fulfilling a surveillance function - cerebral inflammatory reactions depend heavily on 
intraparenchymal elements of the brain. The only resident immune cells of the brain are the 
so called microglia. Microglial cells are actually macrophages and as is typical for 
macrophages they release - among many other immunomodulating molecules - the pro-
inflammatory cytokine TNF. Microglial cells become activated in regions surrounding brain 
tissue lesions whether acivation is induced by AD-induced amyloid plaques, by ischemic 
lesions or by other pathological conditions. In fact, activation of microglia occurs 
independently of whether the damage to a neuron is irreversible (necrosis) or the reaction of 
the cells has a transient character only. In either case, activated microglial cells are a sensitive 
marker of affected brain regions in a wide variety of neurodegenerative diseases. In this 
chapter we discuss not only neurodegenerative consequences and several of the basic 
mechanism underlying vascular pathology and neurotoxicity, but also the prospects that 
microglial activation may provide a reliable marker for neuroimaging and that intelligent 
drugs can be directed to affected brain sites. 
2. SOME BASIC ASPECTS OF CEREBRAL INFLAMMATION 
The previously accepted concept of the brain as an immunologically privileged organ 
appears to be no longer tenable. Initially it was conceived that the brain’s lack of a lymphatic 
drainage system (Cserr and Knopf 1992) contributed to an unusual tolerance for 
transplanted tissue. However, more recent insights indicate that a lymphatic-like system 
exists in the brain. Formerly, the immune and nervous systems were considered as making 
autonomous contributions to physiological homeostasis (Barker and Billingham 1977). 
Contemporary research has revealed that the blood-brain barrier (BBB) is, under certain 
conditions, less restrictive than had been thought to the migration of monocytes, 
lymphocytes, or natural killer cells, irrespective of antigen specificity (Mucke and Eddleston 
1993). Nevertheless, inflammation threshold of the CNS is still considerably higher than that 
of the periphery, leading to a delay between peripheral and CNS inflammation during a 
general inflammatory response. For example, rapid recruitment of neutrophils into the CNS 
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is virtually absent, and monocytes are only recruited after a delay of several days. The reasons 
for this higher threshold are at least threefold. First, because only activated T lymphocytes 
traverse the BBB, the pool of peripherally activated T cells that enter the CNS for immune 
surveillance is relatively small (Hickey, Hsu et al. 1991). Yet, without peripheral T cell 
activation, antigens escape detection; thus, brain transplants survive despite an antigen 
mismatch (Head and Griffin 1985). Second, there is an active suppression of antigen 
expression leading to T lymphocytes not recognizing their target nor activating inflammatory 
mechanisms (Hart and Fabry 1995). Third, adhesion molecule expression, essential in cell to 
cell contacts during inflammatory cell migration, is low on cerebral endothelial cells 
(Lassmann, Rossler et al. 1991). CNS immune responses usually take milder courses, and it is 
not clear yet whether this relative deficit is explicable solely by the lack of immunological 
structures, or is compounded by counter-regulatory mechanisms. Recent evidence indicates 
that CNS immune responses are indeed downregulated, with a key role proposed for 
electrically active neurons (Neumann and Wekerle 1998). Both in vitro and in vivo studies 
have established that astrocytes and microglia (as brain resident macrophages), in addition to 
immune cells of peripheral origin, can initiate an inflammatory cascade within the CNS 
(Owens, Renno et al. 1994). Also, all components of the complement system are found in 
the brain and are produced by astrocytes, microglia, and, surprisingly, also by neurons. 
Cytokines and chemokines are released not only from microglia, astrocytes, and lymphocytes 
but from neurons as well. Cytokines and growth factors function as mediators of the innate 
immune response and regulate stress responses, induction of proliferation and/or induction 
of apoptosis. Depending on their overall effect on immune cells pro- and anti-inflammatory 
cytokines may be distinguished. Pro-inflammatory cytokines induce an inflammatory 
response upon tissue damage. Whether this damage comes from ischemia or other 
pathological conditions, cytokine induction is a common feature in essentially all 
neurodegenerative diseases but with a great variation in its functional and temporal dynamic 
expressions. In general, inflammation can be seen as an overall reaction to tissue damage 
which may have a restorative character but has also been considered as detrimental because 
of its neurotoxic actions. Today neuroinflammation is rather seen as part of the normal 
physiological repertoire of the brain. 
Among the pro-inflammatory cytokines tumor necrosis factor (TNF), lymphotoxin-alpha 
and -beta (LTơ and Ƣ), interferon-ƣ, and the interleukins IL-1Ƣ, IL-2 and IL-6 are the most 
prominent (Cacquevel, Lebeurrier et al. 2004; Clarkson, Rahman et al. 2004; Sjogren, 
Folkesson et al. 2004). For stroke patients, circulating blood levels of TNF and IL-6 
especially during the first week after the stroke appear to be predictive for outcome as 
shown in some recent clinical studies (Vila, Castillo et al. 2000; Intiso, Zarrelli et al. 2004; 
Smith, Emsley et al. 2004). Recent studies also provide evidence for strong expression of 
cytokines in the early stages of cognitive impairment that precede onset of full-blown 
dementia (Kropholler, Boellaard et al. 2007; Magaki, Mueller et al. 2007). 
Glutamate- and aspartate-induced or –mediated neuronal cell death, defined as the process 
of excitotoxicity, is generally believed to be a key event in neurodegeneration not only in 
stroke but also in neurodegenerative diseases such as AD and PD (Glazner and Mattson 
2000; Harkany, Abraham et al. 2000; Mattson, LaFerla et al. 2000; Mattson and Camandola 
2001; Mattson and Chan 2003; Rogawski and Wenk 2003). Permanent tonic and slightly but 
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chronically elevated extracellular glutamate and/or intracellular calcium levels could underlie 
certain aspects of neuronal damage or dysfunction in the pathogenesis of diseases like AD 
and PD (Glazner and Mattson 2000; Harkany, Abraham et al. 2000; Mattson, LaFerla et al. 
2000; Mattson and Camandola 2001; Mattson and Chan 2003; Rogawski and Wenk 2003). 
The excitotoxic efficacy of glutamate and aspartate is disproportionally enhanced under 
conditions of acute or permanent ischemia. Because of failing cation-pump activity the 
affected cells become overloaded with sodium, calcium and chloride ions, thereby depleting 
the energy generating capacity of the cell because of excessive mitochondrial calcium 
accumulation. Here too, immunological mediators such as TNF directly influence the 
survival of neuronal cells (Cooper, Kalaria et al. 2000). In this review we describe the 
common features of innate immune responses in neurodegenerative disease, with emphasis 
on TNF and TNF receptors, and discuss the beneficial and detrimental effects of 
neuroinflammatory responses at the level of signal transduction. We present new views on 
neuroprotective approaches mediated by TNF receptor systems and their downstream 
signaling pathways and discuss possibilities for improved diagnostics by imaging 
inflammatory processes such as microglial activation that may rescue neurons with, as a 
consequence, a rescue of behavioral brain function. 
3. COMMON INFLAMMATORY FEATURES IN NORMAL BRAIN 
Inflammatory mediators such as pro-inflammatory cytokines were detected in normal (non-
pathological) brain tissue by many groups as reviewed by Vitkovic and coworkers (Vitkovic, 
Bockaert et al. 2000). Many functions like sleep regulation, fever, “sickness behavior” and 
even inherent neuronal plasticity functions like long term potentiation (LTP) are influenced 
in normal brain by cytokines (Albensi and Mattson 2000; Bluthe, Laye et al. 2000; Bluthe, 
Michaud et al. 2000), such as IL-1, IL-6 or TNF. Vitkovic and coworkers proposed that 
cytokines be viewed as neuromodulators. For example, in a very recent study it was shown 
that IL-1Ƣ has different signaling pathways in hippocampal neurons and astrocytes. IL-1Ƣ is 
able to induce stimulation of NF-NB in astrocytes generally considered as a neuroprotective 
mediator. In neurons, however, IL-1Ƣ activates the mitogen activated protein kinase p38 and 
induces CREB activation (Srinivasan, Yen et al. 2004). IL-1ơ was recently shown to play a 
role in hippocampal memory processing (Depino, Alonso et al. 2004). 
Under non-pathogenic conditions TNF is believed to be involved, together with NF-NB, in 
neuronal functioning, such as hippocampal synaptic plasticity (Albensi and Mattson 2000) 
and ionotropic glutamate receptor modulation (Furukawa and Mattson 1998). Under such 
conditions TNF can be detected in various neuronal and glial cells, while at the same time 
the TNF-receptors (TNFR1 and TNFR2) are barely detectable (Fontaine, Mohand-Said et al. 
2002; Neumann, Schweigreiter et al. 2002). However, upon various stress and noxious 
stimulations TNF and its receptors become strongly upregulated (Fontaine, Mohand-Said et 
al. 2002; Laabich, Li et al. 2002). Indeed, many studies have shown that basic levels of 
cytokines and their receptors can be found in almost all brain areas (Vitkovic, Bockaert et al. 
2000). It is, therefore, difficult to determine which cytokine- and/or cytokine receptor level 
constitute an „inflammatory response“ and under which circumstances and expression levels 
we should speak of neuromodulatory involvement of these cytokines. 
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4. INFLAMMATORY SIGNALS IN NEURODEGENERATIVE DISORDERS 
AND STROKE: MARKERS FOR DAMAGE OR PROTECTION? 
It has long been known that in stroke clear signs of inflammation can be found very early 
[for reviews see (Dirnagl 2004)]. Elevated TNF levels have been repeatedly reported to occur 
shortly after middle cerebral artery occlusion (an animal model for stroke) or after closed 
head injury (Shohami, Novikov et al. 1994; Yang, Gong et al. 1999) at a time point that 
precedes infiltration of polymorphonuclear neutrophils. This indicates that TNF, expressed 
by microglia and also by neurons, may initiate infiltration of peripheral macrophages and 
lymphocytes. Thus it may be concluded that TNF (among other cytokines) plays a major 
role in initiating the immune response in stroke. 
The role of TNF as an immune mediator is not limited to CVAs. It also plays a role in other 
neurodegenerative disorders, like Alzheimer’s disease (Figure 1.), Parkinson’s syndrome, 
Prion diseases (i.e. transmissible spongiform encephalopathies, such as Creutzfeld-Jakob 
disease in humans or BSE in cows) and other diseases, where a strong involvement of the 
immune system is an important hallmark of the pathogenic process. Production of 
inflammatory mediators such as IL-1Ƣ, TNF, some chemokines, like IP-10, MCP1, MIP1ơ 
or proteins such as S100Ƣ, iNOS, and GFAP is associated with neural injury in AD and PD. 
This has often been described as the “cytokine cycle”, which leads to an ongoing 
inflammatory process (Ringheim and Conant 2004). Inflammation has been thought to 
promote development of disease pathology (Casserly and Topol 2004) rather than playing 
the classical role of the innate immune system as a mechanism for tissue protection. In fact, 
the “smoking gun” of inflammatory mediators can be seen in all kinds of neurodegenerative 
disorders. The level of certain cytokines in the cerebrospinal fluid of stroke patients, but also 
in patients suffering from AD correlates with disease outcome (Vila, Castillo et al. 2000; 
Intiso, Zarrelli et al. 2004; Smith, Emsley et al. 2004; Hansson, Zetterberg et al. 2006). 
Figure 1. Dense Alzheimer plaque in the brain of a APPSL/PS-1 transgenic mouse stained 
with thioflavin (green) and immunostaining against TNFR2 (red) (by Granic, Nyakas, Luiten, 
Eisel, unpublished result). 
The above could indicate that inflammation is playing an important and active part in disease 
development. However, the same picture would emerge were one to consider cytokine levels 
as dependent on the level of tissue damage. The significance of cytokine levels as markers 
for a neurodegenerative disease process may be interpreted in two ways. If we consider the 
innate immune response as a reaction to adverse stimuli and tissue damage, then cytokine 
and chemokine signaling should have the functions of guiding severely damaged cells into 
apoptosis and of activating an immune response. At the same time cells or tissue 
components that survive the noxious stimulus may do so as a result of cytokine-mediated 
survival signals. This means that resident macrophages and lymphocytes infiltrating the 
tissue upon damage should also be considered as protective, as suggested also by others 
(Wang and Feuerstein 2004). The immune response may overshoot in certain distress 
situations and clinicians may wish to use immunosuppressive drugs for counterbalancing. 
However, in stroke, glucocorticoids, which are potent anti-inflammatory drugs, have been 
shown to be without any therapeutic benefit and the literature is controversial on the effect 
of such treatment (Abraham, Harkany et al. 2000; Davis and Donnan 2004; Norris 2004; 
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Poungvarin 2004). Clearly, new and probably better concepts for the treatment of 
neurodegenerative diseases may arise once we get a better understanding of the signaling 
mechanisms underlying degenerative and protective immune responses. 
For AD it should be emphasized that the theory of inflammation as a primary disease-
aggravating hallmark, as opposed to a secondary or even a disease-ameliorating factor, 
remains a hypothesis. One should be aware that our current knowledge of microglia is still 
incomplete, speculative, and mainly based upon in vitro observations rather than in vivo 
studies (Rozemuller and van Muiswinkel 2000). Indeed, B or T cells and immunoglobulins 
(Igs) are not readily detectable in the Alzheimer dementia brain and are found only in very 
small amounts in relation to amyloid plaques (without IgM/IgA) (Eikelenboom and Stam 
1982). Likewise, although the presence of leukocytes has been demonstrated, their role in 
Alzheimer dementia has not been established (Myllykangas-Luosujarvi and Isomaki 1994). 
As such, the evidence for an antigen-driven acquired immune response in Alzheimer 
dementia, with T cells eliminating amyloid and B cells producing AƢ-specific antibodies, is 
not as overt as in well-established neuroinflammatory diseases [e.g., multiple sclerosis,(Marx, 
Blasko et al. 1998)]. 
5. NEUROINFLAMMATORY IMAGING 
Visualising neuroinflammation in neurodegenerative diseases, including Alzheimer dementia, 
is of interest, first for clarifying the pathophysiology, second for selecting patient subgroups 
that are candidates for anti-inflammatory treatment, and finally for monitoring patients 
during trials with such anti-inflammatory agents. Here, we review and discuss current 
neuroinflammatory imaging modalities, both structural and functional. Structural imaging 
aims to describe in detail the spatial relationship of neurodegenerative and inflammatory 
consequences, like mass effects, edema, vascular congestion, thrombosis, petechial 
hemorrhages, secondary demyelination, gliosis, and finally neuronal destruction, necrosis, or 
atrophy, as well as visualizing other (nonspecific) structural changes. Alternatively, functional 
imaging aims to assess the early and late consequences of brain-function or biochemistry 
during neurodegenerative processes. 
5.1. Computed Tomography (CT) Imaging and Magnetic Resonance Imaging (MRI) 
CT and, to a greater extent, MRI (gadolinium-enhanced) with its excellent soft-tissue 
contrast resolution (used mainly for the evaluation of white matter and posterior fossa) are 
able to detect CNS changes caused by localized inflammatory and degenerative processes 
(Sze and Zimmerman 1988). The degenerative processes and inflammation must already be 
at an advanced stage before they can be resolved by one of these imaging modalities. 
Sensitivity is poor at the early stages of AD (when anatomical changes are not yet 
detectable). But, in chronic processes, these modalities may also detect structural changes 
that cannot be revealed otherwise. Both CT and MRI are too insensitive to detect microglial 
nodules, and, for this reason, the neuroimaging appearance early in the course of 
neurodegenerative diseases is usually normal (Ketonen and Tuite 1992). In addition, these 
imaging modalities show poor correlation with histopathological findings (Kim, Tien et al. 
1996). Although MRI is useful in the work-up of patients with dementia because it shows 
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the presence of space-occupying lesions, ventricular dilatation, cerebral atrophy, widening of 
sulci, or infarcts, this technique is not of particular value in the direct diagnosis of Alzheimer 
dementia. Promising results have been made with volumetric measurements of the 
(para)hippocampal and amygdala region (Scheltens 1999). Cecil et al. (Cecil and Lenkinski 
1998) reviewed the newer structural or metabolic imaging tools in brain inflammation and 
concluded that proton MR spectroscopy is a sensitive and specific imaging tool in 
Creutzfeldt-Jakob disease, herpes simplex encephalitis, and AIDS, and recommended its use 
in longitudinal studies for predicting and monitoring the response to therapy (Cecil and 
Lenkinski 1998). Likewise, Bitsch et al. (Bitsch, Bruhn et al. 1999) found that the increases of 
choline and myo-inositol corresponded to the histopathologically verified glial proliferation 
and the infiltration of subcortical grey matter structures with foamy macrophages. More 
recently, Rovaris et al. (Rovaris, Viti et al. 2000) reported on the value of magnetization 
transfer imaging in measuring brain involvement in systemic immune-mediated diseases. It 
was found that magnetization transfer imaging provides information about brain damage 
with increased pathological specificity and detects subtle microscopic abnormalities in 
normal brain tissue, that go undetected with conventional scanning. However, in some 
immune-mediated diseases microscopic brain tissue damage seemed to be absent despite 
macroscopic MRI lesions or clinical evidence of CNS involvement (Rovaris, Viti et al. 2000). 
5.2. Functional Imaging Using Radiopharmaceuticals 
Nuclear medicine provides several techniques for the detection of inflammation. Studies 
demonstrating inflammatory lesions were reported as early as 1959, when Athens et al. 
(Athens, Mauer et al. 1959) labeled leukocytes by intravenous injection of diisopropylfluoro-
phospate labeled with 32P and demonstrated skin blisters in volunteers. Classically, 
scintigraphic imaging of inflammation has been done with 67Gallium-citrate, radiolabeled 
leukocytes, nanocolloids, nonspecific human immunoglobulins (HIGs), and 18F-
deoxyglucose (FDG). Uptake mechanisms included direct binding to relevant inflammatory 
cells or proteins (radiolabeled leukocytes, 67Gallium-citrate, HIG) over hyperemia, and 
binding to lactoferrin excreted in loco by leukocytes or to siderophores produced by 
microorganisms (67Gallium-citrate). In addition, nonspecific local increases in blood supply, 
extravasation through vessels with increased permeability may give rise to expansion of the 
local interstitial fluid space (67Gallium-citrate, nanocolloid, HIG). Finally, high glucose 
uptake is often seen in inflammatory cells (FDG-PET) (Corstens and van der Meer 1999), 
but inflammatory processes in CNS tissue cannot easily be distinguished because of the high 
rate of energy metabolism in otherwise unaffected tissue (even in AD). Radiolabeled 
leukocytes used in cerebral ischemia to detect inflammation accumulated well in massive 
infarcts with severe neurological impairments and little improvement (Stevens, Van de Wiele 
et al. 1998) but are of little use in Alzheimer dementia. This is because of the minor 
hemodynamic and permeability changes (little or no vasodilatation), the slow cellular 
turnover, and the predominant mononuclear cell infiltrate of chronic processes. 
Attempts have been made to visualize inflammation with divalent cobalt radioisotopes, using 
positron emission tomography (PET) and single photon-emission computed tomography 
(SPECT). Both in vivo and in vitro experiments have shown that Ca2+ accumulates in the 
damaged nerve cell body and degenerating axons by two mechanisms: (1) a passive influx 
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caused by a shortage of ATP following ischemia or chronic excitotoxic overstimulation of 
nerve cells, resulting in the disappearance of the membrane potential, and (2) neuronal and 
glial uptake by divalent cation-permeable kainate-activated non-N-methyl-D-aspartate 
glutamate receptor-operated channels in the membrane (Gramsbergen, Veenma-van der 
Duin et al. 1988; Muller, Moller et al. 1992; Dubinsky 1993; Gibbons, Brorson et al. 1993; 
Hartley, Kurth et al. 1993; Linde, Laursen et al. 1996). 57Co (SPECT) and 55Co (PET), both 
as Ca2+-analogs, can reflect Ca2+-influx in ischemically or neurotoxically damaged cerebral 
tissue. In this way, both 57Co SPECT and 55Co PET have been shown capable of visualizing 
focal neurodegenerative changes, reactive gliosis, endangered brain tissue, and/or ongoing 
neuronal tissue decay, including inflammatory lesions in various brain diseases, for example, 
multiple sclerosis, trauma, tumors, and stroke (Pruss, Akeson et al. 1991; Williams, Pregenzer 
et al. 1992; Jansen, Willemsen et al. 1995; Jansen, van der Naalt et al. 1996; Jansen, Dierckx 
et al. 1997; Stevens, Van de Wiele et al. 1998; De Reuck, Stevens et al. 1999). 
The limitations of 57Co SPECT and 55Co PET should also be mentioned here. Because of 
the long physical half-life (270 days) of 57Co, only a limited dose can be injected which is 
responsible for the low count rate and the resulting low statistics. Alternatively, the PET-
radionuclide 55Co has been used (physical half-life 17.5 hours). Moreover, whether divalent 
radioactive Co visualizes specific aspects of neuronal damage or BBB integrity is still 
uncertain. To what extent 57Co and 55Co really visualize calcium-mediated processes (in vivo) 
and therefore reflect identical molecular uptake mechanisms has yet to be determined, 
although the cerebral uptake of intravenously administered radioactive 45Ca and 60Co in 
neuronal damage is highly similar (Gramsbergen, Veenma-van der Duin et al. 1988). Finally, 
the exact cellular site of accumulation of radioactivity is, as yet, not known. As for 
inflammatory imaging, however, it is interesting to note that calcium may also accumulate in 
activated leukocytes and that for both 55Co and 57Co only 12% of the total fraction is in its 
free form while the remainder is bound to leukocytes or plasma proteins (Haverstick and 
Gray 1993; Clementi, Martino et al. 1994; Jansen, Knollema et al. 1996). 
Often, semiquantitative analyses are based on a regional normalisation of radioactivity with 
the cerebellum as reference region and thus normalisation factor. A regional rather than a 
global normalization (with whole brain as normalisation factor) may be preferred because a 
region-specific normalization is known to be more sensitive for diseases in which various 
regions are pathophysiologically involved, as in Alzheimer dementia (Syed, Eagger et al. 
1992). Although some reports described the pathological involvement of the cerebellum in 
Alzheimer dementia (Joachim, Morris et al. 1989), this region was chosen as the 
normalisation region because it has both low pathologic susceptibility and absence or at least 
minimal presence of upregulated inflammatory mediators (Rozemuller, Stam et al. 1990). A 
previous study had already concluded that the cerebellum is the more appropriate choice of 
reference region in the quantification of perfusion single-photon emission computed 
tomography (SPECT) in primary degenerative dementia (Talbot, Lloyd et al. 1994). With 
regard to perfusion SPECT imaging, the cerebellum was shown to be scintigraphically 
uninvolved (Pickut, Dierckx et al. 1999). 
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5.3. Imaging of Activated Microglia in Alzheimer Dementia 
PK11195 (1-[2-chlorophenyl]-N-[1-methyl-propyl]-3-isoquinoline carboxamide) is a specific 
and selective high-affinity ligand for the peripheral benzodiazepine receptor (PBR) and, in 
this way, can be used as a marker for neuroinflammatory lesions (Cagnin, Gerhard et al. 
2002; Versijpt, Van Laere et al. 2003; Chen, Baidoo et al. 2004). The PBR is structurally and 
pharmacologically distinct from the central benzodiazepine receptor (associated with ƣ-
aminobutyric acid-regulated chloride-channels) and earned its name based on its localization 
outside the CNS and its high affinity for several 1,4-benzodiazepines. It has neither 
anxiolytic nor spasmolytic activity or interactions with other receptors and has been 
classified as an antagonist or partial agonist (Parola, Yamamura et al. 1993). As such, Banati 
et al. (Banati, Myers et al. 1997) showed an increased PK11195 binding to activated microglia 
after facial nerve axotomy, a lesion causing a retrograde neuronal reaction without nerve cell 
death with a rapid proliferation and activation of microglia while keeping the BBB intact. 
The peak of PK11195 binding was observed 4 days after the peripheral nerve lesion, which 
is consistent with the well-known time course of microglial activation. Moreover, 
photoemulsion microautoradiography confirmed the restriction of PK11195 binding to 
activated (i.e., PBR-expressing) microglia, where the full transformation of microglia into 
parenchymal phagocytes is not necessary to reach maximal levels of PK11195 binding. It 
was concluded that PK11195 is a well-suited marker of microglial activation in areas of 
subtle brain pathology, without BBB disturbance, or the presence of macrophages (Banati, 
Myers et al. 1997; Chen, Baidoo et al. 2004). The PBR is found in highest concentrations in 
kidneys, colon membranes, heart, steroid hormone-producing cells of the adrenal cortex, 
ovaries, and testes, and several cell types of the immune system, such as mast cells and 
macrophages, a localization that is highly concordant with an immunohistochemical study on 
post mortem human tissue (Bribes, Carriere et al. 2004). It is also present in low 
concentrations throughout the brain, primarily associated with the choroid plexus, 
ependymal linings, and glial cells. Although the specific function of the PBR remains 
unknown, it is generally accepted to be involved in lipid metabolism and/or transport, heme 
biosynthesis, cell proliferation, or ion channel functions (Zisterer and Williams 1997). Its 
immunomodulatory role includes the ability to induce monocyte chemotaxis, modulate 
cytokine expression and superoxide generation, and stimulate antibody-producing cell 
formation (Zavala, Taupin et al. 1990). Interestingly, the PBR has the ability to reflect 
neuronal injury, neurotoxicity, and inflammatory lesions without BBB damage, by a rise in 
the number of binding sites in the case of activated microglia (Guilarte, Kuhlmann et al. 
1995; Banati, Newcombe et al. 2000), as previously indicated autoradiographically for AD 
(Diorio, Welner et al. 1991; Kuhlmann and Guilarte 2000). 
In vivo visualization of the human PBR has been performed with 11C-radiolabeled PK11195 
for PET in various diseases, like glial neoplasms, ischemic stroke, multiple sclerosis, 
Rasmussen’s encephalitis, Alzheimer dementia, and Parkinson’s disease. A signal of activated 
microglia was produced, which was unrelated to the influx of blood-borne macrophages 
(1996; Perl, Olanow et al. 1998; Di Patre, Read et al. 1999; Cummings 2000). The potential 
of this approach was shown in multiple sclerosis, where significant 11C-PK11195 binding 
was detected in areas where MRI did not show any abnormalities. For instance, PK11195-
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related signals were localised in deafferented grey matter regions such as the lateral geniculate 
body (to which the optic nerve projects) and visual cortex of patients with previous optic 
neuritis. 11C-PK11195 PET has also been applied in early and mild dementia patients 
revealing an increased regional binding in the entorhinal, temporoparietal, and cingulate 
cortex. Moreover, serial volumetric MRI scans revealed that areas with high 11C-PK11195 
binding subsequently showed the highest rate of atrophy up to 12-24 months later, 
indicating that the presence of a local immune response in cortical areas did indeed reflect an 
active disease process associated with tissue loss. Comparison with FDG-PET revealed that 
areas with high 11C-PK11195 binding were also characterized by decreased regional glucose 
use. In one patient with isolated memory impairment without dementia, the pattern of 
atrophy as seen by volumetric MRI imaging was predicted by the initial distribution of 
increased 11C-PK11195 binding (Waldemar 1995). 
Recently, PK11195 radiolabeled with iodine for SPECT has become available. 123I-labeled 
iodo-PK11195 is a suitable agent for visualization of the PBR and indirectly for the imaging 
of neuroinflammatory lesions (Mann, Mohr et al. 1992). In a recent pilot study, [123I]iodo-
PK11195 was also applied in Alzheimer dementia, which showed a distinct difference in 
ligand uptake between Alzheimer dementia patients and controls, indicating the 
pathophysiological involvement of microglia in frontal, temporal, and parietal cortical 
regions that were pathognomonically compromised in patients with Alzheimer dementia 
(Kuhlmann and Guilarte 2000). Moreover, inverse correlations were found between regional 
[123I]iodo-PK11195 uptake values and cognitive test results. Mean uptake values were 
increased in various neocortical regions pathognomonically compromised in Alzheimer 
dementia, and significance was particularly reached in frontal neocortical regions. Although 
somewhat unexpected, this is in concordance with a very recent study where an intense 
immunoreactivity for the immune and inflammatory mediator CD40L, expressed on 
microglia and involved in microglia-dependent neuron death, was found throughout the 
frontal cortex of AD patients (Diorio, Welner et al. 1991). Also, this frontal increase in 
[123I]iodo-PK11195 uptake could possibly indicate the progression together with the 
spreading of active inflammation towards more frontal regions in patients already at an 
advanced stage of the disease, although the mean mini mental state examination score in that 
study was at a moderate level of 19. This advanced neuropathological stage is in 
concordance with the frontal perfusion deficits observed in the present study, deficits that 
typically are observed later in the course of the disease (1996). Regarding this progression 
towards more frontal regions, recent biopsy results also showed that the progressive 
neurological impairment in Alzheimer dementia patients is accompanied by a significant 
increase in senile plaques, neurofibrillary tangles, and microglial cell activation in the frontal 
cortex (Di Patre, Read et al. 1999). However, group analyses should be carefully interpreted 
because there is a marked heterogeneity in Alzheimer dementia patients concerning stage of 
the disease, progression pattern, predominant topographical lesion, and cognitive subtype, 
with a substantial overlap between Alzheimer dementia and other neurodegenerative 
conditions (Waldemar 1995; 1996; Perl, Olanow et al. 1998; Di Patre, Read et al. 1999; 
Cummings 2000). Such heterogeneity may contribute to the rather large range of 
neuropsychological scores of Alzheimer dementia patients and may also be reflected in the 
higher variability of [123I]iodo-PK11195 uptake in Alzheimer dementia patients as compared 
with controls. Concerning this heterogeneity, behavioral as well as cognitive variability has 
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been correlated with PET and SPECT findings (Waldemar 1995). Two subgroups with 
distinct progression rates were already segregated by neuropsychological and cerebral 
metabolic profiles, in which one rapidly deteriorating group had a significantly greater 
impairment in executive functions attributed to the frontal lobe and a concomitant greater 
frontal hypo-metabolism revealed by PET scanning (Mann, Mohr et al. 1992). Age 
difference between AD patients and controls may explain at least some of the perfusion 
SPECT findings, but it cannot explain the increased [123I]iodo-PK11195 uptake in Alzheimer 
dementia patients because age-related increases in 11C PK11195 uptake have been described 
only in the thalamus, and no age-related effect at all was found in the present study (Banati, 
Newcombe et al. 2000; Cagnin, Gerhard et al. 2002). Moreover, the age discrepancy between 
Alzheimer dementia patients and controls probably led to an underestimation of the actual 
[123I]iodo-PK11195 uptake as a result of the fact that atrophy was not taken into account. 
Atrophy is more prominent in the older AD group, particularly in the left meso-temporal 
region, because this area, encompassing the hippocampus, is known for its substantial 
atrophy in Alzheimer dementia patients (Eagger, Syed et al. 1992). 
The literature reviewed here and other reports indicate that the radioligand PK11195, 
developed both for SPECT and PET, can be considered as a highly sensitive cellular marker 
for the functional monitoring of microglia in vivo, useful for the visualisation of chronic 
neurodegeneration without BBB breakdown nor other imaging findings. 
6. INFLAMMATORY MOLECULES AS POSSIBLE DRUG TARGETS FOR 
NOVEL THERAPEUTIC STRATEGIES 
Exploiting neuroinflammation for diagnostic neuroimaging can certainly help to develop 
therapeutic strategies that are adapted to the individual needs of patients with 
neurodegenerative disorders. Moreover, targeting neuroinflammatory molecules could also 
help to develop drug targeting strategies that act specifically at the site of brain inflammation 
where drug action would be needed. Therefore, it is important to understand the 
inflammatory responses in the brain during neurodegenerative diseases. Next we will 
examine the role of TNF and TNF receptor-mediated signals and their role in 
neurodegenerative diseases. 
6.1. TNF in Neural Injury and in Neuroprotection 
In 1999, Nancy J. Rothwell (Rothwell 1999) published a remarkable paper titled with the 
question: “Cytokines – killers in the brain?”. Rothwell and many others who performed a 
range of studies in different disease models and including various transgenic and knockout 
mouse models, have in fact shown that strong upregulation of pro-inflammatory cytokines 
like IL-1Ƣ, TNF, interferon-ƣ or IL-6 and others are potent triggers of damage in the brain 
which can be attributed to strong inflammatory responses [for reviews see (Wang, Asensio et 
al. 2002) and (Eisel 2002)]. For a long time a prevalent idea was therefore to consider 
inflammatory responses to be a major player in the pathological process despite well-known 
beneficial effects [(Feuerstein, Wang et al. 1997; Rothwell 1999; Chong, Shin et al. 2002) and 
others]. This was especially true for cytokines like Il-1 or TNF. TNF indeed can induce 
programmed cell death or apoptosis via TNF receptor 1 (TNFR1) and depending on the cell 
type also in conjunction with TNF receptor 2 (TNFR2) (Wajant, Pfizenmaier et al. 2003). In 
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fact there is some evidence that TNF might contribute in part to the disease process as for 
example in the abnormally processed Alzheimer protein amyloid Ƣ (AƢ)-induced neuronal 
cytotoxicity. It was shown that TNFR1 overexpressing neurons are more sensitive to AƢ-
induced toxicity when compared to TNFR1 knock-out neurons (Li, Yang et al. 2004). This 
study however ignored the well-known fact that overexpressed TNFRs have the tendency to 
participate in ligand-independent signaling. Moreover, in these studies only short term 
effects (within 60 minutes) were investigated. If we consider the model systems for brain-
ischemia or even chronic diseases, like AD, we should be aware of the fact that we talk about 
mechanisms lasting from days to several years. These are real clinical situations where disease 
exacerbating and ameliorating effects overlap. In disease models researchers, for the sake of 
clarity, try to exclude as many disturbing factors as possible and therefore look for 
immediate responses. Usually long term responses are more difficult to investigate as too 
many different parameters are involved. Yet, the time course is important or even critical, 
especially in neurodegenerative diseases. 
In 1994 the group of Mark Mattson (Cheng, Christakos et al. 1994; Bruce, Boling et al. 1996) 
published for the first time the observation that TNF can have neuroprotective effects on 
neurons treated with excitotoxic substances. Suzuki and co-workers (Suzuki, Hide et al. 
2004) showed that extracellular ATP-activated P2X7 microglia (microglia containing a 
specific subtype of ATP receptors) protect neurons against glutamate-induced toxicity 
primarily because they are able to release TNF. It was reported by some groups that under 
certain conditions TNFR1 exerts neuroprotective signaling (Carlson, Bacchi et al. 1998), 
while deletion of the TNFR1 and TNFR2 prevents cell death in motor neurons after facial 
nerve axotomy in adult mice (Raivich, Liu et al. 2002) supporting the notion that not all 
neuronal populations respond in a similar way to TNF signals. 
Several groups in recent years have provided evidence that the protective function of TNF 
in many neurodegenerative disease models like ischemia or glutamate/NMDA mediated 
excitotoxicity needs the activation of nuclear factor-NB (NF-NB) [(Barger, Horster et al. 
1995; Furukawa and Mattson 1998; Marchetti, Klein et al. 2004); for a review see (Mattson, 
Culmsee et al. 2000)] and PKB/Akt phosphorylation (Diem, Meyer et al. 2001; Fontaine, 
Mohand-Said et al. 2002; Yang, Shaw et al. 2002; Marchetti, Klein et al. 2004). Inhibition of 
base level NF-NB activation induces apoptosis in neurons (Chiarugi 2002). Similarly, TNFR 
mediated NF-NB activation is important for recovery after traumatic spinal cord injury (Kim, 
Xu et al. 2001). 
Interestingly, the protective function of TNF/TNFR mediated signaling can be extended 
also to the autoimmune disease multiple sclerosis (MS), which was proven by the disastrous 
outcome of a clinical study using soluble TNFR as TNF scavenger (1999). A likely 
explanation for this negative effect of TNF scavenging may be found in the neglect of a 
divergent action of this cytokine in MS. This conclusion of a possibly predominant beneficial 
effect of TNF is supported by recent findings in a murine experimental autoimmune 
encephalitis (EAE) model. In this study by Kassiotis and Kollias (Kassiotis and Kollias 2001) 
it was shown that TNFR2 activation by TNF is a prerequisite for recovery from the disease. 
In a toxin mediated demyelination model, another group (Arnett, Mason et al. 2001) could 
also demonstrate that TNFR2 is needed for remyelination, which is an essential feature of 
therapeutic approaches in MS. A similar picture emerged from studies with interferon ƣ 
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knock-out animals. Although interferon ƣ plays a major role as mediator for a massive 
inflammatory response in MS, it seems that at the same time it is also necessary for the 
containment of inflammation (Willenborg, Fordham et al. 1996). 
Pro-inflammatory cytokine function in brain diseases becomes even more complicated when 
different brain areas are compared. Staining for TNF or TNFR, in the mammalian brain 
reveals that different neuronal and non-neuronal cell types display different endogenous 
TNF and TNFR levels in diseased and non-diseased brain [(Fontaine, Mohand-Said et al. 
2002) Eisel, Granic, Luiten and Nyakas, unpublished observations]. In the retina, for 
example (Fontaine, Mohand-Said et al. 2002), TNF and TNFRs are mainly expressed in the 
ganglion cells of the inner plexiform layer. However, no TNF expression was present in the 
outer nuclear layer (photoreceptor containing cells), while TNFR expression was revealed in 
the outer nuclear layer in cells resembling Müller glia. TNFR specific staining was however 
only present upon exposure of the tissue to ischemic conditions with the strongest signals at 
6 hrs after ischemia but still readily detectable after 24 hrs. Photoreceptor cells of the outer 
nuclear layer therefore were not positive for either TNF or TNFR stainings. Interestingly, 
susceptibility to ischemic lesions is also reduced in photoreceptor cells, whereas those cell 
layers that are strongly positive for TNF and TNFRs showed the most prominent sensitivity 
to the ischemic conditions (Fontaine, Mohand-Said et al. 2002). From these observations 
alone one could conclude that there are differential cellular responses to cytokines like TNF. 
In fact this was recently very convincingly proven for IL-1Ƣ which in hippocampal neurons 
activates the mitogen activated protein (MAP) kinase pathway and CREB, and at the same 
time in hippocampal astrocytes activates NF-NB (Srinivasan, Yen et al. 2004). From the 
many studies on the effects of TNF on either survival or loss of neuronal cells and tissue, 
diverse views have emerged. An explanation for this seemingly contradictory outcome of the 
observed TNF effects may lie in the different protocols, cellular models, availability of tools 
but also different cellular susceptibilities due to molecular mechanisms. In the case of 
TNFRs for a long time it was difficult to differentiate between TNFR1 and TNFR2 
mediated signaling. Distinct TNFR2 mediated signals were unknown until recently and a 
differentiation in signaling pathways that started with two different TNF receptors was not 
considered as a molecular model to explain differences in TNF action on neuronal tissues. 
However, since genetically manipulated mice lacking TNFR1 and TNFR2 have become 
available together with specific agonistic antibodies against these two TNF receptors, the 
contribution of distinct signal transduction pathways in neurodegeneration and 
neuroprotection can now be investigated in vivo. 
A molecular mechanism for the regulation of TNFR2 signaling was shown in T cells 
(Pimentel-Muinos and Seed 1999). During IL-2 driven T cell proliferation, RIP, a Ser/Thr 
kinase required for NF-NB activation through TNFR1, is upregulated. In the presence of 
RIP, TNFR2 activates apoptosis, whereas in the absence of RIP, TNFR2 activates NF-NB. 
Right now it would be pure speculation to translate this mechanism of TNFR2 signal 
modulation from T cells to neurons. However, given the many similarities in signaling 
between T cells and neurons it would be tempting to test this hypothesis. 
A very special brain region in respect to its vulnerability towards TNF is the substantia nigra 
(SN), the midbrain region which harbors dopaminergic neurons innervating the striatum. 
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Loss of these dopaminergic neurons is the cause of the typical symptoms in PD. In the 
1980s taking of newly synthesized illegal drugs led to cases of severe juvenile Parkinsonian 
syndrome in some young Californians. The culprit substance was very soon found to be 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine, better known under its shorter name MPTP [see 
(Langston, Forno et al. 1999)]. Since that time researchers have used this substance for 
induction of Parkinsonian syndromes in experimental animals. The induction of Parkinson-
like symptoms by treatment of rodents with MPTP is reduced in the absence of TNF 
(Ferger, Leng et al. 2004). This is in accordance with another novel transgenic mouse model 
with inducible low and high expression of TNF in the SN. High level TNF expressing 
transgenic mice have reduced numbers of tyrosine hydroxylase positive cells in the SN (TH 
is an enzyme necessary for dopamine production) and develop Parkinson-like symptoms at 
20 to 80 days of age. Low levels of TNF, on the other hand, were overall found to be 
neuroprotective on TH positive cells of the SN when 6-hydroxy-dopamine (6-OHDA) was 
used to induce lesions (Chertoff, Di Paolo et al. 2011). In dopaminergic neurons of the SN 
increased TNF levels induce apoptosis and seem to be involved in the pathology of MPTP-
induced lesions whereas low levels of TNF appear to exert a predominantly protective action 
on SN cells. 
The retinal ischemia model serves as a highly reproducible stroke model as the retina is part 
of the CNS. In this model Fontaine and co-workers (Fontaine, Mohand-Said et al. 2002) 
could convincingly demonstrate that the dual role of TNF can be explained by the 
antagonistic functions of TNFR1 and TNFR2. Using mice deficient for TNF, TNFR1 or 
TNFR2, respectively, they found that the size of lesions upon retinal ischemia induction was 
only marginally larger in mice deficient for TNF when compared to wild type mice. Here, 
unlike the situation with MPTP-induced lesions in the SN (as explained above), TNF is 
clearly not necessary for neuronal cell death. However, mice deficient for TNFR1 showed 
strong protection against retinal ischemia, whereas mice deficient for TNFR2 proved to be 
more sensitive to ischemic insult than wild type control animals (Figure 2.). 
  
Figure 2. TNF (a-c) and TNFR (g-i) upregulation upon retinal ischemia induction. Note 
that without ischemia neither TNFR1 nor TNFR2 is detectable (g and j) (modified after 
Fontaine et al., 2002) (Fontaine, Mohand-Said et al. 2002). 
From these results it can be concluded that TNFR1 and TNFR2 have opposite effects and 
that TNF has to be considered as a reactive cytokine involved in cellular stress responses 
rather then being part of the pathological process. Interestingly, upon retinal ischemia in the 
highly protected TNFR1 deficient mice, strong phosphorylation of the protein kinase B 
(PKB/Akt) was observed, but not in wild type, TNF -, or TNFR2 deficient mice. PKB/Akt 
is a signaling molecule downstream of the phosphoinositol 3-phosphate dependent kinase 
(PI3K), which can be pharmacologically blocked by the substances wortmannin and 
LY249002. Ischemia applied in the presence of LY249002 in TNFR1 deficient mice proved 
that PKB/Akt phosphorylation is indeed necessary for TNFR2 mediated neuronal 
protection. The involvement of PKB/Akt phosphorylation in neuroprotection was observed 
earlier in other neuroprotective signaling pathways (Zheng, Kar et al. 2000; Vincent, Mobley 
et al. 2004; Wu, Zhu et al. 2004) such as in the IGF and BDNF signaling pathways. 
However, a TNFR2 dependent PKB/Akt phosphorylation was unknown up to that time 
point. 
From the experiences gathered from TNF transgenic mouse models with more general 
expression patterns in the brain before and given the fact that TNF expression in human 
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neurodegenerative diseases is rather restricted to local brain areas, we tried to improve our 
understanding of TNF function in the brain by using a cell type-restricted neuron-specific 
promoter to guide TNF expression. A transgenic mouse model (NR2B/TNF) in which TNF 
is expressed under the control of the promoter of the ionotropic glutamate receptor subunit 
NMDAR2B led to a deeper insight in TNFR2 mediated neuroprotective signals. Initially, it 
was observed that TNF expression in the cortex and hippocampus did not lead to severe 
pathology as observed in other TNF overexpressing mouse models (Campbell, Stalder et al. 
1997; Akassoglou, Bauer et al. 1998; Akassoglou, Bauer et al. 1999). However, it proved to 
be difficult to determine whether the absence of such a forebrain TNF effect should be 
attributed to a moderate TNF expression in the forebrain or to a regional cell type restricted 
expression of TNF (or a combination of both). Microglia were activated in the brain areas 
with TNF expression and the biological activity of transgenic TNF was proven. 
According to previous observations TNF and some other cytokines were thought to induce 
cell death and to be part of the pathological machinery in neurodegenerative diseases. This 
hypothesis did not hold up when wild type and NR2B/TNF transgenic neuronal cultures 
were compared for their sensitivity to glutamate. Instead of being prone to cell death, TNF 
expressing cortical neurons from NR2B/TNF transgenic mice were almost completely 
resistant to increasing doses of glutamate. In addition, NR2B/TNF neurons exhibit 
constitutively high levels of PKB/Akt phosphorylation. This neuroprotective effect could be 
mimicked in vitro by pretreatment of wild type cortical neurons with TNF followed by 
exposure to toxic doses of glutamate. Such a neuroprotective potential triggered by TNF 
pretreatment was even further enhanced in neurons from TNFR1 knock-out mice, whereas 
TNFR2 knock-out neurons were more sensitive to TNF-induced apoptosis and could not be 
protected against glutamate. From these studies we conclude that treatment of neurons with 
TNF results in resistance to excitotoxic cell death. Apparently this resistance is a result of 
TNFR2 mediated signaling which can also be demonstrated by specifically triggering TNFR2 

































































Figure 3. TNFR1 and TNFR2 mediated signaling pathways converge with NMDA receptor 
signaling on the level of PKB/Akt activation in a model of excitotoxic conditions. 
Based on the neuroprotective potential of TNF receptor-mediated signaling we explored the 
character of the downstream intracellular signaling pathway underlying this protective 
mechanism. Our studies pointed to the involvement of a PI3K dependent PKB/Akt-
mediated NF-NB activation and we were able to demonstrate that NF-NB activation is 
essential for neuroprotection. We were surprised, however, to find that NF-NB activation by 
TNFR1 offered no neuroprotection over multiple time points in the experimental setting of 
primary cortical neurons treated with glutamate plus or minus TNF pretreatment, and, even 
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more when TNFR1 and TNFR2 signaling p50 and p65 NF-NB molecules were activated. 
Apparently both TNFR1 and TNFR2 can activate NF-NB but with different cellular effects. 
This led to the question as to the basis for the difference between TNFR1 and TNFR2-
mediated NF-NB activation. It turned out that TNFR1 and TNFR2-mediated NF-NB 
activations differ strongly in their kinetics. Stimulation of TNFR1 activates NF-NB for 
roughly 1 to 3 hrs, whereas TNFR2- mediated NF-NB activation under the same conditions 
lasts for up to 24 hrs. These time differences in NF-NB kinetics could explain why TNFR2, 
unlike TNFR1, mediates neuroprotection (Marchetti, Klein et al. 2004). 
6.2. PKB/Akt and NF-NB: Important Crossroads in Neuroprotection 
Several groups have shown previously that PKB/Akt signaling in neurons is 
neuroprotective. Among the signals that induce PKB/Akt activation are insulin like growth 
factor (IGF), brain derived neuronal growth factor (BDNF) and TNF (Diem, Meyer et al. 
2001; Fontaine, Mohand-Said et al. 2002; Marchetti, Klein et al. 2004). Interestingly, besides 
neurotrophic factors the ionotropic N-methyl-D-aspartate glutamate receptor (NMDAR), a 
key player in excitotoxic signaling, also activates PKB/Akt and NF-NB (Lilienbaum and 
Israel 2003). In TNFR2-mediated neuroprotection experiments it could be shown that 
TNFR2-mediated phosphorylation of PKB/Akt and NF-NB activation is enhanced by 
NMDAR signaling (Marchetti, Klein et al. 2004). This is a significant finding in view of the 
presumed importance of glutamate in many degenerative processes. 
The most prevalent form of PKB/Akt in the brain is Akt3 (Yang, Tschopp et al. 2004) and 
it is therefore likely that Akt3 is a key player in neuroprotection. TNF mediated NF-NB 
activation via PI3K and PKB/Akt was shown to be dependent on the composition of the 
inhibitor of NB kinase complex or IKK. Cells with higher levels of the ơ form of IKK 
appear to be more responsive to PI3K induced NF-NB activation, whereas IKKơ makes 
TNF-mediated NF-NB activation less responsive to PI3K inhibitors (Gustin, Ozes et al. 
2004). In MCF-7 cells, a non-neuronal breast cancer cell line, it was shown that PI3K and 
PKB/Akt mediated NF-NB activation protects against TNF mediated apoptosis itself 
(Burow, Weldon et al. 2000). Signaling pathways are obviously highly dependent on the 
cellular and environmental circumstances. Neurons as non-proliferating cells might be 
endowed with completely different signaling pathways as compared to proliferating cells 
(Benn and Woolf 2004). A protective function of TNFR2-mediated signaling, however, 
might also be present in other tissues as was demonstrated in a mouse model in which 
overexpression of a non-cleavable murine form of membrane TNF in endothelial cells 
protected against Con A-mediated liver shock (Willuweit, Sass et al. 2001). The membrane-
bound form of TNF is the main activator of TNFR2, whereas the soluble form of TNF 
binds with much higher affinity to TNFR1 (Grell, Douni et al. 1995) and it is therefore likely 
that endothelial membrane TNF expression-mediated liver shock protection might be mainly 
mediated via TNFR2 signaling. 
In a very recent report, highly relevant for neuroprotective signaling, the point of 
transmembrane TNF signaling versus soluble TNF signaling was demonstrated to play a 
very prominent role. Wang et al. (Wang, Feuerstein et al. 2004) reported that DPH-067517-
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mediated inhibition of TACE (the Tumor Necrosis Factor-ơ converting enzyme) protected 
rats from focal brain ischemia. TACE is important for cleavage of the membrane-bound 
form of TNF and its conversion into the soluble form of TNF (therefore TACE inhibits 
conversion of TNF from a ligand for TNFR2 into the main ligand for TNFR1), Here again 
TNFR2-mediated neuroprotective signaling mechanisms proved to play a prominent role. 
How does TNF mediate PKB/Akt phosphorylation? For the time being there is no direct 
experimental physical link between TNFR1 or TNFR2 and the PI3K pathway. However, 
from various tumor cell lines it was reported that the NF-NB-inducing kinase (NIK) and 
NF-NB activated by TNF lead to downregulation of PTEN (phosphatase and tensin 
homolog deleted on chromosome ten). PTEN in turn is a strong antagonist of the 
PI3K/Akt pathway. This may lead to an autoregulatory loop which could result in a 
sustained increase in PKB/Akt and in turn NF-NB activation (Kim, Domon-Dell et al. 
2004). TNFR2-mediated NF-kB and a long lasting upregulation of PKB/Akt, as seen in 
TNF and glutamate-treated cortical neurons (Marchetti, Klein et al. 2004), could be a result 
of such an autoregulatory loop. The activation of NF-NB and PKB/Akt by NMDAR was 
described in an excellent article by Lilienbaum and Israel (Lilienbaum and Israel 2003). 
What mechanisms lead to TNF-mediated neuroprotection? Long term TNF treatment of 
hippocampal neurons was shown to have a modulatory effect on glutamate receptors 
(NMDA; AMPA, Kainate) (Tancredi, D'Arcangelo et al. 1992; Albensi and Mattson 2000). A 
great number of protective signaling molecules are known to target both PKB/Akt and NF-
NB. The list includes BAD, Bcl-X, the group of inhibitors of apoptosis proteins (IAPs) and 
other more or less specific molecules - for example, calbindin. Interestingly, Bad 
phosphorylation, described as an important anti-apoptotic signaling pathway of PKB/Akt, 
seems not to be affected in primary cortical neurons treated with glutamate and TNF 
(Marchetti, Klein et al. 2004). It is tempting to speculate that the early response in the form 
of gene transcription responding to NF-NB as seen with TNFR1-mediated signals may be 
different from a late or longer lasting response as seen with TNFR2-mediated signals. Does 
time matter here as well? 
7. NEUROINFLAMMATION, MICROGLIAL ACTIVATION AND 
NEURODEGENERATION: ADDITIONAL PATHWAYS 
In dementing disorders with mild cognitive impairment (MCI), as seen in early stage AD, 
microglial activation with cytokine production are already present (Kropholler, Boellaard et 
al. 2007; Magaki, Mueller et al. 2007). In the pathogenic pathways initiated by microglial 
activation, expression of the enzyme indoleamine 2,3-dioxygenase (IDO) may play a pivotal 
role. IDO catalyzes the first and rate limiting step in the kynurenine pathway, which is the 
major catabolic pathway for tryptophan, the precursor of the neurotransmitter serotonin 
(Takikawa 2005). The effects of IDO expression triggered by microglial mobilization are 
mainly twofold; activation of the kynurenine pathway reduces the biosynthesis of serotonin 
by decreasing the availability of tryptophan while simultaneously generating neuroactive 
intermediates, like quinolinic acid (QUIN) and 3-hydroxykynurenine, both implicated in 
neurotoxicity. Reduced availability of brain serotonin may be associated with behavioral 
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symptoms like sickness behavior and depression, and may also render neurons more 
vulnerable to excitotoxic brain damage through increased neuronal excitability (Berends, 
Luiten et al. 2005). 
In general, IDO expression in the brain can be induced by a variety of pro-inflammatory 
stimuli (O'Connor, Lawson et al. 2009). The main stimulus is the cytokine interferon ƣ 
(IFNƣ). Human and murine microglia expresses IDO after IFNƣ stimulation (Alberati-Giani, 
Ricciardi-Castagnoli et al. 1996). Neurons and astrocytes can also express IDO after IFNƣ 
stimulation, but levels are much lower than in microglia, and may fail to lead to production 
of quinolinic acid at a detectable level (Guillemin, Smythe et al. 2005). 
Other cytokines can trigger IDO expression. TNF has been shown to induce IDO release 
synergistically with IFNƣ in human macrophages (Currier, Ziegler et al. 2000). IFNƢ also 
activates IDO expression (Guillemin, Kerr et al. 2001). Non-cytokine stimuli such as LPS 
were demonstrated to induce IDO in monocytes by a mechanism independent of IFNƣ 
(Fujigaki, Saito et al. 2001). Various other pathological stimuli can also induce IDO. E.g. the 
pathogenic Alzheimer peptide AƢ1-42 can lead to up-regulation of the cellular expression of 
IDO with, as a consequence, increased quinolinic acid production (Guillemin, Smythe et al. 
2003; Guillemin, Brew et al. 2005). Furthermore elevated IDO immunoreactivity was found 
in human material from AD patients, while quinolinic acid is also implicated in the 
neuropathology of AD. 
The neurotoxic effect of IDO activation is thought to be mediated by the excitotoxicity 
exerted by the agonist action of quinolinic acid on the NMDA receptor. Indeed, quinolinic 
acid has long been used as a lesioning agent to reliably ablate specific brain areas (Schwarcz, 
Whetsell et al. 1983). These neurotoxic effects have been implicated in several 
neurodegenerative diseases including Huntington’s chorea (Estrada Sanchez, Mejia-Toiber et 
al. 2008), AD (Ting, Brew et al. 2007), stroke (Darlington, Mackay et al. 2007) and 
amyotrophic lateral sclerosis (Guillemin, Meininger et al. 2005). Quinolinic acid was shown 
to be able to directly cause apoptosis in astrocytes (Guillemin, Wang et al. 2005) and 
deregulate glutamate levels by increasing synaptic release and decreasing astrocytic uptake 
(Tavares, Tasca et al. 2002). Apoptosis is mediated by excitotoxic mechanisms, increased 
intracellular calcium concentration and deregulated energy balance, followed by oxidative 
stress and cell death (Foster, Collins et al. 1983). The intermediate metabolite 3-
hydroxykynurenine is neurotoxic through oxidative stress (Okuda, Nishiyama et al. 1996), 
while kynurenic acid, the other major metabolite of the IDO cascade, functions as an 
NMDA receptor antagonist (Swartz, During et al. 1990) that can counteract quinolinic acid-
mediated excitotoxicity and has been described as neuroprotective in ischemia (Gigler, 
Szenasi et al. 2007). 
8. NEUROINFLAMMATION: CAN INFLAMMATION LEAD TO 
IMPROVEMENTS IN DIAGNOSIS AND TREATMENT OF 
NEURODEGENERATIVE DISEASES? 
Apart from its direct effects on neuronal cell death and neuronal survival, newly disclosed 
findings also point to unsuspected indirect pathways that link inflammatory mechanisms to 
neuronal functioning. In this respect we pay specific attention to the interaction between 
neuroinflammatory mediators and serotonergic neuronal processes and its possible 
44 
consequences for the development of neuronal damage in neurodegenerative diseases like 
cerebral ischemia, PD and AD. 
It has been known for more than two decades, that exposure to cytokines, such as IFNƣ, 
leads to strong activation of indoleamine 2,3-dioxygenase (IDO), the rate limiting enzyme in 
the L-tryptophan-kynurenine pathway (Takikawa, Kuroiwa et al. 1988). High IDO activity 
converts L-tryptophan to kynurenine and in this way depletes cells in the nervous system of 
L-tryptophan, the essential precursor for synthesis of the neurotransmitter serotonin or 5-
hydroxytryptamine (5-HT). Cerebral ischemia, and probably many other neurodegenerative 
conditions can lead (Farkas, Donka et al. 2004), via activation of microglia, to IDO 
expression and in this way to 5-HT depletion. More recent studies have now provided 
compelling evidence that TNF in particular is a potent activator of IDO (Fujigaki, Saito et al. 
2001) and via this pathway may link innate neuroinflammatory mechanisms to loss of 5-HT. 
With 5-HT depletion the brain loses one of its endogenous neuroprotective transmitter 
systems as evidenced by our demonstration of the neuroprotective efficacy of 5-HT1A 
agonists in ischemic stroke experiments (Harkany, Mulder et al. 2001; Oosterink, Harkany et 
al. 2003). In line with this sequence of events, TNF and its receptor systems can indirectly 
play a causal role in depletion of 5-HT as an endogenous biological protective mechanism, 
and may become an unexpected additonal target for neuroprotective therapy. In this respect 
it was a striking recent finding that we could visualize high levels of IDO immunoreactivity 
in post-mortem brain samples from AD patients, localized in microglia in and near amyloid 
plaques in cortex and hippocampus. Ongoing studies on this brain material are now focusing 
on the interactions between microglial activation, high IDO expression and 5-HT 
concentrations in this neurodegenerative disease. 
The data provided here can give no more than a partial overview of the rich research topic 
of neuroinflammation in degenerative diseases. The data presented were selected to stress 
specific points in neuroinflammation: 
Firstly, neuroinflammation gives us new and exciting opportunities for development of 
better diagnostic tools in neuroimaging. This is important in diseases, like AD and other 
neurodegenerative syndromes that can only be firmly diagnosed at present on post-mortem 
tissue. Neuroinflammation may also once it gives rise to more precise diagnostic analyses of 
clinical patients, permit more straightforward therapeutic approaches. 
Secondly, there is a question to be resolved. Is the innate immune system part of the 
problem or part of the solution in the pathogenesis of neurodegenerative diseases, such as 
stroke, AD or PD. We argue that the protective signaling pathway of TNFR2 opens the road 
to new concepts in the development of neuroprotective drugs. Agonists triggering TNFR2-
mediated responses should be considered as well as antagonists that block TNFR1 function. 
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ABSTRACT 
TNFơ plays important functional roles in the central nervous system during normal 
physiological circumstances via intricate signaling mechanisms between its receptors, TNF 
receptor 1 (TNFR1) and TNF receptor 2 (TNFR2). Although the roles of TNFR1 and 
TNFR2 in the diseased brain have received considerable attention, their functions on 
behavior and cognition in a non-inflammatory physiological aged environment are still 
unknown. In the present study we investigated the functional roles of TNFR1 and TNFR2 
in learning and memory, motor performance and anxiety-like behavior via several behavioral 
and cognitive assessments in young and aged mice, deficient of either TNFR1 or TNFR2. 
Results from this study show that deletion of TNFR2 impairs novel object recognition, 
spatial memory recognition, contextual fear conditioning, motor performance and can 
increase anxiety-like behavior in young adult mice. Concerning the functions of TNFR1 and 
TNFR2 functioning in an aged environment, age caused memory impairment in spatial 
memory recognition independent of genotype. However, both young and aged mice 
deficient of TNFR2 performed poorly in the contextual fear conditioning test. These mice 
displayed decreased anxiety-like behavior, whereas mice deficient of TNFR1 were 
insusceptible to the effect of aging on anxiety-like behavior. This study provides novel 
knowledge on TNFR1 and TNFR2 functioning in behavior and cognition in young and aged 
mice in a non-inflammatory physiological environment. 
KEYWORDS: Aging; Cognition; Anxiety; Behavior; Novel object recognition; Spatial 
recognition memory; Contextual fear conditioning 
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1. INTRODUCTION 
Tumor necrosis factor alpha (TNFơ) exerts a broad range of biological functions in the 
nervous system via its two receptors; tumor necrosis factor ơ receptor 1 (TNFR1) and tumor 
necrosis factor ơ receptor 2 (TNFR2) (Wajant, Pfizenmaier et al. 2003; Naude, den Boer et 
al. 2011). TNFR1-induced signaling initiates the production of pro-inflammatory factors and 
can induce a pro-apoptotic environment in neuronal tissue, whereas TNFR2 stimulation 
promotes neuronal survival (Fontaine, Mohand-Said et al. 2002). TNFơ and its receptors 
have attracted mounting interest regarding their physiological functions in the nervous 
system on cognition, behavior, neurogenesis of the developing brain and maintenance of 
neuroplasticity and their roles in the pathology of neurological diseases (Sriram and 
O'Callaghan 2007; McCoy and Tansey 2008; Clark, Alleva et al. 2010). 
Aging is a biological process characterized by time-dependent functional declines, influenced 
by numerous environmental and physiological factors. A dysregulation of the innate and 
adaptive immune system is hypothesized as a prominent key player in the aging process 
which is accompanied by increased inflammatory cytokines, in particular TNFơ (Corona, 
Fenn et al. 2011). TNFơ and its receptors have been investigated extensively in aged-
associated chronic brain diseases (Mogi, Harada et al. 1994; Paganelli, Di Iorio et al. 2002; 
Clark, Alleva et al. 2010; Baune B. 2012). However, studies concerning their roles in the 
healthy aged brain are sparse. It has been shown that ageing can contribute to impaired 
neuronal TNFơ receptor expression in vitro (Patel and Brewer 2008), and in vivo hippocampal 
TNFR2 is decreased in aged (22 months) rats (Sama, Mohmmad Abdul et al. 2012). The 
roles of TNFR1 and TNFR2 on cognition and behavior have been described in young adult 
TNFR1 or TNFR2 knockout mice concerning their effect on anxiety-like behavior (Simen, 
Duman et al. 2006; Quintana, Molinero et al. 2007), memory performance (Baune, Wiede et 
al. 2008) and depressive-like behavior (Simen, Duman et al. 2006). However, the effect of an 
aged physiological environment on TNFR1 and TNFR2 mediated functioning in behavior 
and cognition is still unclear. A recent study showed that administering an anti-TNF 
biologic, that preferentially inhibits TNFR1 signaling, to aged (22 months) rats led to 
improved memory performance in the Morris Water Maze test (Marques, Mesquita et al. 
2012). These studies indicate that age can play an important role on TNFơ receptor 
functioning during non-pathological aging. The aim of this study is to investigate the effect 
of an aged non-inflammatory physiological environment on TNFR1 and TNFR2 mediated 
effects on cognitive, behavioral, and motor functioning via various behavioral assessments in 
young adult and aged WT, TNFR1-/- and TNFR2-/- mice. 
2. MATERIALS AND METHODS 
2.1. Animals 
TNFR1-/- (Rothe, Lesslauer et al. 1993) and TNFR2-/- (Lucas, Juillard et al. 1997) mice were 
initially acquired from Horst Bluethmann (Hoffmann-La Roche, Basel, Switzerland). 
Genotyping of TNFR1-/- mice was performed using PCR with primers TNF-R1–2883 5Ȩ-
CTCTCTTGTGATCAGCACTG-3Ȩ and Neo-34 5Ȩ-CCCGCTTCAGTGACAACGTC-3Ȩ, 
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resulting in a 1 kb PCR product for the detection of the TNFR1-/- null allele, and TNFR1–
2883 and TNFR1–4938 5Ȩ-AGAAATCTCAAGACAATTCTCTGC-3Ȩ, resulting in a 500 bp 
fragment for the wild-type allele. Genotyping of the TNFR2-/- mice was performed similarly 
as for TNFR1-/- mice using TNFR2-A primer 5Ȩ-CCTCTCATGCTGTCCCCGGATT-3Ȩ and 
Neo- IL4 5Ȩ-GCGCATCGCCTTCTATCGCC-3Ȩ, resulting in a PCR product of 700 bp for 
the detection of the TNFR2 null allele, and TNFR2-A and TNFR2-B 5Ȩ-
AGCTCCAGGCACAAGGGCGGG-3Ȩ, resulting in a 300 bp fragment for the wild-type 
allele. All mice were kept in a C57Bl/6 background. 
TNFR1 and TNFR2 knockout animals were bred in-house and WT animals were obtained 
from Harlan laboratories, The Netherlands. All animals were housed in the same room at the 
animal research facility of the Department of Molecular Neurobiology, at least a month 
before behavioral experiments were conducted. Animals were individually housed (home 
cage dimensions, height; 135 mm, width; 150 mm and length; 330 mm) under normal 
laboratory conditions (air-conditioned, 21±2qC), humidity-controlled room (§50%), 12/12 h 
light/dark cycle (light on from 08:00-20:00). Autoclaved wood shavings were used as home 
cage bedding. Food and water were available ad libitum. All animal experiments were 
approved by the animal ethical committee of the University of Groningen (DEC, application 
number; 4408C). Animals used for this study were closely monitored for any signs of 
pathology and inflammatory reactions. Home cage locomotor activity test was performed in 
15 months old TNFR1-/- (n=7), TNFR2-/- (n=6) and WT (n=5) control mice. Elevated plus 
maze, spontaneous alternation test, recognition memory and spatial memory test, balance 
beam, wire-hanging, contextual fear conditioning test were conducted on 3 months old 
(indicated as “young” animals in this study) TNFR1-/- (n=10), TNFR2-/- (n=10) and WT 
(n=10) control mice and concurrently in separate 22 months old (indicated as “aged” 
animals in this study) TNFR1-/- (n=10), TNFR2-/- (n=10) and WT (n=10) control mice, all 
of the C57Bl/6 strain. 
2.2. Behavioral test procedures 
All of the behavioral tests were performed in the same room adjacent to the room where the 
animals were housed. Experimental results were performed and evaluated by two raters. 
Since most tests were evaluated visually, all of the animals were provided with a randomized 
code and one of the two raters was blind to the genotype of the animals in order to 
minimize biased observation. Mean values of the blinded rater and non-blinded rater were 
used. After each test mice were given at least 1 week to recover. Tests were performed in the 
following sequence; elevated plus maze, spontaneous alternation test, recognition memory 
and spatial memory test, balance beam, wire-hanging, and contextual fear conditioning test. 
Testing sequence was planned according to the burdensome of an experimental procedure 
by starting with the least burdensome tests in order to minimize effects of stressful events on 
subsequent testing procedures (Figure 1). Home cage activity test was performed in a 
separate group of animals. Home cage bedding was also not replaced at least 2 days prior any 
of the experimental procedures performed. 
 
Figure 1. Graphical description of the sequence in which experiments were performed with 
respective time intervals between the indicated experiments. 
2.2.1. Home cage activity test 
Mice were tested individually over a 1-week period under non-stressful conditions to assess 
general locomotor activity. Each home cage was equipped with an overhead infrared sensor, 
which connected to a computer to register locomotor activity. 
2.2.2. Elevated plus maze test 
The elevated plus maze test was used to measure anxiety-related exploration. Mice were 
placed in the center of a plus-shaped maze that was elevated at 60 cm above the ground. 
Two arms opposite each other were enclosed and the other two served as the open arms 
without walls. Mice were allowed to explore the maze freely for eight minutes. Transitions 
were scored as the mice moved from one arm to the other. Arm entry was considered to be 
complete when the mouse had placed at least three paws in the arm. Furthermore, the total 
amount of time spent in the center zone, dark arms or open arms were recorded visually 
(Rodgers, Cao et al. 1997). 
2.2.3. Spontaneous alternation test 
Short-term spatial memory performance as an expression of working memory was 
investigated by recording spontaneous (since it is not reinforced) alternation behavior in a Y-
maze paradigm. The test was performed in a symmetrical, transparent plastic tubular Y 
maze. Mice were placed in a Y maze for eight min and the entrances chosen were recorded. 
Arm entry was considered to be complete when the mouse had placed at least three paws in 
the arm. The series of arm entries was recorded visually. Percentage alternation is the 
number of triads containing entries into all three arms divided by the maximum possible 
alternations (the total number of arms entered minus 2) X 100 (Lalonde 2002). 
2.2.4. Recognition memory and spatial memory test 
Novel object recognition and spatial recognition tests were carried out to investigate 
memory performance for subtle visual cues. The test is based on the assumption that 
rodents explore a novel object more than a familiar one but only if they remember the 
familiar object. The recognition memory and spatial memory task was performed as 
described (Williams, Herring et al. 2007) with modifications. The test was conducted in a 
circular shaped arena (80 cm in diameter and 40 cm in height) on three consecutive days. An 
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overhead camera was used to record the animal’s behavior for subsequent analysis. Prior to 
the start of testing, animals individually received one habituation session where they were 
allowed to explore the arena for 10 min (day 1). During the sample phase (day 2), each 
animal was allowed to explore two identical non-transparent black glass objects with the 
same shape and size that were placed in a symmetrical position 10 cm away from the barrier. 
On the following day (day 3) the mouse was returned to the arena that now contained a 
newly introduced non-transparent black glass object with a different shape and an identical 
copy of the object previously seen during the sample phase. Again the animal was allowed to 
explore for 10 min with the same fixed location as day 2. On the last day of the test (day 4) 
the novel object was moved 90° to another location in the arena that the animal again was 
allowed to explore for 10 min. Exploration of the objects was scored when the mouse's nose 
was oriented within one cm toward the object and its vibrissae were moving (Clark, Zola et 
al. 2000). The exploratory preference was expressed as the ratio of the time spent exploring 
the novel object over that spent on the two objects. The entire arena and all of the objects 
were cleaned with 95% ethanol (and completely dried) before another mouse was tested. 
2.2.5. Balance beam test 
The balance beam test was used to assess motor coordination and balance of mice. Mice 
were placed 100 cm from a safety platform on an 11 mm thick square wooden beam that 
was 50 cm above surface level. Each animal was given three trials during a single day of 
testing. Measurement was taken during the last trial. Latency was measured by the time taken 
to reach the platform and used as an indicator of the mice’s motor functioning. 
2.2.6. Wire-hanging test 
The wire-hanging test is based on the animal’s prehensile reflex and refers to an animal's 
ability to grasp a horizontal wire with its forepaws and to remain suspended. The test is used 
to measure the motor function and deficits of rodents. A metal wire 80 cm in length was 
placed horizontally between two vertical bars at a height of 50 cm. The mice were brought 
close to the wire by the experimenter until they could grasp it with their front paws; they 
were then let go. The time they could hang on and their hanging method was recorded and 
used as a measure for their motor functioning and scoring was performed as described by 




0 Fell off the wire within the first 30 seconds 
1 Held on to the wire for more than 30 seconds 
2 Held on to the wire with four paws for at least 5 seconds 
3 Held on to the wire with four paws and able to place tail on the wire for at least 
30 seconds 
4 Held on with four paws, able to get tail on, and traveled along the wire in either 
direction for at least 5 seconds 
5 Traveled to one of the vertical points within the 30-sec test period 
 
Table 1. Scoring criteria for assessment of the wire-hanging test 
2.2.7. Contextual fear conditioning 
Freezing response upon an unconditioned stimulus, like a mild foot shock, is measured. 
Mice were individually put into a transparent cage with metallic bars at the bottom, through 
which mild electric shocks could be applied. Mice were put in the cage and left to explore 
freely. After 3 minutes an electrical shock of 0.7 mA was administered for two seconds. Mice 
remained in the cage for an additional 30 seconds after the shock was given. Mice were 
placed in the same chamber 24 hours later and their freezing behavior was observed for 
three minutes, in the absence of a shock. To measure their recollection of the shock, freeze 
response was scored for every 10 seconds. Total amount of freezing is expressed in 
percentage of time (Chen, Kim et al. 1996). 
2.3. Statistical analysis 
Differences among multiple means were assessed, as indicated, by one-way or two-way 
analysis of variance (ANOVA), followed by a Bonferroni test performed with GraphPad 
Prism version 5.0 for Windows. Differences between two means were assessed by paired 
Student’s t test. Data are presented as a mean value ± the standard error of the mean 
(S.E.M.). 
3. RESULTS 
Results are ordered according to their relevant assessments as follows; learning and memory 
(spontaneous alternation, novel object and spatial memory, and contextual fear 
conditioning), motor performance (balance beam and wire hanging), and anxiety-like 
behavior (elevated plus maze). 
3.1. Home cage activity test 
General home cage locomotor activity was assessed under normal housing conditions as 
previously described in this manuscript. These measures were performed to control for 
altered locomotor activity associated with genotype that might affect performance in most of 
the experimental assessments. No significant differences were found in movement activity 
(number of running wheel revolutions) in between WT vs. TNFR1-/-, WT vs. TNFR2-/- and 
TNFR1-/-vs. TNFR2-/- mice (Table 2). These results are in accordance with previous studies 
(Simen, Duman et al. 2006; Baune, Wiede et al. 2008). 
Table 2 
 Detections S.E.M. Group differences p-values 
WT 2756 214 TNFR1-/- vs. wild type 0.24 
TNFR1-/- 3523 463 TNFR2-/- vs. wild type 0.89 
TNFR2-/- 2803 230 TNFR1-/- vs. TNFR2-/- 0.19 
 
Table 2. Home cage activity test 
3.2. Spontaneous alternation 
Short-term memory was measured with the Y maze spontaneous alternation test in young 
and aged WT, TNFR1-/- and TNFR2-/- mice. No significant differences between the young 
WT vs. TNFR1-/-, WT vs. TNFR2-/-, and, TNFR1-/- vs. TNFR2-/- were observed. No 
differences were observed between these groups in the aged mice (Table 3). Aging did not 
have an effect on short term memory performance between any of the experimental groups. 
Aged WT mice had nevertheless significantly fewer entries into the arms of the Y maze 
compared to the young WT mice (Table 3). 
Table 3 























8 27.6±1.4 31.2±1.7 22.7±1.9
a 25.4±2.2 32.6±2.2 
 
ap<0.05, aged wild type to young wild type. 
 
Table 3. Spontaneous alternation test 
3.3. Novel object recognition and spatial memory 
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Equal amount of interactions (~50%) to both introduced objects were observed in all of 
experimental groups (Figures 2A, 2B, 2D, and 2E), indicating that the animals did not have a 
preference to a particular object introduced to the arena. A significant greater interest in the 
novel introduced object was observed in the young WT and TNFR1-/- mice, whereas no 
difference was observed in young TNFR2-/- animals. Further analysis revealed a significant 
difference in novel object recognition ability between WT, TNFR1-/-, and TNFR2-/- mice 
when the interaction of genotype and age was investigated (Figure 2A). In the aged animals, 
only WT animals showed a significant greater interest to the novel object (Figure 2B). No 
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effect of aging was found in the novel object recognition test between the young and aged 
WT, TNFR1-/- and TNFR2-/- mice, indicating that TNFR2-/- mice displayed reduced novel 
object recognition memory compared to WT and TNFR1-/- mice (Figure 2C). However, 
further analysis for the interaction of age and genotype in the novel object recognition task 
revealed a significant difference between WT, TNFR1-/-, and TNFR2-/- mice (Figure 2C). 
Young WT, TNFR1-/- and TNFR2-/- mice all had significant more interactions with the 
relocated object (Figure 2D). Analysis for the interaction of age and genotype in the spatial 
recognition task revealed a significant difference between young WT, TNFR1-/-, and 
TNFR2-/- mice, indicating that young TNFR2-/- mice displayed reduced spatial memory 
performance compared to WT and TNFR1-/- mice (Figure 2D). Aged WT, TNFR1-/-, and 
TNFR2-/- mice did not display more interest to the spatially relocated object (Figure 2E). 
Aged WT, TNFR1-/-, and TNFR2-/- mice performed significantly worse in the spatial 
memory test compared to their respective younger counterparts (Figure 2F). The total 
mobility was determined by the% of time mice were mobile over all three days. No 
significant differences in the% of mobility between young WT, TNFR1-/- and TNFR2-/- and 
young mice vs. their aged genotype was observed (Figure 2G). 
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Figure 2. The effect of aging and TNF receptors on novel object recognition and 
spatial memory. Data are expressed as ratio of interactions with new object compared to 
object that served as invariable. Ratio of interactions spent with newly introduced object in 
(A) young adult WT, TNFR1-/- and TNFR2-/ and (B) aged WT, TNFR1-/- and TNFR2-/- 
mice. (C) Comparison of novel object recognition between young and aged WT, TNFR1-/- 
and TNFR2-/- mice. Spatial memory recognition performance (D) between young adult 
WT, TNFR1-/- and TNFR2-/ mice and (E) aged WT, TNFR1-/- and TNFR2-/ mice. (F) 
Difference between young and aged WT, TNFR1-/- and TNFR2-/- mice in spatial memory 
recognition performance. (G) Mobility is expressed as% of movement in young and aged 
WT, TNFR1-/- and TNFR2-/- mice. Error bars indicate the standard S.E.M. (*p < 0.05, ** 
p < 0.001, *** p<0.0001). Two-way ANOVA revealed a significant interaction between 
novel object recognition index and genotype in young mice (a, F(2.53) = 3.72, p = 0.03). 
Two-way ANOVA also revealed a significant interaction between age and genotype in the 
novel object recognition test (b, F(2.54) = 4.46, p = 0.016). Two-way ANOVA revealed a 
significant interaction between spatial recognition index and genotype in young mice (c, 
F(2.54) = 3.42, p = 0.04). 
3.4. Contextual fear conditioning 
Young TNFR2-/- exhibited a significant reduced freezing response compared to the young 
WT and TNFR1-/- mice (Table 4). The same effect was also observed in aged mice where 
aged TNFR2-/- mice displayed a significant impaired freezing response compared to the aged 
TNFR1-/- and aged WT mice (Table 4). 
 
Table 4 
 Young animals Aged animals  
 

















conditioning       
Freeze response 
(%) 50.0±3.4 43.8±5.9 25.9±3.6
a,b 56.8±5.1 48.8±3.9 22.2±4.7c,d
Balance beam       
Crossing time (sec) 11.3±0.8 8.9±0.7 8.4±1.0 29.2±6.2e 24.0±4.0f 32.9±7.2g
Wire-hanging       
Score (out of 5) 4.2±0.4 4.3±0.3 2.2±0.7h,i 0.7±0.3 0.2±0.2 0.4±0.3 
 
ap<0.001, young TNFR2-/- to young wild type; 
bp<0.05, young TNFR2-/- to young TNFR1-/-; 
cp<0.0001, aged TNFR2-/- to aged wild type; 
dp<0.001, aged TNFR2-/- to aged TNFR1; 
ep<0.05, aged wild type to young wild type; 
fp<0.05, aged TNFR1-/- to young TNFR1-/-; 
gp<0.0001, aged TNFR2-/- to young TNFR2-/-; 
hp<0.05, young TNFR2-/- to young wild type; 
i p<0.05, young TNFR2-/- to young TNFR1-/-. 
Table 4. Balance beam, wire-hanging and contextual fear conditioning test 
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3.5. Balance beam 
Young WT, TNFR1-/- and TNFR2-/- mice passed the balance beam at an equal speed 
(Table 4). No significant differences between aged WT, TNFR1-/- and TNFR2-/- mice 
were found for time of crossing. Aging significantly increased the latency of the WT, 
TNFR1-/- and TNFR2-/-mice to cross the beam when compared to their younger 
counterparts (Table 4). 
3.6. Wire-hanging 
Young TNFR2-/- mice performed significantly worse compared to young WT mice and 
TNFR1-/- mice in the wire-hanging test (Table 4). Because all of the aged mice performed 
poorly, no significant differences between the aged groups were observed (Table 4). Of note, 
no significant differences in body weights between groups were observed. 
3.7. Elevated plus maze 
The elevated plus maze test was performed in order to determine anxiety-like behavior. All 
mice spent more time in the dark than in the light, or the center of the maze. In the young 
group, it was observed that young TNFR2-/- mice spent significantly more time in the dark 
arms and less time in the center, compared to young WT control mice (Figure 3A). 
Interestingly, aged TNFR1-/- and TNFR2-/- mice on the other hand, spent significantly less 
time in the dark arms of the maze and more time in the center of the maze compared to 
aged WT mice (Figure 3B). Aged WT control mice spent significantly less time in the light 
and center arm and more time in the dark arms compared to the young WT control mice. 
No affect was observed between young and aged TNFR1-/- mice. Aged TNFR2-/- mice 
spent significantly less time in the dark arm and more time in the center compared to young 
TNFR2-/- mice (Figure 3C). Interestingly, a significant difference of time spent in the dark 
and center was observed between WT, TNFR1-/-, and TNFR2-/- mice when the interaction 
of genotype and age was investigated (Figure 3C). Aged WT mice exhibited significantly less 
activity assessed by number of entries into the arms of the maze compared to young WT 
controls. Young and aged TNFR1-/- mice did not display differences in number of entries. 
Aged TNFR2-/- mice had significantly more entries than their younger counterparts (Figure 
3D). Further analysis indicated a significant interaction of age and genotype on the number 
of entries between WT, TNFR1-/- and, TNFR2-/- mice (Figure 3D). 
 
 
Figure 3. Evaluation of anxiety-like behavior in the elevated plus maze using (A) 
young adult and (B) aged WT, TNFR1 -/- and TNFR2-/- mice. (C) Comparison between 
young adult and aged mice in anxiety-like behavior. (D) The number of entries into 
individual arms of the plus maze of all groups tested. Error bars indicate S.E.M. (*p < 0.05, 
** p < 0.001, *** p<0.0001). Two-way ANOVA revealed a significant interaction between 
age and genotype (a, F(2.41) = 10.62, p = 0.0002; b, F(2.41) = 11.95, p < 0.0001; c, F(2.41) = 13.74, 





Table. Summary of behavioral phenotypes. Table represents young adult TNFR1-/- and 
TNFR2-/- mice compared with young adult mice and old animals compared with young 
adults of their respective genotype. ȹ, represent increased behavioral phenotype relative to 
the behavioral test (ȹ, p<0.05; ȹȹ, p<0.001, ȹȹȹ, p<0.0001). Ȼ represent decreased 
behavioral phenotype relative to the behavioral test (Ȼ, p<0.05; ȻȻ, p<0.001, ȻȻȻ, 
p<0.0001). a, young adult TNFR2-/- mice had impaired novel object recognition compared 
with young adult wild type and TNFR1-/- mice, determined by two-way ANOVA analyses 
for interaction between novel object recognition index and genotype (p=0.03). b, young 
adult TNFR2-/- mice had impaired spatial recognition compared with young adult wild type 
and TNFR1-/- mice, determined by two-way ANOVA analyses for interaction between novel 
object recognition index and genotype (p=0.016). 
4. DISCUSSION 
The goal of this study was to determine if a non-inflammatory, aged physiological 
environment alters TNFR1 and TNFR2 dependent functioning in behavior and cognition. 
This was determined via a behavioral approach, assessing several behavioral and cognitive 
tasks in young adult and aged WT, TNFR1-/- and TNFR2-/- mice. No differences in home 
cage locomotor activity were found between WT, TNFR1-/- and TNFR2-/- mice which is in 
accordance with previous studies (Simen, Duman et al. 2006; Baune, Wiede et al. 2008). 
Therefore, results from the behavioral tests performed in this study were not affected by 
alterations in activity due to genotype during testing as opposed to results under home cage 
 Behavioral test Wild type TNFR1-/- TNFR2-/-Age group 
Young 
dult a
Control group 0 0 Spontaneous 
alternation (working 
memory Old 0 0 0 
Young 
adult 
Control group 0 ȻaNovel object 
recognition 
Old 0 0 0 
Young 
adult 
Control group 0 ȻbSpatial recognition 
Old ȻȻȻ ȻȻȻ ȻȻȻ 
Young 
adult 








Old 0 0 0 
Young 
adult 
Control group 0 0 Balance beam 
Ȼ ȻȻ ȻȻ Old 
Young 
adult 





ȻȻȻ ȻȻȻ ȻȻȻ Old 
Young 
adult 
Control group 0 ȹȹ Anxiety-like 
behavior 
Elevated plus maze 
(anxiety-like behavior) 
ȹȹȹ 0 Old Ȼ 
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and unchallenged condition. Of note, studies have shown that TNFR1 can have detrimental 
effects on memory and neuronal survival (Shen and Pervaiz 2006; He, Zhong et al. 2007). 
The functions induced by TNFơ signaling are complex and is highly dependable on the 
environment in which it occurs. In this manuscript, experiments were performed in TNFR1-
/- and TNFR2-/- mice that were not subjected to any disease or injury. Some caution should 
be taken when interpreting our findings, since these animals were born with a permanent 
lack of either TNFR1 or TNFR2. This might contribute to adaptive processes during aging. 
Therefore pharmacological approaches to antagonize either TNFR1 or TNFR2 or inducible 
TNFR1 and TNFR2 animal knockout models will be a sensible approach to further verify 
our data. 
The main findings of this study are summarized as follows (see Table 5): (1) Memory 
functioning; TNFR2 may play an important function in novel object-, spatial-memory and 
contextual fear conditioning test in younger animals. Recognition ability in novel object 
recognition and contextual fear conditioning decreased in aged animals independent of 
genotype. Thus, age did not have a genotype-specific effect on memory dependent 
functioning. (2) TNFR2 may play an important role in muscular functioning in young adult 
mice, observed in the wire hanging task. Furthermore, (3) anxiety-like behavior; young adult 
TNFR2-/- mice displayed increased anxiety-like behavior compared to young WT and 
TNFR1-/- mice, whereas old TNFR2-/- mice had decreased anxiety-like behavior compared 
with old WT and TNFR1-/- mice. 
Learning and memory 
This study shows that young TNFR2-/- mice display impaired performance compared to the 
young WT and TNFR1-/- mice in the novel object recognition test. Findings from this study 
are not in accordance with a previous study by Baune and co-workers, showing that TNFR1-
/- and TNFR2-/- (8-12 weeks of age) mice did not exhibit significant learning deficits in the 
novel object recognition task compared to WT mice (Baune, Wiede et al. 2008). In the aged 
animals, WT mice spent a significant amount of time with the newly introduced object, 
whereas the same trend was observed in aged TNFR1-/- and TNFR2-/-. Our data indicate 
that the aged WT, TNFR1-/- and TNFR2-/-animals did display impaired novel object 
recognition compared to their respective younger counterparts. With respect to the WT 
animals, our finding is in accordance with a previous study that illustrated that C57BL/6 
mice with similar ages used as the current study did not display age-associated impairment in 
the novel object recognition test (Vaucher, Reymond et al. 2002). 
In the spatial memory assessment (spatial object recognition), young TNFR2-/- mice, 
similarly to the novel object recognition test, displayed spatial memory impairments 
compared to young WT and TNFR1-/- mice. A study by Baune reported that TNFR1-/- and 
TNFR2-/- mice of 8-12 weeks of age displayed impaired recognition ability in a spatial 
recognition compared to WT animals tested with the Barnes Maze [15]. However, the 
variance outcomes of our results as opposed to that reported by Baune might be due to the 
different experimental methodologies used. Aged WT, TNFR1-/- and TNFR2-/-mice showed 
impaired spatial memory recognition compared to their younger correspondent genotypes. 
This may be indicative as a result of aging and not genotype. Our data are in accordance with 
other studies, in which age related hippocampal changes have been associated with age-
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related spatial memory impairment (Begega, Cienfuegos et al. 2001; Havekes, Abel et al. 
2011; Klencklen, Despres et al. 2012). 
Aged animals did not display deficits in retention of memories for contextual fear 
conditioning. This finding is in agreement with a previous study that showed that aged 
C57BL/6 mice did not display impaired memory performance for contextual fear 
conditioning (Gould and Feiro 2005). Both young and aged TNFR2-/- animals displayed 
deficits in retention of memories for contextual fear conditioning. Our findings contradict 
that of a previous study, showing that young adult TNFR1-/- but not TNFR2-/- displayed 
impaired freezing response in a fear conditioning test [14]. The results showing that both 
young and aged TNFR2-/- mice displayed deficits in retention of memories for contextual 
fear conditioning indicate that the absence of TNFR2 and not age causes impaired memory 
performance in the contextual fear conditioning test. TNFR2 may play a role in amygdala-
mediated functioning independent on the effect of aging since memory of the contextual 
fear conditioning test is dependent hippocampus and amygdala brain regions (Eichenbaum 
1996; Raineki, Holman et al. 2010; Orsini, Kim et al. 2011). 
Results from our study supports that the absence of TNFR2 or sole presence of TNFR1 can 
impair learning and memory. TNFơ receptors may play important functional roles in 
neuronal development and maintenance. TNFR2 is important in neurogenesis and cell 
proliferation, while activation via TNFR1 is the responsible factor of TNFơ for negative 
regulation of neurogenesis in the adult hippocampus (Iosif, Ekdahl et al. 2006). Zhang and 
colleagues showed in mice that increased TNFơ expression in the thalamus is already present 
during early processes of aging and is mainly produced by microglia (Zhang, Li et al. 2013). 
Soluble TNFơ have been proposed to play a role in microglia-neuron crosstalk that can 
contribute to neuronal aging (Sama, Mohmmad Abdul et al. 2012; Zhang, Li et al. 2013). The 
effect of TNFR1 may be increased since increased TNFR1 have been observed in the 
hippocampus of aged rats (Sama, Mohmmad Abdul et al. 2012). In this regard, a study by 
Sama and colleagues showed that administration of a soluble dominant negative TNFơ, that 
preferentially inhibits TNFơ\TNFR1 signaling, improved learning and memory in aged rats 
(Sama, Mohmmad Abdul et al. 2012). It would therefore be reasonable to expect that the 
aged TNFR1-/- mice in this study would have shown improved learning and memory 
performance. However, aged TNFR1-/- mice exhibited similar cognitive performance than 
the aged WT mice. This finding might be a result of a mechanistic adaptation during the 
course of aging due to the absence of TNFR1 since birth of these mice. 
Normal and pathological aging is associated with learning and memory deficits, and a decline 
in working memory has been shown in several animal and human studies (Lamberty and 
Gower 1992; Mendelsohn and Larrick 2011; Wang, Gamo et al. 2011). We did not observe 
these age-related changes to working memory between any of our groups, measured with the 
spontaneous alternation test. Our finding with mice of 22 months of age can be explained by 
a study by Da Silva, showing that working memory was not affected in aged mice younger 
than 25 months (Da Silva Costa-Aze, Dauphin et al. 2011). 
Motor performance 
Aging is not only associated with learning and memory impairment but also with motor 
dysfunction (Dean, Scozzafava et al. 1981). The motor performance deficit in elderly can be 
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the result of nervous system or of neuromuscular impairment or both (Seidler, Bernard et al. 
2010). The prefrontal cortex, basal ganglia and cerebellum are the main control regions for 
motor function, and in particular the frontal cortex and basal ganglia are prone to aging 
effects (Seidler, Bernard et al. 2010). We did not find any significant differences between the 
young WT and TNFR1-/- or TNFR2-/- animals in the balance beam test. However, aging had 
a significant effect on coordination skills in all three groups tested. 
Muscular strength of the animals was tested in the wire-hanging test. Young TNFR2-/- mice 
performed significantly worse in this test compared to WT or TNFR1-/- mice. This finding 
may be explained by the specific functions of TNFơ and its receptors in skeletal muscle. 
Both TNFR1 and TNFR2 are expressed in skeletal muscle tissue (Uysal, Wiesbrock et al. 
1997; Zhang, Pilon et al. 2000). The majority of reported data on this topic mainly describes 
TNFR1 mediated functions in muscle tissue, however the role of TNFR2 is still largely 
unknown. It has been shown that TNFR1 is responsible for impaired skeletal muscle 
functioning, especially when TNFơ is increased (Hardin, Campbell et al. 2008; Wei, Chen et 
al. 2008). In this respect, data from our study could lead to the speculation that the sole 
presence of TNFR1 or the lack of TNFR2 in TNFR2-/- mice may have caused reduced 
performance in the wire-hanging test or that the presence of TNFR2 may counterbalance 
the effects of TNFR1 signaling. In accordance with other studies, our findings showed that 
aging in general has an effect on muscular strength and/or neuromuscular function (Dean, 
Scozzafava et al. 1981; Joseph, Bartus et al. 1983), possibly also due to increased bodyweight 
of the aged animals. 
Anxiety-like behavior 
In this study, young TNFR2-/- mice displayed increased anxiety-like behavior compared to 
the young WT mice. This finding is also in accordance with a previous study, showing that 
younger TNFR2-/- mice displayed increased anxiety-like behavior evaluated by the elevated 
plus maze behavioral test (Gimsa, Kanitz et al. 2012). However, another study by Simen and 
colleagues showed that there were no significant anxiety-like behavioral differences between 
WT and TNFR2-/- mice using the elevated plus maze test (Simen, Duman et al. 2006). In the 
aged mice, WT animals spent significant more time in the dark arms of the elevated plus 
maze compared to aged TNFR1-/- and TNFR2-/- mice. However, aged TNFR1-/- and 
TNFR2-/- mice spent more time in the center of the maze that aged WT mice. This may be 
an indication that aged TNFR1-/- and TNFR2-/- mice displayed reduced anxiety-like behavior 
or may have been indecisive regarding the preference of arms chosen. 
Concerning the effect of age, our results show a clear difference between younger and aged 
WT animals, namely WT aged mice spent significantly less time in the open arms, while the 
time spent in the dark arms was dramatically increased. These findings are in accordance 
with findings as assessed by the elevated plus maze from a previous study done by 
Fahlstrom and coworkers (Fahlstrom, Zeberg et al. 2011) showing that WT aged mice spent 
less time in the open arms. Of note, other studies showed that aging did not have an effect 
on anxiety behavior in rodents based upon observation of defecation and/or urinations as a 
sign of anxiety (Edstrom and Ulfhake 2005; Altun, Bergman et al. 2007; Fahlstrom, Zeberg 
et al. 2011). However, the interpretation of anxiety from the different methodologies of 
testing anxiety and exploratory can be misleading (Fahlstrom, Zeberg et al. 2011). 
According to our best knowledge, the effect of aging on TNFơ and its receptor functioning 
in anxiety-like behavior have not been published before. Interestingly, in this setting, young 
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TNFR1-/- mice did not display significant changes to anxiety-like behavior compared to 
young WT control, neither did old TNFR1-/- show changes in anxiety-like behavior 
compared to their young counterparts. This finding indicates that the absence of TNFR1 or 
sole presence of TNFR2 in TNFR1-/- mice therefore may prevent anxiety-like behavior in an 
aged environment. Intriguingly, the effect of age had an inverse relationship in TNFR2-/- 
animals compared to WT mice, in which the effect of age resulted in reduced anxiety-like 
behavior in TNFR2-/- mice. This same effect was observed regarding the number of entries 
in the elevated plus maze. 
Conclusions 
Using a broad spectrum of behavioral tests in this study we were able to reveal that deletion 
of TNFR2 may impair novel object recognition, spatial memory, contextual fear 
conditioning, motor functions and can increase anxiety-like behavior in young mice. 
However, young and aged TNFR2-/- mice performed equally poor in the contextual fear 
conditioning test. An aged environment caused impaired performance in spatial memory, 
independent of genotype. Concerning the role of an aged physiological environment on 
TNFR1 and TNFR2 mediated functioning; aging resulted in decreased anxiety-like behavior 
in TNFR2-/- mice, whereas TNFR1-/- mice were resistant to changes in anxiety-like 
behavior mediated by aging. This study indicates that TNFR2 may have important 
physiological roles in hippocampus-associated memory and muscular functioning during 
younger age that diminishes with age. Furthermore, TNFR2 may play differential functions 
in anxiety-like behavior in a young and aged environment. Results from this behavioral study 
merits further molecular investigations to determine the underlying mechanisms involved in 
TNFR1 and TNFR2 mediated signaling during normal physiological aging. 
CONFLICT OF INTEREST 
All authors declare that there are no conflicts of interest. 
ACKNOWLEDGEMENTS 
This study was also supported by the School of Behavioral and Cognitive Neurosciences 
(BCN) to PJWN, ND and KM. 
 63 
CHAPTER 4 
The role of indoleamine 2,3-dioxygenase in a mouse 
model of neuroinflammation induced depression 
Nikoletta Dobos1,2, Erik F.J. de Vries3, Ido P. Kema4, Konstantinos Patas1, Marloes Prins1, 
Ingrid M. Nijholt1, Rudi A. Dierckx3, Jakob Korf2, Johan A. den Boer2,3, Paul G.M. Luiten1,2 
and Ulrich L.M. Eisel1
1Department of Molecular Neurobiology, University of Groningen, The Netherlands; 2Department of 
Psychiatry, 3Department of Nuclear Medicine and Molecular Imaging, 4Department of Laboratory 
Medicine, University Medical Center Groningen, The Netherland. 
Journal of Alzheimer’s Disease 28 (2011) 1–11 
64 
ABSTRACT 
Indoleamine 2,3-dioxygenase (IDO), an enzyme which is activated by pro-inflammatory 
cytokines, has been suggested as a potential link between neuroinflammatory processes in 
neurodegenerative diseases - like Alzheimer’s disease- and depression. 
The present study aimed to determine whether neuroinflammation-induced increased IDO 
levels in the mammalian brain will lead to depressive-like behavior. 
Neuroinflammation was initiated in mice by a single intracerebroventricular injection of 
lipopolysaccharide (LPS). Cerebral inflammation was monitored 1, 2, 3 and 4 days after the 
injection with small-animal positron emission tomography (PET) using the inflammatory 
marker [11C]PK11195. In the presence or absence of systemically applied 1-methyl-
tryptophan (1-MT), a competitive IDO-inhibitor, we assessed the development of 
depressive-like behavioral symptoms in parallel with IDO expression and activity. 
The PK11195 PET signal reached a highly significant peak 3 days after LPS injection, while 
these animals displayed a significant increase of depressive-like behavior in the forced swim 
test (FST) compared to vehicle injected animals. These findings were paralleled by a 
significant increase of IDO in the brainstem, and an increased kynurenine/tryptophan ratio 
in the serum. Moreover, we report here for the first time, that inhibition of IDO by 1-MT in 
centrally induced neuroinflammation under experimental conditions can prevent the 
development of depressive-like behavior. 
KEYWORDS: indoleamine 2,3-dioxygenase (IDO), neuroinflammation, depression, 
positron emission tomography (PET), lipopolysaccharide (LPS) 
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1. INTRODUCTION 
Neuroinflammation is defined as the activation of an immune response in the central 
nervous system (CNS) (Streit 2006). During neuroinflammation microglia, the most 
important resident immune cells, become activated (Dobos, Korf et al. 2010) and as a 
consequence their morphology starts to change and secretion of pro-inflammatory cytokines, 
such as interferon ƣ (IFNƣ) (Kawanokuchi, Mizuno et al. 2006), tumor necrosis factor ơ 
(TNFơ) (Nishioku, Matsumoto et al. 2010) or interleukin 6 (Kakimura, Kitamura et al. 2002), 
is initiated. An important hallmark of activated microglia is the expression of peripheral 
benzodiazepine receptors (PBRs) on the outer membrane of the mitochondria, which allows 
the non-invasive detection their activated state by means of labeled PBR ligands. Ligands 
such as the isoquinoline PK11195 (1-[2-chlorophenyl]-N-methyl-N-[1-methylpropyl]-3-
isoquinoline carboxamide) bind the 18-kDa subunit of the PBRs (Doorduin, de Vries et al. 
2008). When labeled with carbon-11, PK11195 can be used as a sensitive marker for 
positron emission tomography (PET) to visualize and quantify microglial activation in vivo 
associated with various conditions triggered by inflammatory or neurodegenerative processes 
(Cagnin, Kassiou et al. 2007; Doorduin, de Vries et al. 2008). 
Chronic inflammatory changes have been shown to play a key role in the pathogenesis of 
neurodegenerative diseases, like Alzheimer’s disease (AD) (Heneka, O'Banion et al. 2010). 
The typical hallmarks of AD are extracellular depositions of amyloid Ƣ, intracellular 
aggregates of the protein tau, but besides these features, activation of microglia, elevated 
cytokine and chemokine levels have been shown as well (Heneka, O'Banion et al. 2010). It 
has been shown, that AD is often accompanied by symptoms of depression, and patients are 
under a long-time treatment against depression before clinically diagnosed for AD (Jost and 
Grossberg 1996). Meta-analysis on retrospective and prospective studies revealed that the 
history of depression approximately doubles the risk of developing dementia. Several studies 
support the hypothesis that depression is a likely risk factor for dementia in general and for 
Alzheimer’s disease specifically (Jorm 2000; Jorm 2001). 
Inflammation is an important hallmark of sepsis as well. It has been recently shown that 
severe sepsis can lead to cognitive impairment and functional disability (Iwashyna, Ely et al. 
2010). 
During peripheral infection, either acute or chronic, the immune system is activated e.g. by 
macrophage stimulation, and pro-inflammatory cytokines are released, which act also on the 
brain causing sickness behavior. Sickness behavior shares similar features with major 
depression. Both are characterized by malaise, weakness, loss of appetite, lethargy, or 
decreased interest in the surroundings. However, sickness behavior breaks off when the 
pathogen is eliminated. When the peripheral immune system is continuously activated, like in 
chronic inflammatory diseases, such as rheumatoid arthritis, osteoarthritis or inflammatory 
lung disease, the resulting chronic activation of the immune system in the brain can lead to 
the development of depression. Depression may thus represent a maladaptive version of 
cytokine-induced sickness behavior (Dantzer, O'Connor et al. 2008). In 1991, R.S. Smith 
proposed the macrophage theory of depression (Smith 1991) which triggered a growing 
body of evidence supporting the notion that inflammation can increase the risk of 
developing major depression (Miller, Maletic et al. 2009). The overall idea being that the 
overexpression of pro-inflammatory agents is associated with increased activity of the 
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ubiquitous intracellular enzyme indoleamine 2,3-dioxygenase (IDO), which catalyzes 
tryptophan catabolism through the kynurenine pathway (Leonard 2007; Dantzer, O'Connor 
et al. 2008). The depletion of tryptophan in brain cells reduces the production of brain 
serotonin (5-HT) (Leonard 2007; Dantzer, O'Connor et al. 2008). The degradation of 
tryptophan along the kynurenine pathway also generates neurotoxins, like quinolinic acid 
(QUIN) an NMDA receptor agonists, or 3-hydroxykynurenine (3-HK), which leads to 
apoptosis in neurons, which can add to local excitotoxic neuronal overstimulation next to 
modulating serotonergic neurotransmission (Muller and Schwarz 2007). Taken together, 
cytokine-induced IDO-mediated tryptophan depletion (Russo, Kema et al. 2009) and 
QUIN-mediated neurotoxicity (Maes, Mihaylova et al. 2007; Muller and Schwarz 2007) are 
hypothesized to be involved in the pathophysiology of mood disorders, like major 
depression. Nevertheless, it has been also shown that the metabolism of tryptophan by IDO 
through the kynurenine pathway is increased in AD (Guillemin, Brew et al. 2005). 
Lipopolysaccharide (LPS) injection in rodents is often used as an experimental model for 
systemic immune challenges. LPS-injected mice display immediate sickness behavior after 
peripheral injection of LPS whereas depressive-like behavior seems to emerge in a shifted 
temporal frame, when sickness is already abated (Dantzer, O'Connor et al. 2008; Moreau, 
Andre et al. 2008). Accordingly, IDO activation and concomitant depressive-like behavior 
has been shown to be causally interrelated in this mouse model (O'Connor, Lawson et al. 
2009). 
Previous studies demonstrated that systemic exposure to LPS induces chronic central 
neuroinflammation (Qin, Wu et al. 2007) as well as cerebral IDO activation (Lestage, Verrier 
et al. 2002; Andre, O'Connor et al. 2008). In our study, we measured IDO activity and 
expression after intracerebroventricular LPS injection and assessed the development of 
depressive-like symptoms in the presence or absence of 1-methyl tryptophan (1-MT), a 
competitive IDO-inhibitor. Neuroinflammation was monitored over time by small animal 
positron emission tomography (PET). 
We report here for the first time that the inhibition of IDO in centrally induced 
neuroinflammation is sufficient to prevent the development of depressive-like behavior in 
mice. 
2. MATERIALS AND METHODS 
Ethics statement 
All animal care and treatments were reviewed and approved by the Ethical Committee for 
the use of experimental animals of the University of Groningen under licence number 
DEC5461. 
2.1. Animals 
Three months old male C57Bl/6J mice (n=8-10/group, groups: Placebo/PBS, 1-MT/PBS, 
Placebo/LPS, 1-MT/LPS) were obtained from Harlan (Horst, The Netherlands). Animals 
were individually housed under normal laboratory conditions (air-conditioned (21±2qC), 
humidity-controlled room, 12/12 h light/dark cycle (light on from 08:00-20:00). Food and 
water were available ad libitum. In all cases the weight of the animals was monitored on a 
daily basis. 
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2.2. Intracerebroventricular LPS injection 
Before fixation in a stereotactic apparatus mice were anaesthetized with avertin (250 mg/kg 
by intraperitoneal injection). Periprocedural analgesia was provided with finadyne (2.5 
mg/kg, subcutaneously). The coordinates for the bilateral intracerebroventricular (ICV) 
injections were -2.5 mm dorsal/ventral, -1.0 mm lateral and -0.5 mm anterior/posterior from 
bregma (Keith B. J. Franklin 1997). The holes were drilled perpendicularly to the previously 
exposed skull. 1 Ƭl endotoxin-free phosphate buffered saline (PBS) or 5 Ƭg 
lipopolysaccharide (LPS, L-6529, serotype 055:B5, Sigma-Aldrich) dissolved in 1 Ƭl PBS was 
injected into the lateral ventricles using a 1 Ƭl Hamilton needle (cat. nr.170431, Omnilabo) 
fitted to a 25 Ƭl Hamilton syringe. This dose of LPS was previously shown to induce 
significant neuroinflammation (Milatovic, Zaja-Milatovic et al. 2004; Aid, Langenbach et al. 
2008; Choi, Langenbach et al. 2008; Aid, Parikh et al. 2010). A syringe pump (TSE system, 
Bad Homburg, Germany) was used for injection at a constant rate of 0.3 Ƭl/min. After 
injection the needle was kept in the ventricles for an additional 5 minutes and subsequently 
slowly removed from the brain. The incision was sealed with dental cement. 
2.3. Slow-release pellet implantation 
Four days prior to ICV injection, mice were initially anaesthetized by 5% isoflurane in an 
induction chamber. After anaesthetic induction, the animals were placed in an open circuit 
system and 2% isoflurane was administered via a nose-cone. The competitive IDO inhibitor 
1-methyl-DL-tryptophan (1-MT) was applied via a slow release pellet implanted 
subcutaneously beneath the dorsal skin surface. Pellets were designed to continuously release 
5 mg/day of drug for 21 days (Innovative Research of America, Sarasota, FL, USA) 
(O'Connor, Lawson et al. 2009). Similar drug free pellets served as placebo. 
2.4. Synthesis of [11C]-PK11195 
The PET tracer [11C]-PK11195 was produced at the University Medical Center Groningen 
according to the procedure described by Cremer et al. (Cremer, Hume et al. 1992). The 
product was obtained in 32±10% radiochemical yield as a sterile solution in 10% ethanol in 
saline. The radiochemical purity was always >95% and the specific activity was 110±69 
GBq/Ƭmol. 
2.5. Micro-PET imaging 
Mice were anaesthetized by 5% isoflurane (Pharmachemie, The Netherlands) mixed with 
medical air in an induction chamber. Anesthesia was maintained with 2% isoflurane in 
medical air at a flow of 2 ml/min via a nose-cone. Mice were injected intravenously with 
7.5±2.5 MBq [11C]-PK11195 via the penile vein and positioned in a small animal PET 
camera (Focus 220, Siemens Medical Solutions USA, Inc.) in a transaxial position with their 
heads in the field of view. A transmission scan with a 57Co point source was acquired for the 
correction of attenuation by tissue. Ten minutes after tracer injection, a 30-minute static 
emission scan was started. After completion of the emission scan, the animals were allowed 
to recover. Emission sinograms were iteratively reconstructed (OSEM2d, 4 iterations) after 
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being normalized, corrected for attenuation and decay of radioactivity. Regions-of-interest 
were manually drawn over the whole mouse brain in the reconstructed images using the 
microPET® ASIProTM VM6.6.2.0 software. Tracer uptake in regions-of-interest (ROI) was 
obtained in Bq/cm3 and converted into the standardized uptake value (SUV), defined as: 
[tissue activity concentration (MBq/cm3)]/[(injected dose (MBq)/body weight (g)]. 
2.6. Elevated plus maze 
The elevated plus maze test was used to measure anxiety-related exploration (Ostroveanu, 
van der Zee et al. 2009). The test consisted of a plus-shaped maze, 50 cm above the floor, 
with two opposite arms closed by high side walls and two opposite open arms without walls 
(50 cm long, 5 cm wide). The mouse was placed in the center of the maze and was allowed 
to explore the maze freely for 8 min. Exploratory activity, time spent in the dark arms, open 
arms and center zone were recorded visually by two raters (one of them was blind to the 
experiment). The ratio of time spent in the open (light) and closed (dark) arms and in the 
center to total time spent in the maze was calculated for each group. A lower ratio of time 
spent in the open arms and total time is indicative for higher anxiety levels. 
2.7. Spontaneous alternation 
Short-term spatial memory performance (working memory) was investigated by recording 
spontaneous (since it is not reinforced) alternation behavior in a Y-maze paradigm (Dolga, 
Granic et al. 2009). The maze consisted of three tubular and transparent plexiglas arms 
forming the Y. All three arms were 5 cm in diameter, 27.5 cm long, and at a 120° angle from 
each other. The experimental room contained visual cues for spatial orientation. The mouse 
(naive to the maze) was placed into the centre of the Y maze and allowed to explore the 
maze freely during an 8-min session. The series of arm entries (considered to be completed 
when all four paws of the animal entered the arm) was recorded visually by two raters (one 
of them was blind to the experiment). Alternation was defined as successive entries into the 
three arms on overlapping triplet sets. Working memory was assessed by the alternation 
percentage, which was calculated as the ratio of actual to possible alternations (defined as the 
total number of arm entries minus two). Exploratory activity was assessed by counting the 
total number of arm entries. 
2.8. Forced swim test 
The forced swim test is a widely used paradigm to measure antidepressant activity and 
depressive-like behavior in animal models (Cryan and Mombereau 2004). A cylinder (22 cm 
height × 11.5 cm diameter) was filled with water (23-25 °C) up to a height of 17 cm. The 
animal was placed inside the cylinder and immobility time was recorded over a 7 min test 
period. Afterwards the mouse was dried and returned to its cage. Between testing sessions 
the water was refreshed. 
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2.9. Protein analysis 
Immediately after the PET scans and behavioral experiments, mice were sacrificed by CO2 
inhalation. Brains were quickly dissected, snap-frozen in liquid nitrogen and stored at -80 °C 
until homogenization and Western blotting (Ostroveanu, Van der Zee et al. 2007). 
Antibodies (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) were used for IDO (rat 
monoclonal antibody), and HPRT (hypoxanthine-guanine phosphoribosyltransferase) as an 
internal standard to correct for variations in protein content (rabbit polyclonal antibody), 
and stained with horseradish peroxidase-conjugated secondary antibodies (goat-anti-mouse, 
donkey-anti-rabbit, respectively) The proteins were detected using Enhanced 
Chemiluminescence (Pierce ® ECL Western Blotting Substrate, Rockford, IL, USA) and the 
Molecular Image Chemidoc XRS+ System (Biorad). The results were analyzed using Image 
Lab software (BioRad). 
2.10. Serum tryptophan and kynurenine quantification 
We used as an in vivo index of IDO activity the ratio of the blood levels 
of kynurenine/tryptophan. Nevertheless, it is known, that tryptophan 2,3-dioxygenase 
(TDO) also catabolyzes tryptophan into kynurenine, but since 1-MT specifically inhibits 
IDO, but not TDO, we could use the results of the ratio of kynurenine/tryptophan as a 
reflection of IDO activity. (Mellor and Munn 2004) Tryptophan and kynurenine 
concentrations in serum were determined by an automated on-line solid-phase extraction-
liquid chromatographic-tandem mass spectrometric (XLC-MS/MS) method with deuterated 
internal standards as described previously (de Jong, Smit et al. 2009). 
2.11. Statistical analysis 
The data in Fig. 1F were analyzed by 2-way analysis of variance (ANOVA), and the data in 
Fig. 4. were analyzed by 3-way ANOVA with repeated measures. All other data were 
analyzed by one-way ANOVA, followed by the LSD post-hoc test to determine the 
differences between the selected groups using the program SPSS 16.0 for Windows. A p-
value *<0.05 was considered to be statistically significant (p-value **<0.005: highly 
significant, a p-value ***<0.0005: extremely significant). Data are presented as a mean value 
± the standard error of the mean (SEM). 
3. RESULTS 
3.1. Intracerebroventricular LPS injection-induced neuroinflammation culminates 3 
days after injection 
We evaluated the temporal course of in vivo cerebral inflammation in the mouse brain using 
micro-PET. (Fig.1D). PK11195 binding potential peaked 3 days after the ICV injection of 
either LPS (F(7,57)=5.099, p<0.0005) or, interestingly, also after injection of PBS (p0.05) 
with similar kinetics. Glial activation was significantly higher at day 3 and 4 in LPS injected 
mice when compared to PBS injected mice. Already on the fourth post-operative day the 
inflammatory response started to decline (Fig. 1D). 
 Figure 1. Microglia activation in the 
brain visualized by small animal PET. 
Representative pictures of a mouse PET 
scan (A-C). Microglia activation is 
depicted using colours for high (red) or 
low (purple) [11C]-PK11195 uptake. A) 
transversal section, B) coronal section, C) 
sagittal section. Brain (ROI) is indicated 
by the arrow. D) Standardized uptake 
value (SUV) versus days after ICV 
injection. 1 Ƭl endotoxin-free phosphate 
buffered saline (PBS) or 5 Ƭg 
lipopolysaccharide (LPS) dissolved in 1 Ƭl 
PBS was injected into the lateral 
ventricles. Data represent mean SUVs ± 
SEM as a percentage of control, PBS 
injected animals on day 1. Number of 
scanned animals: 1. day PBS=13, 
LPS=14, 2. day: PBS=6, LPS=7, 3. day: 
PBS=8, LPS=7, 4. day: PBS=5, LPS=5, 
*p<0.05, **p<0.005, ***p<0.0005. E) 
Diagram of the time course of the PET 
scanning design. F) SUVs 3 days after 
injection in placebo or 1-MT pretreated, 
PBS or LPS injected mice. Four days 
prior to ICV injection, the IDO inhibitor 
1-methyl-tryptophan (1-MT) was applied 
via a slow release pellet (continuously 
release 5 mg/day of drug/placebo) 
implanted subcutaneously beneath the 
dorsal skin surface. Data represent mean 
SUVs ± SEM as a percentage of the 
Placebo/PBS group. Number of scanned 
animals: Placebo/PBS=6, 1-MT/PBS=6, 
Placebo/LPS=7, 1-MT/LPS=6 *p<0.05, 
**p<0.005, ***p<0.0005. G) Schematic 




3.2. Pretreatment with 1-MT does not have a significant influence on LPS-induced 
neuroinflammation 
Microglia activation was measured by PET analysis on the 3rd post-operative day. The results 
analyzed by 2-way ANOVA, showed a significant effect of pretreatment (placebo or 1-MT) 
(F(4.827), p<0.05) and treatment (PBS or LPS) (F(74.309), p<0.0005). These results 
corroborate previous findings that ICV injection of LPS indeed induces central 
neuroinflammation. Most interestingly, there was no significant interaction between 
pretreatment and treatment (F(1.393), p>0.05), which means 1-MT does not have a 
significant influence on LPS-induced neuroinflammation. (Fig.1F). 
3.3. LPS induces depressive-like behavior 3 days after ICV injection 
A group of animals was tested 3 days after ICV PBS or ICV LPS injection, when 
neuroinflammation peaked. Depressive-like behavior was significantly increased after ICV 
LPS injection as tested in the forced swim test (F(1,11)=5,323, p<0.05, Fig.2G). 
3.4. Inhibition of IDO abrogates the development of LPS-induced depressive-like 
behavior 
On day 4 after ICV injection, LPS increased the immobility time in the forced swim test 
(F(3,26)=3.36, p<0.05) in placebo/LPS mice, compared to either placebo/PBS (p<0.05) or 
1-MT/PBS (p<0.05) mice. This effect of LPS was completely inhibited by 1-MT 
pretreatment (p<0.05) (Fig.2A). These results demonstrated that IDO inhibition prior to 
ICV LPS injection was sufficient to prevent the development of LPS-induced depression-
like behavior. 
 
Figure 2. The effect of neuroinflammation on behavior and the consequences of IDO 
inhibition. A) Forced swim test, a widely used paradigm to measure antidepressant activity 
and depressive-like behavior in animal models. The animal was placed inside the cylinder and 
immobility time was recorded over a 7 min test period. Data represent mean values ± SEM, 
*p<0.05 B) Elevated plus maze test was used to measure anxiety-related exploration. The 
mouse was placed in the center of the maze and was allowed to explore the maze freely for 8 
min. Exploratory activity, time spent in the dark arms, open arms and center zone were 
recorded visually. The ratio of time spent in the open and closed arms and in the center was 
calculated for each group. A lower ratio of time spent in the open arms and total time is 
indicative for higher anxiety levels. Data represent mean values ± SEM in percentage. 
C,D) Spontaneous alternation test. Short-term spatial memory performance (working 
memory) was investigated by recording spontaneous alternation behavior in a Y-maze 
paradigm. The mouse was placed into the centre of the Y maze and allowed to explore the 
72 
 73 
maze freely during an 8-min session. The series of arm entries was recorded visually. 
Alternation was defined as successive entries into the three arms on overlapping triplet sets. 
Working memory was assessed by the alternation percentage, which was calculated as the 
ratio of actual to possible alternations (defined as the total number of arm entries minus 
two). Exploratory activity was assessed by counting the total number of arm entries. Data 
represent mean values ± SEM, *p<0.05. E) Spontaneous alternation test 3 days after ICV 
PBS or ICV LPS injection. Data represent mean values ± SEM in percentage. F) Forced 
swim test 3 days after ICV PBS or ICV LPS injection. Data represent mean values ± SEM, 
*p<0.05. 
3.5. ICV administered LPS did not affect anxiety-related behavior or working 
memory 
ICV administered LPS did not affect anxiety behavior in the elevated plus maze on day 4 
(time spent in the open arms (F(3,31)=0.41, p>0.05), in the center (F(3,31)=0.84, p>0.05), in 
the dark (F(3,31)=0.82, p>0.05) when compared to placebo/PBS injected mice (Fig.2B). 1-
MT also did not affect anxiety behavior (time spent in the open arms (F(3,31)=0.41, 
p>0.05), in the center (F(3,31)=0.84, p>0.05), in the dark (F(3,31)=0.82, p>0.05) when 
compared to placebo/PBS or placebo/LPS injected animals. Working memory, measured in 
the spontaneous alternation task (number of alternations (F(3,33)=0.89, p>0.05, Fig.2C)) 
and exploratory behavior (number of entries (F(3,33)=2.08, p>0.05, Fig.2D) were not 
affected by LPS treatment nor by application of 1-MT. Overall, these results showed that 
neither ICV injected LPS nor concurrent IDO inhibition could affect anxiety-like behavior 
and working memory performances. 
Also, a separate group of animals were tested 3 days after ICV PBS or ICV LPS injection. 
No abnormalities were found in the working memory (number of alternations: 
F(1,13)=1.117, p>0.05, Fig.2E) and exploratory behavior (number of entries: F(1,13)=1.859, 
p>0.05, data not shown) as tested in spontaneous alternation test. 
3.6. LPS treatment increases IDO levels in the brainstem 4 days after injection 
A significant increase of IDO (F(3,131)=6.388, p<0.05) was detected in the brainstem of 
placebo/LPS (p<0.05) and 1-MT/LPS (p<0.005), compared to both PBS groups (Fig.3A). 
In the other brain regions, no significant differences among the four groups was observed 
(cerebellum (F(3,49)=0.37, p>0.05), cortex (F(3,52)=0.24, p>0.05), hippocampus 
(F(3,93)=0.36, p>0.05), hypothalamus (F(3,51)=0.70, p>0.05), olfactory bulb 
(F(3,109)=0.69, p>0.05), and striatum (F(3,56)=0.815, p>0.05 ). 
 
Figure 3. A) IDO protein expression in different regions of the brain. Mice were 
sacrificed, brains were quickly dissected, snap-frozen and Western blotting was done. Data 
represent mean values ± SEM as a percentage of the Placebo/PBS group. *p<0.05, 
**p<0.005. B) IDO activity in serum. Tryptophan and kynurenine concentrations in serum 
were determined by an automated on-line solid-phase extraction-liquid chromatographic-
tandem mass spectrometric (XLC-MS/MS) method. IDO activity is defined as the ratio of 
the concentration of kynurenine and tryptophan. Data represent mean values ± SEM as a 
percentage of the Placebo/PBS group. ***p<0.0005. 
3.7. 1-MT inhibits IDO activity in the serum after ICV LPS injection 
ICV LPS injection led to increased IDO activity, defined as a ratio of kynurenine and 
tryptophan, measured in the serum, which could be completely inhibited by 1-MT 
(F(3,26)=10.611, p<0.0005). (Fig.3B). 
3.8. ICV injection of LPS results in a robust reduction in body weight 
Cerebral inflammation was paralleled by considerable weight reductions in both LPS groups 
after injection, but was normalized by the time of behavioral assessment (Fig.4). The data 
were analyzed by 3-way ANOVA with repeated measures, showing a significant effect of 
time (days) (F(36.101), p<0.0005) and also, there was a significant interaction between time 
and treatment (PBS or LPS) (F(22.041), p<0.0005). There was no interaction effect between 
pretreatment (placebo or 1-MT) and treatment (PBS or LPS) (F(6.000), p>0.05). Source of 
significance was analyzed by univariate measures. No significant difference was observed on 
day -4 (F(0.454), p>0.05), day -3 (F(0.453), p>0.05), day 0 (F(0.777), p>0.05) and day 4 
(F(4.022), p>0.05). There was a significant difference on day 1 (F(8.661), p<0.05), day 2 
(F(10.662), p<0.05) and day 3 (F(7.162), p<0.05). 
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Figure 4. Changes of the body weight of the animals during the experiment. ICV LPS 
injection took place at day 0. Data represent mean values ± SEM. 
4. DISCUSSION 
In the study presented here we used an animal model for depression in neuroinflammatory 
conditions, such as Alzheimer’s disease. Our results provide some evidence that LPS-
induced neuroinflammation leads to increased IDO protein levels in the brainstem, which is 
accompanied by the onset of depressive-like behavior. This behavioral phenomenon can be 
completely blocked by IDO inhibition suggesting a causal relation between the behavioral 
expression and IDO activation. 
Several studies have shown that peripheral inflammation can cause central 
neuroinflammatory responses which might be causal for depressive-like behavior. Although 
the question still remains, whether central inflammation alone is sufficient to lead to 
depressive-like behavior. 
O'Connor et al. showed that the inhibition of IDO by 1-MT in the context of systemic LPS 
administration can normalize plasma and brain kynurenine/tryptophan ratios, while only 
kynurenine levels were altered (O'Connor, Lawson et al. 2009), which is consistent with the 
data presented here. We also found a significant increase of the kynurenine/tryptophan ratio 
in the serum of ICV LPS-injected animals, whereas tryptophan levels remained unchanged. 
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We used microPET to monitor the ongoing cerebral innate immune responses and 
dissociate cytokine-induced sickness from depressive-like behavior. Our findings clearly 
showed that cerebral inflammation was considerably higher, as expected, in ICV LPS 
injected mice and reached its peak 3 days after the ICV injection. The 4th post-injection day - 
when sickness-behavior is imperceptible - was chosen to perform behavioral studies to 
measure depressive-like behavior. On the 4th post-injection day - when the placebo/LPS 
treated animals exhibited increased depressive-like behavior in the forced swim test – 
cerebral inflammation was almost gone. This was confirmed by reduced body weight in both 
LPS groups during the first two post-injection days and subsequent restoration by the time 
of behavioral assessment (Fig.4.). The reduced food intake might affect the tryptophan levels 
in the blood, but that can not be the reason of the higher kynurenine/tryptophan ratio, since 
the 1-MT/LPS group showed a dramatic decrease in the body weight as well, but did not 
show increased kynurenine/tryptophan ratio. No differences were observed in the general 
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activity of the mice when the behavioral tests were done, as seen also in the total arm entries 
in the elevated plus maze test (data not shown) or in the spontaneous alternation test 
(Fig.2.). We also did not observe any differences in working memory, exploratory behavior 
and anxiety-like behavior between PBS and LPS-treated groups (Fig.2.), indicating that 
locomotor activity was normal by the time mice were tested in the forced swim test. 
Behavioral tests were also performed on day 3 (Fig.2), showing the same results, namely: 
working memory and exploratory behavior were not affected, as tested in the spontaneous 
alternation test, but significantly increased immobility was observed in the forced swim test 
in the LPS-treated group. Statistical analysis showed that depressive-like behavior after ICV 
LPS injection was more robust on the 4th post-operative day than on the 3rd (p values are: 
0.02, and 0.04, respectively), making the hypothesis stronger, that depressive-like behavior 
lasts longer after a neuroinflammatory response. 
It is important to mention that a limitation of the present study, especially in relation to 
neurodegenerative diseases, e.g. AD, is that no long-term consequences of ICV LPS-
injection and/or IDO inhibition were assessed. Indeed, it has been previously shown that 
chronic LPS infusion directly in the 4th ventricle in rats can result in impaired cognitive 
performance (Hauss-Wegrzyniak, Dobrzanski et al. 1998). We therefore hypothesize that an 
acute and transient LPS challenge might not be sufficient to unequivocally confound the 
elaborate and pleiotropic physiology of brain cytokines normally involved in cognitive 
processes (McAfoose and Baune 2009). 
Taken together, our findings further support the hypothesis that depression-like behavior 
remains even when temporally induced sickness behavior has waned. The temporal profile 
showed a different pattern from that described in previous studies (Frenois, Moreau et al. 
2007; Fu, Zunich et al. 2010), but it should be noted that we used larger doses of LPS to 
induce the immunological challenge in our study. More importantly, we mainly measured 
reactivity of resident brain cells in response to ICV LPS injection, which might be delayed 
when compared to the immediate sickness-inducing vagal afference and monocytic 
infiltration to the CNS following systemic LPS exposure. 
We further demonstrate for the first time that the inhibition of IDO by 1-MT pretreatment 
in the context of centrally LPS-induced neuroinflammation is sufficient to prevent the 
development of depressive-like behavior. Since IDO in our study was inhibited systemically 
(O'Connor, Lawson et al. 2009), we cannot ascertain whether this finding is associated with 
direct central IDO inhibition or reduction of CNS influx of peripheral kynurenine, which 
has been previously shown to induce depressive-like behavior (O'Connor, Lawson et al. 
2009). It may very well be the result of a combined effect of peripheral and central IDO 
inhibition. It has been shown that even much lower doses of LPS can cross the brain to 
blood direction (Banks and Robinson 2010), leading to a subsequent peripheral 
inflammation, as it has been already also shown that lower dose of ICV injected LPS leads to 
increased production of central and peripheral TNFơ (Faggioni, Fantuzzi et al. 1995). We 
also measured TNFơ expression in the liver, and we found an increase of TNFơ in both LPS 
treated groups (Results in %: Placebo/PBS: 100±12, 1-MT/PBS: 99±12, Placebo/LPS: 
131±15, 1-MT/LPS: 154±15) indicating peripheral inflammation in our paradigm, although 
this effect is not because of the dose of LPS we used in this study, but because the immune 
privilege of the brain is not absolute and there is a constitutive communication of the brain 
and the periphery (Galea, Bechmann et al. 2007). 
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It was shown that IDO mRNA expression was reduced in whole brain homogenates of 1-
MT/LPS treated mice (O'Connor, Lawson et al. 2009), which was however not observed in 
the context of Bacille Calmette-Guérin-induced infection (O'Connor, Lawson et al. 2009). In 
any case, those measurements were conducted in whole brain homogenates, so we cannot 
exclude the possibility that brain IDO expression or cytokine signaling is regionally altered. 
Indeed, our data show that IDO protein expression is increased in the brainstem of LPS 
injected mice, independently of pretreatment with placebo or 1-MT. Although we did not 
measure cytokine expression levels in the brain, our results clearly argue in favor of a post-
translational inhibition of IDO by 1-MT. Down-regulation of IDO expression in other brain 
regions was not found, but even if it was, this does not necessarily mean it would be a direct 
effect of 1-MT. 
Our PET findings are consistent with a moderate, but not significant anti-inflammatory 
effect of 1-MT, as shown by the reduction of peripheral benzodiazepine receptors expressed 
in the brains of 1-MT/LPS relative to placebo/LPS treated mice. O’Connor et al. 
(O'Connor, Lawson et al. 2009) have shown that the presence of 1-MT did not modify the 
expression of pro-inflammatory cytokines in mice upon peripheral injection of LPS. 
However, direct as well as accumulative immune effects of the various neuroactive 
tryptophan catabolites have to be taken into account. Indeed, Maes et al. (Maes, Mihaylova 
et al. 2007) have shown in vitro that kynurenine and kynurenic acid (KYNA) display anti-
inflammatory properties via reduction of stimulated IFNƣ and TNFơ production. In 
addition, Doorduin et al. (Doorduin, de Vries et al. 2008) comment that PBRs are also 
expressed in activated astrocytes, which preferentially produce KYNA (Guillemin, Smith et 
al. 2000; Muller and Schwarz 2007). We therefore hypothesize that IDO inhibition in 
microglia mitigates the production of pro-inflammatory QUIN, which in combination with a 
shortage of anti-inflammatory astrocyte-derived KYNA upon LPS challenge, might leave the 
brain of 1-MT/LPS mice in a neuroinflammatory state lower than placebo/LPS mice, but 
greater than the placebo/PBS animals. 
We have found significantly higher levels of IDO in the brainstem of LPS injected mice. It 
has been shown that physical stressors – such as trauma or infection – rapidly affect the 
brainstem, where coordinated processing of autonomic, immune and neuroendocrine 
information takes place (Ulrich-Lai and Herman 2009). Interestingly, injection of mice with 
LPS selectively increases immediate-early gene expression within serotonergic neurons of the 
interfascicular part of the dorsal raphe nucleus (Hollis, Evans et al. 2006). These neurons 
comprise a unique, anatomically and functionally distinct immune-responsive subpopulation 
within the brainstem Raphe complex that essentially differs from the neuronal population 
responding to anxiety- and stress-related stimuli (Lowry, Hollis et al. 2007). This may explain 
the “paradox” of decreased behavioral activity but increased (Linthorst, Flachskamm et al. 
1995) or unchanged (O'Connor, Lawson et al. 2009) serotonergic neurotransmission 
following acute immune stimulation. 
In conclusion, our findings indicate that neuroinflammation induces depressive-like 
symptoms in an animal model, which can be abolished by inhibiting the effects of IDO. 
Moreover, this study does not only provide evidence of a pathogenic role of cerebral 
inflammation in the precipitation of depression, but suggests also that symptoms often 
concurring with depression, such as anxiety, feelings of misery and impaired working 
memory are the consequences of some other processes and apparently dissociated from 
brainstem serotonin neurotransmission. 
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ABSTRACT 
Interferon beta (IFNƢ) has been successfully used for a long time in the treatment of 
Multiple Sclerosis (MS). Nevertheless, a direct connection between IFNƢ-therapy and 
neuropsychiatric complications, e.g. agitation, depression, anxiety and memory loss comes 
from recent clinical observations. 30-40% of MS patients treated with IFNƢ develop major 
depression, however after the withdrawal of the treatment, a complete remission of the 
symptoms was observed. 
IFNƢ is a potent inducer of indoleamine 2,3-dioxygenase (IDO), a tryptophan catabolising 
enzyme, which has been shown to play an important role in depression. 
The aim of the present study was to determine whether IFNƢ-therapy is responsible for 
neuropsychiatric problems the interferon ơ/Ƣ receptors. To investigate the effect of IFNƢ, 
wildtype and interferon ơ/Ƣ receptor knock out (IFNRKO) mice were injected with IFNƢ 
for seven consecutive days. PBS injected wildtype and IFNRKO animals were used as 
controls. 
We report here for the first time, that IFNƢ induces learning and memory problems and 
depressive-like behavior via the IFNơ/Ƣ receptors as observed in wildtype IFNƢ-injected 
animals. Furthermore, IDO expression in the brain stem and cortex and IDO activity in the 
blood of the wildtype, IFNƢ injected mice were found to be increased. From these results, 
we hypothesize, that IFNƢ induced IDO expression and higher activity might be responsible 
for the depressive-like behavior after IFNƢ treatment. 
KEYWORDS: Interferon beta (IFNƢ), indoleamine 2,3-dioxygenase (IDO), depressive-like 
behavior, Multiple Sclerosis (MS), neuroinflammation 
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1. INTRODUCTION 
Multiple Sclerosis (MS) is an inflammatory disorder of the central nervous system (CNS). 
The disease is the most common cause of neurological disability in young and middle aged 
adults (Feinstein 2000). The most important feature of the disease is the damaged myelin 
sheaths. Demyelination leads to physical and cognitive disability. Hitherto, there is no cure 
for the disease, only therapies that can treat and guard the relapse of MS. As a first-line 
therapy in MS, interferon beta (IFNƢ) is used successfully. Interferon beta is a member of 
the interferon type I family. These cytokines have the ability to modulate immune responses 
(Sternberg, Chadha et al. 2008). IFNƢ is able to slow the progression of brain atrophy in MS 
and reduces the relapse rate by approximately 30% (Farrell and Giovannoni 2010; Rudick 
and Goelz 2011). However, a growing body of evidence shows that interferon-therapy, 
including IFNƢ can have serious side effects. Especially interferon alpha (IFNơ)-induced 
depression and cognitive deficits have been widely investigated (Merimsky and Chaitchik 
1992; Valentine, Meyers et al. 1998). Although not much is known about the psycho-
neurological effects of IFNƢ clinical observations suggest a direct connection between 
IFNƢ-therapy and neuropsychiatric complications such as agitation, depression, anxiety and 
memory loss (Moriuchi, Shimizu et al. 1996; Feinstein 2006; Paul, Ricour et al. 2007; 
Fragoso, Frota et al. 2010). It has been previously shown in vitro and in vivo that all cell types 
of the central nervous system can respond to type I interferons (Njenga, Pease et al. 1997; 
Paul, Ricour et al. 2007). Recently, IFNƢ induced apoptosis has been also shown in vitro (Yen 
and Ganea 2009; Dedoni, Olianas et al. 2010). 
The transcription of interferons is regulated by interferon regulatory factors (IRFs). IRFs 
have a key role in antiviral defense, immune response and apoptosis. IRF3 and IRF7 are 
critical for the transcriptional regulation of IFNƢ (Paun and Pitha 2007). Under physiological 
conditions, IRF3 and IRF7 are expressed constitutively at low levels in the cytosol. Upon a 
viral infection, in the early phase, IRF3 and IRF7 monomers get phosphorylated and form 
homo- and heterodimers, which translocate to the nucleus. In the nucleus, IRF dimers 
interact with the co-activator cyclic-AMP-responsive-element-binding protein (CBP) or 
p300. This holocomplex binds to the target DNA sequence (e.g. type I IFN genes), resulting 
in the initiation of the transcription of type I IFN genes (Honda and Taniguchi 2006). In the 
later phase of the viral infection, type I IFNs bind to the type I IFN receptor (also called 
interferon ơ/Ƣ receptor) which activates the IFN-stimulated gene factor 3 (ISGF3) which is 
responsible for the stimulation of the IFN-stimulated response element (ISRE) of a gene 
promoter, e.g. the IRF7 gene. Similarly to the early phase, the newly synthetized IRF7 forms 
homo- or heterodimers with IRF3, get phosphorylated, translocate to the nucleus which 
results in even more expression of type I IFNs. IRF3 only initiates the expression of IFNƢ, 
whereas IRF7 activates IFNơ and IFNƢ genes (Honda and Taniguchi 2006; Paun and Pitha 
2007). 
In chronic inflammatory disorders, like MS, the abnormal peripheral autoimmune processes 
generate autoimmune inflammatory cascades in the brain and this chronic inflammation and 
activation of the immune system can lead to the development of major depression (Dobos, 
de Vries et al. 2011). The lifetime prevalence of major depression in people living with MS is 
approximately 50% (Feinstein 2006). In 1987, Minden et al. showed in their study, that 54% 
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of MS patients reported at least one major depressive episode after the onset of their illness 
(Minden, Orav et al. 1987). 
It is known, that MS patients show an increased pro-inflammatory cytokine profile (Link 
1998; Trenova, Manova et al. 2011). These pro-inflammatory cytokines, e.g. TNF alpha 
(TNFơ), interferon gamma (IFNƣ), or interleukin 6 (IL-6) are known to be an effective 
stimulator of an ubiquitous intracellular enzyme, indoleamine 2,3-dioxygenase (IDO), which 
catalyzes tryptophan catabolism through the kynurenine pathway (Leonard 2007; Dantzer, 
O'Connor et al. 2008). IFNƢ has been described as a potential stimulator of IDO (Carlin, 
Borden et al. 1987; Carlin, Borden et al. 1989). Neurotoxins, which are responsible for 
neuronal death, like quinolinic acid (QUIN), an NMDA receptor agonists, or 3-
hydroxykynurenine (3-HK) are generated in the kynurenine-pathway, whereas the decreased 
tryptophan level in brain cells reduces the production of brain serotonin (5-HT) possibly 
leading to altered serotonergic neurotransmission (Muller and Schwarz 2007; Dobos, de 
Vries et al. 2011). Taken together, neuroinflammation-induced increased IDO expression 
and activity is accompanied by the onset of depressive-like behavior (Dobos, de Vries et al. 
2011). 
Moreover, it has been shown that stimulation of ISRE can lead to IDO expression as well 
(Suh, Zhao et al. 2007). 
Also, cognitive impairment has been associated with MS. Rao et. al showed (Rao, Leo et al. 
1991), that approximately 40% of MS patients suffer from cognitive decline (Rao, Leo et al. 
1991; Rao 1995; Feinstein 2006). 
Although there is clear evidence that IFNƢ-treatment in patients increases the risk of the 
development of major depression and cognitive impairment, the site of action of systemic 
IFNƢ remains undefined with regard to its central nervous system consequences. To 
investigate whether IFNƢ-treatment can lead to depressive-like behavior and cognitve 
impairment and whether this effect is via the IFNơ/Ƣ receptor we used wildtype and mutant 
mice with a deletion of IFNơ/Ƣ receptor (IFNRKO). We tested the behavioral changes of 
wildtype and IFNRKO animals after 1 week of intraperitoneal (IP) injection of IFNƢ. 
Afterwards, IDO expression and activity was measured. We report here for the first time, 
that 7 consecutive days of IP injected IFNƢ is able to increase significantly the activity and 
expression of IDO and leads to the development of depressive-like behavior and deficits in 
learning and memory. 
2. MATERIALS AND METHODS 
2.1. Animals 
Approximately 3 months old male C57Bl/6J (wildtype, wt) mice (n=10/group) were 
obtained from Harlan (Horst, The Netherlands). 24 weeks old male conditional mutant mice 
with a deletion of interferon ơ/Ƣ receptor (IFNRKO) (n=10/group) were kindly provided 
by Dr. T. Blank and Prof. Dr. M. Prinz (Freiburg, Germany). The following groups were 
used: wildtype mice treated with PBS (wt/PBS), wildtype mice treated with IFNƢ 
(wt/IFNƢ), IFNRKO mice treated with PBS (IFNRKO/PBS) and IFNRKO mice treated 
with IFNƢ (IFNRKO/IFNƢ). Upon arrival the animals were individually housed under 
normal laboratory conditions (air-conditioned (21±2qC), humidity-controlled room, 12/12 h 
light/dark cycle (light on from 08:00-20:00)). Food and water were available ad libitum. The 
treatments were started after 2 weeks of acclimatization. All animal care and treatments were 
carried out in accordance with the regulations of the Ethical Committee for the use of 
experimental animals of the University of Groningen (licence number DEC4408B). 
2.2. Generation of interferon ơ/Ƣ receptor knock out mice 
Inactivation of the type I IFN receptor gene in embryonic stem (ES) cells was achieved by 
homologous recombination (Muller, Steinhoff et al. 1994). IFNRKO mice were obtained 
with a mendelian frequency, proved fertile, and had no apparent phenotypic anomalies by 6 
months of age. They were backcrossed 20 times to C57Bl/6 and provided by the Prinz lab, 
Freiburg. 
2.3. Timeline of the experiment 
Upon arrival, the animals were housed individually. After 2 weeks acclimatization, animals 
were injected for 7 consecutive days with IFNƢ. Injection was performed every day ~9 a.m. 
On the 6th day of injection, the training session of the fear conditioning paradigm was 
performed. On the 7th day, retention of the fear conditioning test and the forced swim test 
was done. After completion of the behavior tests, animals were sacrificed and brain and 
blood samples were collected for further analysis (Fig.1). 
Figure 1. Diagram of the time course of the experiment. 
2.4. Intraperitoneal injection 
Animals were injected intraperitoneally either with 0.2 ml IFNƢ solution (100.000 IU/ml, 
Hycult Biotechnology) or endotoxin-free phosphate buffered saline (PBS) for 7 consecutive 
days. 
2.5. Fear conditioning 
The fear conditioning test is an associative learning test in which mice learn to fear a neutral 
environment (testing box) because the environment was associated with a mild electrical foot 
shock during a training session. The contextual fear conditioning experiments were 
performed as described previously (Ostroveanu, van der Zee et al. 2010) using a computer-
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controlled fear conditioning system (Ethovision, Noldus, Wageningen, The Netherlands). 
The test was done in a Plexiglas cage (44 × 24 × 44 cm) with a constantly illuminated fear 
conditioning box (12 V, 10 W halogen lamp, 100–500 lux). The training (conditioning) 
consisted of a single trial. The mouse was exposed to the conditioning context (180 sec), 
followed by a foot shock (0.7 mA, 2 sec, constant current) delivered through a stainless steel 
grid floor. The mouse was removed from the fear conditioning box 30 sec after shock 
termination to avoid an aversive association with the handling procedure. Between testing 
sessions, the box was cleaned with 70% ethanol. Memory tests were performed 24 h after 
fear conditioning. Contextual memory was tested in the fear conditioning box for 180 sec 
without footshock presentation. Freezing, defined as the lack of movement except for 
respiration and heart beat, was assessed as the behavioral parameter of the defensive reaction 
of mice by a time-sampling procedure every 10 sec throughout memory tests. 
2.6. Forced swim test 
The forced swim test is a widely used paradigm to measure antidepressant activity and 
depressive-like behavior in animal models (Cryan and Mombereau 2004). A cylinder (22 cm 
height × 11.5 cm diameter) was filled with water (23-25 °C) up to a height of 17 cm. The 
animal was placed inside the cylinder and immobility time was recorded over a 7 min test 
period. Afterwards the mouse was dried and returned to its cage. 
2.7. Protein analysis 
Immediately after the last behavioral experiment, mice were sacrificed by CO2 inhalation. 
Brains were quickly dissected, snap-frozen in liquid nitrogen and stored at -80 °C until 
homogenization and Western blotting (Ostroveanu, Van der Zee et al. 2007; Dobos, de 
Vries et al. 2011), Antibodies (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) were 
used for IDO (rat monoclonal antibody), and HPRT (hypoxanthine-guanine 
phosphoribosyltransferase) as an internal standard to correct for variations in protein 
content (rabbit polyclonal antibody), and stained with horseradish peroxidase-conjugated 
secondary antibodies (goat-anti-mouse, donkey-anti-rabbit, respectively) The proteins were 
detected using Enhanced Chemiluminescence (Pierce ® ECL Western Blotting Substrate, 
Rockford, IL, USA) and the Molecular Image Chemidoc XRS+ System (Biorad). The results 
were analyzed using Image Lab software (BioRad). 
2.8. Serum tryptophan and kynurenine quantification 
We used as an in vivo index of IDO activity the ratio of the blood levels of 
kynurenine/tryptophan. Tryptophan and kynurenine concentrations in serum were 
determined by an automated on-line solid-phase extraction-liquid chromatographic-tandem 
mass spectrometric (XLC-MS/MS) method with deuterated internal standards as described 
previously (de Jong, Smit et al. 2009). 
2.9. Statistical analysis 
All data were analyzed by one-way analysis of variance (one-way ANOVA), followed by the 
LSD post-hoc test to determine the differences between the selected groups using the 
program SPSS 16.0 for Windows. A p-value *<0.05 was considered to be statistically 
significant (p-value **<0.005: highly significant, a p-value ***<0.0005: extremely significant). 
Data are presented as a mean value ± the standard error of the mean (SEM). 
3. RESULTS 
3. 1. IP injection of IFNƢ impairs memory but does not influence the activity of mice 
during training 
The contextual fear conditioning test was used to investigate the effect of IP IFNƢ injections 
on hippocampus-dependent learning and memory. 1 week of IP injected IFNƢ led to a 
significant increase in freezing behavior in the wt/IFNƢ group when compared either to the 
wt/PBS or both IFNRKO groups (F(3,30)=10.867, p<0.05, Fig.2A). IFNƢ injections did 




Figure 2. Interferon Ƣ induced behavioral changes. A) Fear conditioning paradigm, a 
widely used test for measuring learning and memory impairment in animal models. Data 
represent mean values±SEM, *p < 0.05. B) Basal activity of the mice during the training 
session of the fear conditioning test. C) Forced swim test, a test for measuring 
antidepressant activity and depressive-like behavior in rodents. Data represent mean 
values±SEM, *p < 0.05. 
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3.2. Intraperitoneal injection of IFNƢ induces depressive-like behavior in mice 
After one week IP injection of either PBS or IFNƢ, depressive-like behavior of the mice was 
tested in the forced swim test. Significantly increased immobility was observed in the 
wt/IFNƢ group when compared either to the wt/PBS or both IFNRKO groups. 
(F(3,31)=6.085, p<0.05, Fig.2C). 
3.3. Intraperitoneal IFNƢ treatment increases IDO levels in the brainstem and in the 
cortex 
A significant increase of IDO was detected in the brainstem of the wt/IFNƢ group when 
compared either to the wt/PBS and both IFNRKO groups (F(3,30)=6.335, p<0.05) 
(Fig.3A). Also, IDO was significantly increased in the cortex of wt/IFNƢ group when 
compared either to the wt/PBS or the IFNRKO/IFNƢ groups (F(3,32)=2.364, p<0.05). 
Surprisingly, a significant decrease was found in the hypothalamus of both IFNƢ treated 
groups when compared to the wt/PBS group (F(3,38)=1.934, p<0.05). In the other brain 
regions, no significant differences among the four groups were observed (cerebellum 
(F(3,30)=0.222, p>0.05), hippocampus (F(3,40)=0.543, p>0.05), olfactory bulb 




Figure 3. A) IDO protein expression in different brain regions, measured by western 
blotting. Data represent mean values±SEM as a percentage of the wt/PBS group. *p < 0.05. 
B) IDO activity, defined as the ratio of the concentration of kynurenine and tryptophan 
measured in the serum. Data represent mean values±SEM, *p < 0.05 
3.4. Intraperitoneal IFNƢ treatment results in increased IDO activity in the serum 
IP IFNƢ injection in the wt/IFNƢ animals led to increased IDO activity compared to the 
wt/PBS group and both IFNRKO groups, defined as a ratio of kynurenine and tryptophan 
measured in the serum (F(3,31)=10.247, p<0.005) (Fig.3B). 
4. DISCUSSION 
In the present study, we used wildtype and interferon ơ/Ƣ receptor KO (IFNRKO) mice to 
investigate whether IFNƢ is responsible for the development of depressive-like behavior 
possibly inducing indoleamine 2,3-dioxygenase (IDO) and cognitive impairment through the 
interferon ơ/Ƣ receptor. 
Interferons are key components of the innate immune system with antiviral, antitumoral and 
immunomodulatory function. The most pausible therapeutic effect of IFNƢ is based on its 
immunomodulatory property. IFNƢ is able to reduce antigen presentation, inhibit T-cell 
proliferation and modulate cytokine production (Markowitz 2007; Rudick and Goelz 2011). 
MS is an autoimmune inflammatory disorder. Altered peripherial immune function, damaged 
blood brain barrier, infiltration of autoreactive T cells into the CNS, activated microglia and 
astrocytes, release of inflammatory mediators and toxic molecules are main features in MS. 
Oligodendrocytes and neurons are seriously affected by inflammatory damage, leading to 
demyelination and axon loss (Hemmer, Nessler et al. 2006; Markowitz 2007). IFNƢ has been 
shown to reduce T-cell activation by downregulation of major histocompatibility complex 
(MHC) class II expression on antigen-presenting cells. IFNƢ reduces TH1 pro-inflammatory 
cytokines leading to a shift in the immune response towards the TH2 profile, releasing 
cytokines, such as interleukin 4 and 6 (IL-4 and IL-6), which inhibit the expression of TH1 
cytokines, altering the inflammatory response. Furthermore, T cells express VLA-4 
molecules on the cell surface, which can bind to the VCAM-1 molecules on the surface of 
brain vascular endothelium. This interaction ensures, that activated T cells can cross the 
blood brain barrier. IFNƢ prevents T cells getting into the CNS by downregulation of VLA-
4 expression, and shedding soluble VCAM-1 molecules on the surface of brain vascular 
endothelium cells, therefore the binding of VLA-4 to VCAM-1 is arrested (Markowitz 2007). 
The mechanism of action of interferon Ƣ has been reported previously: it binds to the 
extracellular part of the interferon ơ/Ƣ receptor, which consists of a signaling chain 
(IFNAR1) and a binding chain (IFNAR2), the newly formed complex allows the intracellular 
part of the receptor to interact with Janus kinase 1 (JAK1) and Tyrosine kinase 2 (Tyk2). 
This interaction leads to a phosphorylation cascade and finally to the activation of STATs 
(Signal Transducer and Activator of Transcription), which translocates into the nucleus to 
bind ISRE elements and induce gene transcriptions (Rudick and Goelz 2011). The 
therapeutic effect of IFNƢ can be direct, if IFNƢ binds to its receptor and induces gene 
transcriptions, or indirect when gene transcription alters other cells involved in pathogenic 
mechanisms in MS (Rudick and Goelz 2011). 
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IFNƢ is a safe and effectively used drug as a treatment for multiple sclerosis. However, the 
neuropsychiatric side effects of IFNƢ-therapy must be considered. For instance, Fragoso et. 
al. (Fragoso, Frota et al. 2010) showed that patients undergoing IFNƢ-treatment, without 
previously reported psychiatric diseases, developed severe depression in a relatively short 
period. IFNƢ withdrawal resulted in the complete reduction of the symptoms. 
Cognitive impairment has also been associated with MS. Rao et al. showed (Rao, Leo et al. 
1991), that approximately 40% of MS patients suffer from cognitive decline (Rao, Leo et al. 
1991; Rao 1995; Feinstein 2006). Results are contradictory in concern of the effect of IFNƢ-
treatment on cognition. IFNƢ-therapy has been shown to have a positive effect on cognitive 
decline in a dose-dependent manner (Bastianello, Giugni et al. 2011), however in an other 
study, there was no correlation between IFNƢ-treatment and cognitive improvement 
(Carmona, Masuet et al. 2011). In a cell culture study, Yen and Ganea showed, that IFNƢ 
induces apoptosis in mature dendritic cells via activation of caspase-11/caspase-3, which 
requires activation of STAT1 (Yen and Ganea 2009). Interestingly, the PI3K/Akt pathway 
has been reported to be involved in the Tumor Necrosis Factor Receptor 2 (TNFR2)-
mediated neuroprotection as well (Marchetti, Klein et al. 2004) while the JAK/STAT 
signaling pathway is activated by Necrosis Factor Receptor 1 (TNFR1), which is mainly 
responsible for cell death (Guo, Dunbar et al. 1998). In our recent study, we found an IFNƢ-
induced learning and memory impairment in the wt/IFNƢ group in the fear conditioning 
test, while we did not see any effect of IFNƢ in the IFNRKO group. Taken together, these 
results indicate that IFNƢ might be neurotoxic and responsible for memory impairment via 
IFNơ/Ƣ receptors. 
IFNƢ is known to be an inducer of the tryptophan degrading enzyme, indoleamine 2,3-
dioxygenase (IDO) (Carlin, Borden et al. 1987; Carlin, Borden et al. 1989; Suh, Zhao et al. 
2007). IDO-mediated tryptophan depletion in brain cells results in reduced serotonin levels, 
therefore IDO has been proposed in several studies to play a crucial role in depression 
(Leonard 2007; Muller and Schwarz 2007; Dantzer, O'Connor et al. 2008; Dobos, de Vries et 
al. 2011). Furthermore, in a previous paper we showed that the inhibition of IDO by 1-
methyl-tryptophan (1-MT) can prevent the development of depressive-like behavior (Dobos, 
de Vries et al. 2011). We tested here, whether IFNƢ is able to induce depression via the 
IFNơ/Ƣ receptors. Our forced swim test results clearly show that the wt/IFNƢ group, but 
not the IFNRKO/IFNƢ group developed depressive-like behavior. We also analysed brain 
and blood of the animals, and we found an increase of IDO expression in the brain stem 
and in the cortex and also increased IDO activity in the serum of the wt/IFNƢ group. 
To our best knowledge, we show here the first time that IFNƢ induces learning and memory 
problems and depressive-like behavior via the IFNơ/Ƣ receptors. Although we did not use 
IDO inhibitor, previous and recent results suggest, that IFNƢ-induced IDO expression and 
higher activity might be responsible for the depressive-like behavior after IFNƢ-treatment. 
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Major depression (MD) is the second largest cause of disability in the developed world 
(Belmaker and Agam 2008). Apart from the individual suffering, the lost productivity of MD 
patients and the rising healthcare costs create enormous financial consequences. Also, MD, 
especially its chronic recurrent form, is associated with a severe risk suicide (Belmaker and 
Agam 2008). Furthermore, MD is also a major risk factor and/or source of comorbidity with 
several other disorders, such as cardiovascular diseases (Carney, Freedland et al. 2002), 
neurological disorders, e.g. Alzheimer’s disease (AD), Parkinson’s disease (PD) or multiple 
sclerosis (MS) (Minden, Orav et al. 1987; Jorm 2001; Kanner 2005; Feinstein 2006). 
Therefore, the importance of research on the neurobiology of MD and the mechanisms of 
antidepressant therapy cannot be overstated. 
In light of the fact that neuroinflammation is a quite common finding in various brain 
disorders, particularly neurodegenerative diseases, it might not be surprising that 
neuroinflammation is also implicated in MD. Therefore, the objective of the present thesis 
was to gain more insight in the potential role of neuroinflammation in major depression with 
special emphasis on the activation of the kynurenine pathway. 
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NEUROINFLAMMATION IN NEURODEGENERATION AND MD 
Chapters 1 and 2 provide extensive information on neuroinflammation, its 
neurodegenerative and behavioral consequences, and some of the underlying molecular 
mechanisms, with particular focus on the tumor necrosis factor ơ (TNFơ) pathway. 
What makes neuroinflammation a potential pathogenic factor in MD, however, is a series of 
findings indicating that anti-inflammatory treatment may have antidepressant action (Wager-
Smith and Markou 2011). It has also been shown that continuous activation of the immune 
system in inflammatory diseases can lead to the development of major depression (Dantzer, 
O'Connor et al. 2008). Other studies have revealed a positive correlation between depressive 
symptoms and increased levels of pro-inflammatory cytokines, such as interleukin-1Ƣ (IL-
1Ƣ), interleukin-6 (IL-6), and TNFơ in the serum and brain of depressed patients (Maes, 
Bosmans et al. 1991; Mikova, Yakimova et al. 2001; Dean, Tawadros et al. 2010; Raison, 
Dantzer et al. 2010). It is also well-known, that effective antidepressant therapy is 
characterized by a strong immunomodulatory effect, leading to decreased levels of 
circulating pro-inflammatory cytokines (Szelenyi and Selmeczy 2002). 
Lipopolysaccharide (LPS), a major component of the outer membrane of Gram-negative 
bacteria, is a robust inflammatory agent and frequently applied in experimental inflammatory 
models. It has been revealed that both peripheral and central administration of LPS induces 
chronic neuroinflammation and generates depressive behavior in rodents (Lestage, Verrier et 
al. 2002; Qin, Wu et al. 2007; Andre, O'Connor et al. 2008; Dobos, de Vries et al. 2011). 
Chapter 1 generally focuses on the activation of the kynurenine pathway, the 
neurodegenerative and behavioral consequences of neuroinflammatory conditions, which 
has been experimentally approached in Chapters 4 and 5. 
Also, in Chapter 1, the particular functions of TNFơ, having both neuroprotective as well as 
pro-inflammatory and pro-apoptotic features and being a potent activator of the kynurenine 
pathway has been described. The complex role of TNFơ and its two receptors, tumor 
necrosis factor 1 (TNFR1) and tumor necrosis factor 2 (TNFR2), together with the signaling 
pathways in neuroprotection and neurodegeneration has been further dealth with in Chapter 
2. This chapter also emphasizes the importance of in vivo structural and functional 
neuroimaging techniques. Visualizing neuroinflammation is of interest for diagnosing 
pathological changes in the brain. Neuroimaging techniques are not only reliable tools for 
monitoring disease processes but also offer the option to selectively target certain molecules, 
brain areas or brain disorders. In that respect, the use of radiopharmaceuticals by positron 
emission tomography (PET) and single photon emission computed tomography (SPECT) 
has been discussed. Microglia, the resident immune cells of the brain are the specific target 
of neuroinflammatory imaging (Banati, Goerres et al. 1999). The radiolabeled PK11195 (1-
[2-chlorophenyl]- N -[1-methyl-propyl]-3-isoquinoline carboxamide), a specific and selective 
high-affinity ligand of the peripheral benzodiazepine receptors (PBRs), which are expressed 
on glial cells, is a good marker for neuroinflammation as also detailed in chapter 1, 2 and 4. 
The PK11195 compound has been successfully used in various neuroinflammatory diseases, 
for example to detect active lesions in Multiple Sclerosis patients (Vowinckel, Reutens et al. 
1997), to distinguish Alzheimer’s disease patients from control subjects (Kuhlmann and 
Guilarte 2000), or to prove the involvement of the inflammatory process in the pathologic 
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state of migraine (Cui, Takashima et al. 2009). However, we can argue with good reasons, 
that the detection and analysis of neuroinflammation in an early state of brain disorders 
would serve novel and more specifically targeted therapeutical approaches. 
The obvious role of TNFơ in neuroinflammation has been extensively characterized in these 
chapters, therefore approaching the TNF receptors and modulating the TNFơ signaling 
pathway by pharmaceutical interventions opened new avenues in the development of novel 
drugs for treatment of certain neurodegenerative and chronic inflammatory diseases as well 
as major depression (Russo and Polosa 2005; Smolen, Aletaha et al. 2007; Raison, 
Rutherford et al. 2013). 
It should be noted, that aging itself has neurodegenerative and neuroinflammatory features 
without any remarkable appearance, and affects the signaling pathways, including the TNFơ 
pathway. Therefore it is important to investigate the non-pathological physiological effects 
of TNFơ and its main two receptors - TNFR1 and TNFR2 - during aging. In chapter 3 we 
applied a broad range of behavioral tests to assess behavioral, cognitive and physical changes 
induced by aging on TNFR1 and TNFR2 functioning in the central nervous system. We also 
found that TNFR2 plays an essential role in normal physiological functioning and 
hippocampus-dependent learning and memory, which was found not to be affected by aging. 
Therapeutical approaches of the TNFơ pathway carry many pros and cons. Neuroprotective 
targeting TNFơ itself, or selectively TNFR1 by antagonists or TNFR2 by agonists seems to 
be reasonable, however, the complexity of the signaling pathway present several difficulties. 
For instance, detrimental neurological side-effects, like demyelination have been related to 
anti-TNFơ therapy (Andreadou, Kemanetzoglou et al. 2013; Kaltsonoudis, Voulgari et al. 
2013). Moreover, the lack of activated TNFR1 eventually results in decreased DNA 
synthesis, delayed restoration of liver mass, and increased mortality (Yamada, Kirillova et al. 
1997; Bradham, Plumpe et al. 1998). Furthermore, overexpression or long-term activation of 
TNFR2 has been associated with cellular apoptosis and autoimmune diseases (Bigda, 
Beletsky et al. 1994; Medvedev, Sundan et al. 1994; Depuydt, van Loo et al. 2005). 
In conclusion, the biological environment is largely influencing the TNFơ signaling. Due to 
this fact, our study should be extended to investigate the role of TNFơ, TNFR1 and TNFR2 
in an artificial neuroinflammatory condition. For instance, it would be of interest to use 
mouse models of neurodegeneration or neuroinflammation. 
THE MONOAMINE HYPOTHESIS OF MD 
For decades, neurotransmitter dysregulation has been thought to be the major component of 
neuropsychiatric disorders like depression. According to the well-known monoamine 
hypothesis of depression, MD is a result of the underactivity of monoamines, especially 
serotonin, in the brain. Alteration in serotonergic neurotransmission, decrease in serotonin 
levels or availability of serotonin and elevated serotonin transport have been linked to 
depression (Risch and Nemeroff 1992). Moreover, the first line therapies in depression, like 
the monoamine oxidase inhibitors or the selective serotonin reuptake inhibitors are also 
focusing on the augmentation of neurotransmission or the availability of serotonin (DeVane 
2000). Although the monoamine hypothesis has been the major focus of depression and 
antidepressant research, mounting evidence suggest that this hypothesis is insufficient to 
provide an absolute explanation for the neurobiology of major depression. 
THE KYNURENINE PATHWAY AND THE NEUROINFLAMMATORY 
HYPOTHESIS OF MD 
In 1992, Smith reported the macrophage theory of depression which is based on the findings 
that inflammation is a major component in the development of depression (Smith 1991; 
Dantzer, O'Connor et al. 2008). 
Indoleamine 2,3-dioxygenase (IDO) has been suggested as a potential link between 
neuroinflammation and major depression. IDO catalyzes the first and rate limiting step in 
the degradation of the essential amino acid, tryptophan, through the kynurenine pathway 
(Leonard 2007; Dantzer, O'Connor et al. 2008). Upregulation of IDO by pro-inflammatory 
mediators causes tryptophan depletion in brain cells, resulting in reduced production of 
serotonin, which may lead to MD (Leonard 2007; Dantzer, O'Connor et al. 2008). 
Figure 1. Aging exacerbates depressive-like behavior in mice in response to activation of the 
peripheral innate immune system. (Godbout, Moreau et al. 2008) 
However, studies on the above mentioned hypothesis of inflammation-induced IDO-
mediated tryptophan depletion resulted in contradictory findings. 
LPS has been reported to generate cytokine release and play a role in the development of 
depression via activating the kynurenine pathway and upregulating IDO (O'Connor, Andre 
et al. 2009). For instance, it has been shown that LPS-induced inflammation leads to IDO 
activation and depressive-like behavior but inconsistently results in elevated tryptophan and 
serotonin levels (Godbout, Moreau et al. 2008; Walker, Budac et al. 2013). This phenomena 
was interpreted as a stress response and is not specific to the LPS-induced depressive-like 
behavior (Dunn and Welch 1991; Dunn, Wang et al. 1999; Godbout, Moreau et al. 2008; 
Walker, Budac et al. 2013). 
Thus, the inconclusive monoamine hypothesis of depression should be carefully re-thought 
and rather focus on the overproduction and neurotoxicity of tryptophan catabolites 
(TRYCATs) in the development of depression. 
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It has been shown that the TRYCATs can initiate behavioral effects on their own, 
independently from the serotonin levels. For instance, kynurenine administration was found 
to induce depressive-like behavior in mice (O'Connor, Lawson et al. 2009) and anxiety 
(Salazar, Gonzalez-Rivera et al. 2012). In addition, kynurenine is converted into quinolinic 
acid, a potent N-methyl-D-aspartate (NMDA) agonist and stimulator of glutamate release, 
that exerts its neurotoxicity by inducing excitotoxicity, calcium overload and associated 
oxidative stress (Rios and Santamaria 1991; Schwarcz and Pellicciari 2002; Muller and 
Schwarz 2007; McNally, Bhagwagar et al. 2008; Catena-Dell'Osso, Bellantuono et al. 2011). 
In a vicious circle, glutamate receptor activity can further participate in the development of 
an inflammatory environment within the brain and enhance the cytokine production. 
In Chapter 4 we injected LPS intracerebroventricularly and induced neuroinflammation in 
C57Bl/6 mice. We showed in this experimental model, that LPS-induced neuroinflammation 
peaks 3 days after administration, leads to IDO activation and manifests in depressive-like 
behavior. We could also demonstrate that the depressive-like behavior is dependent on the 
upregulation of the kynurenine pathway, since inhibition of IDO by 1-methyl-tryptophan (1-
MT) could prevent the depressive phenomena. Even though our IDO inhibitory 
experiments in this chapter clearly prove a certain relationship between neuroinflammation, 
IDO activation and depressive-like behavior, the final conclusion should be drawn with 
caution, because the mechanism, how the kynurenine pathway is involved in the 
development of depressive-like behavior, needs further investigations. Therefore, it is 
important to be aware of the limitations of our study. 
To date, the consequences of a long-term neuroinflammation in line with chronic IDO 
inhibition is not known to the best of our knowledge. Since IDO plays also a major role in 
general immune processes, the development of brain-specific IDO inhibitors would be an 
option to treat neuropsychiatric disorders. However, before focusing on the problems of 
administration, dosage and side effects of IDO inhibitors in antidepressant therapies, it is 
essential to know the distribution and regulation of IDO in the brain (Leonard 2010). 
In our study we blocked IDO by 1-methyl-tryptophan, however, targeting other enzymes of 
the kynurenine pathway - like the mostly microglia dependent kynurenine converting 
kynurenine-3-hydroxylase (KMO), or others, like kynureninase or 3-hydroxyanthraniate-3,4-
dioxygenase - and applying specific inhibitors would serve also an interesting therapeutical 
approach. Indeed, it has been reported that the inhibition of KMO results in amelioration of 
several brain disorders (Cozzi, Carpenedo et al. 1999; Moroni, Carpenedo et al. 2003; Richter 
and Hamann 2003; Samadi, Gregoire et al. 2005). 
For instance, it has been shown in experimental autoimmune encephalomyelitis (EAE), 
which is an experimental model of MS, that the expression and activity of KMO are 
significantly increased in the spinal cord of rats resulting in neurotoxic levels of 3-
hydroxykynurenine and quinolinic acid (Chiarugi, Cozzi et al. 2001). Selective inhibition of 
KMO leads to the reduction of 3-hydroxykynurenine and quinolinic acid as well as in the 
accumulation of the neuroprotective kynurenic acid. 
It is known, that MS patients show elevated pro-inflammatory cytokine levels and often 
suffer from cognitive decline and depressive symptoms (Link 1998; Trenova, Manova et al. 
2011). Besides the increased pro-inflammatory cytokines, e.g. TNFơ, IFNƣ and IL-6, the well 
established IFNƢ-therapy may also contribute to the development of depression by 
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activating the kynurenine pathway (Carlin, Borden et al. 1987; Carlin, Borden et al. 1989; 
Leonard 2007; Dantzer, O'Connor et al. 2008). Therefore, in Chapter 5 we have investigated 
the involvement of the kynurenine pathway in depressive-like behavior following IFNƢ 
administration. Wildtype and mutant mice with a deletion of IFNơ/Ƣ receptor (IFNRKO) 
were injected with IFNƢ for 7 consecutive days to see whether IFNƢ is accountable for the 
depressive symptoms and cognitive impairment and whether its effect is via the IFNơ/Ƣ 
receptors. Our results clearly indicate that IFNƢ-treatment leads to the activation of the 
kynurenine pathway, significantly increase the activity and expression of IDO which might 
be responsible for the development of depressive-like behavior and deficits in learning and 
memory through the IFNơ/Ƣ receptors. The main limitation of our study is, that we did not 
use IDO inhibitors for unequivocal evidence of the role of IDO underlying the 
neuropsychiatric impairments. Therefore extension of the study using IDO inhibitors would 
be fundamental. Furthermore, proceeding with the previously presented concept of the 
association between KMO, neurodegeneration and neuroinflammation, the inhibition of 
other enzymes of the kynurenine pathway, particularly KMO, would be of interest. 
IMPLICATIONS FOR THE INVOLVEMENT OF GLUTAMATERGIC 
NEUROTRANSMISSION AND THE KYNURENINE PATHWAY IN 
NEUROPSYCHIATRIC DISORDERS 
Glutamatergic release results in the activation of glutamate receptors at the post-synaptic 
neurons. There are two types of glutamatergic receptors, the ionotropic glutamate receptors, 
(alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, AMPA; N-methyl-D-aspartate, 
NMDA; and kainic acid, KA receptors) are opening cation ion channels into the neurons 
leading to depolarisation/excitation while the other type of glutamatergic receptors are 
metabotropic receptors, which are bound to guanosine-5'-triphosphate (GTP) binding 
proteins (Lees 2000). 
It has been shown, that AMPA receptors potentiate synaptic degeneration and dendritic 
spine loss (Centonze, Muzio et al. 2009; Rossi, Lo Giudice et al. 2012). In MS, AMPA 
receptor mediated cell death of oligodendrocytes leads to demyelination, which is the main 
feature of the disease (Ruiz, Matute et al. 2010). The NMDA receptor has been also 
implicated in synaptic impairment and in the progression of EAE (Grasselli, Rossi et al. 
2013). Grasselli et al. showed that the NMDA receptor hyperactivity results in enhanced 
glutamate release in the synaptic cleft and contributes to mitochondrial dysfunction and 
severe disease course (Grasselli, Rossi et al. 2013). 
It should be noted, that the neurotoxic metabolites produced along the kynurenine pathway, 
such as quinolinic acid or 3-hydroxykynurenine, a pro-apoptotic agent, can robustly 
contribute to the development of MD. Recently, is has been shown in mice that LPS-
induced inflammation which activates the kynurenine pathway leading to depressive-like 
behavior, is mediated by NMDA receptor activation, which can be blocked by 
administration of the NMDA receptor antagonist ketamine in mice (Walker, Budac et al. 
2013). 
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THE EFFECT OF NEUROTOXICITY ON SYNAPTIC PLASTICITY: THE 
SYNAPTOGENIC HYPOTHESIS OF MD 
Cognitive deficits in neurodegenerative diseases and major depression have been associated 
with neuroinflammation (Leonard 2007). Learning and memory problems are early 
manifestations of neurodegeneration in many diseases, such as Alzheimer’s disease, 
Parkinson’s disease or Multiple sclerosis and are linked to hippocampal dysfunction due to 
synaptic loss (Schindowski, Bretteville et al. 2006; Scheff, Price et al. 2007; Sicotte, Kern et 
al. 2008; Nistico, Pignatelli et al. 2012; Calabresi, Castrioto et al. 2013; Marxreiter, Ettle et al. 
2013; Nistico, Mango et al. 2013). 
Neuroinflammation-induced microglia activation and the subsequently released cytokines, 
e.g. TNFơ or IL-1Ƣ have been shown to alter synaptic transmission (Mandolesi, Grasselli et 
al. 2010; Mandolesi, Grasselli et al. 2012). Furthermore, it has been revealed that 
inflammation enhances the glutamate neurotransmission in EAE (Mandolesi, Grasselli et al. 
2010). 
Besides the fact that depressed patients have decreased volumes of cortical and limbic brain 
areas, suggesting neuronal degeneration (Duman and Aghajanian 2012), a decrease in the 
number of synapses have been determined by electron microscopy (Kang, Voleti et al. 2012). 
Interestingly, NMDA neurotoxicity [31-33] and pro-apoptotic mechanisms [34] are both 
prime causes of synaptic loss. 
The synaptogenic hypothesis, a novel theory of MD, is based on the findings that the 
severity of depressive symptoms is negatively correlated with the number of hippocampal 
and prefrontal cortical spine synapses (Hajszan, Szigeti-Buck et al. 2010). However, the 
mechanisms underlying the loss of synapses in MD are much less understood, necessitating 
further investigation of this issue. 
Previously, it has been demonstrated that chronic antidepressant treatment slowly enhances 
synaptic plasticity by increasing the expression of neurotrophic factors, like brain derived 
neurotrophic factor (BDNF) (Bath, Jing et al. 2012). Furthermore, the rapid antidepressant 
action of ketamine, an NMDA receptor antagonist has been linked to synaptogenesis (Li, 
Lee et al. 2010). This study confirmed that ketamine rapidly activated the mammalian target 
of rapamycin pathway (mTOR), resulting in increased synaptic signaling proteins and 
increased number and function of new spine synapses (Li, Lee et al. 2010). 
Additionally, suggesting the crucial role of the kynurenine pathway in synaptic plasticity, 
Forrest et al. reported recently, that inhibition of the kynurenine pathway in utero results in 
synaptic changes in the offsprings via altering the expression of the NMDA receptors 
(Forrest, Khalil et al. 2013). 
These data further lend support to the hypothesis that the kynurenine pathway has a 
significant role in the development and the homeostasis of the central nervous system. 
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OVERALL CONCLUSION 
In summary, current state of knowledge in the field of depression research suggests that 
inflammation contributes to the development of MD by interfering with synaptogenesis in 
different brain areas. It appears that IDO is a critical component of this process by 
converting inflammatory signals into production of synaptotoxic metabolites. 
Advanced future investigations aimed at unraveling the underlying molecular mechanisms 
will be required for a better and solid understanding the complex kynurenine pathway as a 
target for novel antidepressant therapies. 
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Growing body of evidence supports the notion that disturbances in both, the peripheral and 
central immune system contribute to the development of major depression (MD). 
Chronic inflammatory diseases, e.g. Crohn’s disease, rheumatoid arthritis, chronic 
obstructive pulmonary disease or immune therapies, like interferon alpha or interleukin-2 
treatment in cancer patients are all associated with frequent occurrance of MD. Moreover, 
neurodegenerative diseases, such as Alzheimer’s disease, Multiple sclerosis, which are also 
considered as inflammatory diseases have been revealed to be accompanied with depression. 
In the last few decades, depression research became one of the hottest research topics 
mainly due to the fact, that major depression is the leading cause of disability, more than 350 
million people are affected worldwide. Moreover, lost productivity and rising costs of 
healthcare of MD patients leads to vast financial damage. Although there are known 
effective therapies for MD, remarkable proportion of the patients is resistant to any kind of 
antidepressant therapies, thus, the better understanding of the neurobiology of MD is crucial 
in the development of novel therapeutic strategies. Therefore, the rationale of the present 
thesis was to investigate the obvious role of neuroinflammation in depression. 
In particular, our research has been based on the macrophage hypothesis, which emphasizes 
the role of the cytokine signaling in the development of depression. 
As mentioned above, multiple inflammatory processes play a detrimental role in the 
development of depression as well as in neurodegenerative diseases. However, previously the 
brain was irrefutably believed to be an immune privilege organ, this concept has been 
disproved by many studies. Continuous migration of immune cells through the blood brain 
barrier contributes to the homeostasis of the periphery and the brain. Cerebral inflammation 
is associated with the activation of microglia, the resident immune cells of the central 
nervous system (CNS). Upon immune activation, microglia become activated and start 
producing and releasing pro-inflammatory cytokines, such as tumor necrosis factor ơ 
(TNFơ) or interferon ƣ (IFNƣ), subsequently initiating an inflammatory cascade. Under 
experimental conditions, in vitro or ex vivo, monitoring neuroinflammation is widely used. 
Although in vivo visualization of neuroinflammation has developed rapidly in the last years, 
the refinement, optimalization and synchronization of structural and functional techniques 
must be further investigated. Visualization of microglia activation is one of the most 
conventional procedures in the detection of neuroinflammation. In the present thesis, 
Chapter 2 reviews basic neuroinflammatory mechanisms and particularly, the role of TNFơ 
in neuroprotection and neurodegenerative diseases. Furthermore, general neuroimaging 
techniques are also described. 
Recently, immunmodulatory cytokine-therapies or targeting the specific cytokine-receptors 
have gained mounting interest in research. For instance, the biological effects of TNFơ and 
its two main receptors, tumor necrosis factor alpha receptor 1 (TNFR1) and tumor necrosis 
factor alpha receptor 2 (TNFR2) have been extensively investigated in neuropsychiatric 
disorders. However, some promising results bring us closer to the therapeutic use of 
receptor agonists or antagonists, due to the complexity of the receptor crosstalk and the 
important physiological functions of TNFơ, further examinations are necessary. 
Additionally, aging has also been shown to influence the cytokine signaling and receptor 
function. Therefore, in Chapter 3 we intended to study the physiological role of TNFR1 and 
TNFR2 on cognition, behavioral and neuromuscular functioning in young and aged mice 
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using wildtype, TNFR1 and TNFR2 knock out mice. The most important finding of this 
chapter was, that TNFR2 has a fundamental role in hippocampus dependent learning and 
memory and muscle functioning. 
It has been shown that neuroinflammation and pro-inflammatory cytokines are able to 
activate an enzyme, indoleamine 2,3-dioxygenase (IDO) that catalyzes the first and rate-
limiting step of tryptophan catabolism, along the kynurenine pathway. According to the well-
known monoamine hypothesis of depression, the disturbance of the serotonin system is 
responsible for the depressive symptoms. Nevertheless, this hypothesis is not able to 
exclusively characterize the neurobiology of depression, rather should be combined with 
others, like the cytokine-hypothesis and focus on a more complex concept. In this approach, 
since serotonin is synthetised from tryptophan, and IDO is activated upon immune 
challenges, the question is given, whether and how IDO is involved in the pathophysiology 
of depression. 
In Chapter 4 we investigated in our experimental animal model, how cerebral inflammation 
is involved in the expression and activation of IDO and whether the activation of IDO is 
responsible for the depressive-like behavior. Neuroinflammation was monitored by small 
animal positron emission tomography using an activated microglia marker and the behavior 
of the mice was observed. We could demonstrate that inflammation induced depressive-like 
behavior is dependent on the activation of IDO, as it was proven in a group of mice treated 
with a competitive IDO-inhibitor. Interestingly, IDO was found to be upregulated in the 
brain stem of the animals, the most important serotonin producing area of the brain. 
As indicated before, interferon therapies are often accompanied by depressive-symptoms. 
Therefore, the mechanisms behind the effects of interferons are in major focus of research. 
Interferons are immune modulators and potent activators of IDO, thus, consequently might 
be responsible for depression. Indeed, research studies have reported positive correlation 
between the activity of IDO, amount of tryptophan catabolites, and the severity of the 
depressive symptoms. Fortunately, Prof. Dr. Marco Prinz and Dr. Thomas Blank kindly 
offered to test a newly developed interferon ơ/Ƣ receptor knock out mouse line and our 
collaboration aimed to unravel the action of interferon Ƣ (IFNƢ) in concern with 
neuropsychiatric dysfunctions. In Chapter 5 we established, that 7 consecutive days of IFNƢ 
injection is sufficient to provoke the depressive-like behavior and cognitive impairment in 
mice. Moreover, the use of the IFNơ/Ƣ receptor knock out strain we were able to show that 
IFNƢ acts directly through the IFNơ/Ƣ receptors resulting in the abovementioned 
behavioral changes. Furthermore, in accordance with previous studies and the findings of 
Chapter 4, we found elevated IDO expression in the brain stem in wildtype animals treated 
with IFNƢ, allowing us to hypothesize that IFNƢ induced IDO activation is responsible for 
the development of depressive-like behavior and cognitive impairment. 
Overall, the novel findings of this thesis further support the cytokine-hypothesis and provide 
evidence for the involvement of the kynurenine pathway and the upregulation of IDO in 
major depression. As further hypothesized and discussed in Chapter 6, the characterization 
of the signaling mechanisms underlying the regulation and activation of the kynurenine 






Steeds meer bewijs ondersteunt het idee dat verstoringen in zowel het perifere 
immuunsysteem als neuroimmuunsysteem in de hersenen bijdragen aan de ontwikkeling van 
depressie,  meestal aangeduid als ‘major depression’ (MD). 
Chronische ontstekingen, bijvoorbeeld bij de ziekte van Crohn, reumatoïde arthritis, 
chronische obstructieve longziekte, maar ook immuuntherapieën zoals interferon alfa of 
interleukine-2 behandeling van kankerpatiënten, worden frequent geassocieerd met 
depressieve klachten. Ook treden bij neurodegeneratieve ziekten zoals de ziekte van 
Alzheimer en multiple sclerose, die ook kunnen worden beschouwd als ontstekingsziekten, 
vaak depressieve klachten op bij deze patiënten. 
In het afgelopen decennium heeft het onderzoek van depressie een opvallende ontwikkeling 
ondergaan wat vooral het gevolg is van het feit dat MD een van de belangrijkste oorzaken is 
van gedragsstoornissen waardoor meer dan 350 miljoen mensen wereldwijd zijn getroffen. 
MD leidt niet alleen tot verlies van arbeidsproductiviteit maar ook tot alsmaar stijgende 
kosten van gezondheidszorg. Hoewel er effectieve therapieën voor MD beschikbaar zijn, is 
een opmerkelijk deel van de patiënten resistent tegen elke vorm van antidepressie therapie, 
en dus is een beter begrip van de neurobiologie van MD van kritsiche betekenis voor de 
ontwikkeling van nieuwe therapeutische strategieën. Het doel van dit proefschrift was om de 
rol van ontstekingsmechanismen in de hersenen bij depressie nader te onderzoeken. Dit 
onderzoek was met name gebaseerd op de zg. macrofaag hypothese, een hypothese die zich 
richt op de rol van de cytokines als signaalbron bij de ontwikkeling van depressie. 
Zoals hierboven vermeld, spelen verschillende ontstekings processen een belangrijke rol in 
de ontwikkeling van MD en in neurodegeneratieve ziekten in het algemeen. Echter, 
aanvankelijk werd verondersteld dat de hersenen een orgaan was dat niet toegankelijk was 
voor het algemene perifere immuunsysteem. Dit concept is echter inmiddels verlaten nu we 
weten dat ook de hersenen toegankelijk kunnen zijn voor de cellen en boodschappers van 
het perifere immuunsysteem. Migratie van immuuncellen kan onder bepaalde 
omstandigheden altijd optreden waarbij deze immuuncellen de bloed-hersenbarrière 
passeren wat bijdraagt tot de homeostase van de periferie en de hersen. 
Ontstekingsprocessen in de hersenen leiden tot activering van microglia, die algemeen 
worden gezien als de intrinsieke  immuuncellen van het centrale zenuwstelsel (CZS). Na 
immuunactivatie en activering van microglia  beginnen deze cellen met het produceren en 
het vrijgeven van pro-inflammatoire boodschapper moleculen: de cytokines zoals tumor 
necrose factor ơ (TNFơ) en interferon-ƣ (IFNy), die vervolgens een ontstekingscascade in 
gang zetten. Onder experimentele omstandigheden, kan zowel in vitro als ex vivo het 
neuroinflammatie worden gemonitored. Hoewel de in vivo visualisatie van neuroinflammatie 
zich snel ontwikkeld heeft in de afgelopen jaren, is het van groot belang voor het begrijpen 
van dit proces dat voor er onderzoek plaatsvindt aan de verfijning, optimalisatie en 
synchronisatie van structurele en functionele technieken. Visualisatie van microglia activatie 
is een van de meest gebruikelijke procedures voor de detectie van ontstekings processen in 
het centrale zenuwstelsel. Hoofdstuk 2 van dit proefschrift, handelt met name over de basale 
neuroinflammatoire mechanismen en over de rol van het cytokine TNFơ in het bijzonder bij 
neuroprotectie en neurodegeneratieve ziekten. Verder worden algemene neuroimaging 
technieken beschreven. 
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De afgelopen jaren zijn immuunmodulerende cytokine therapieën, die zijn gericht op 
specifieke cytokine receptoren, in toenemde mate  onderwerp van onderzoek en klinische 
toepassing geweest. Zo zijn de biologische effecten van TNFơ en de twee receptoren voor 
dit cytokine, tumor necrosis factor alpha receptor 1 (TNFR1) en tumor necrosis factor alpha 
receptor 2 (TNFR2) uitgebreid onderzocht in neuropsychiatrische aandoeningen. Sommige 
veelbelovende resultaten brengen ons dichter bij het therapeutische gebruik van agonisten of 
antagonisten voor deze receptoren. Door de grote complexiteit van deze  receptoren en de 
manier waarop zij elkaar beinvloeden, en de omvangrijke fysiologische functies van TNFơ, is 
verder onderzoek noodzakelijk. Bovendien wordt signaaloverdracht  door cytokines en haar 
receptorfuncties beinvloedt door het verouderingsproces. Om die reden wilden we in 
hoofdstuk 3 de fysiologische rol van TNFR1 en TNFR2 bij cognitie, gedrag en 
neuromusculaire functioneren bij jonge en oude muizen bestuderen met behulp van 
wildtype, TNFR1 en TNFR2 knock-out muizen. De belangrijkste bevinding van dit 
onderzoek was dat TNFR2 een fundamentele rol speelt bij leer- en geheugenprocessen die 
afhankelijk zijn van een intacte. 
Het is ook aangetoond dat neuroinflammatie en pro-inflammatoire cytokines een enzyme 
kunnen activeren, het indoleamine 2,3 dioxygenase (IDO), dat de eerste en 
snelheidsbepalende stap vormt van het tryptofaan katabolisme, langs de zg. kynurenine 
route. Volgens de bekende monoamine hypothese van depressie, wordt verstoring van het 
serotonine systeem verantwoordelijk geacht voor het ontstaan van de depressieve 
symptomen. Het is echter in toenemende mate duidelijk dat deze monoamine hypothese niet 
een volledige verklaring kan bieden voor de neurobiologie van depressie, en moeten 
combinaties met andere factoren zoals weergegeven in de cytokine-hypothese een beter en 
meer compleet begrip opleveren voor deze complex emotionele stoornis.  
Omdat serotonine wordt gesynthetiseerd uit tryptofaan en het eerder genoemde IDO wordt 
geactiveerd bij activering van het neuroimmuunsysteem, hebben we de vraag gesteld, of en 
hoe IDO betrokken is bij de pathofysiologie van depressie. 
In hoofdstuk 4 hebben we in deze vraag onderzocht in een experimenteel diermodel, en met 
name hoe herseninflammatie bij de expressie en activering van IDO betrokken is, en of de 
activering van IDO verantwoordelijk is voor de depressief gedrag. Het ontstekingsproces 
werd gevolgd door middel van scanning met positron emissie tomografie. Deze techniek 
maakt het mogelijk om geactiveerde microglia te volgen in het levende organisme en 
tegelijkertijd het depressieve gedrag van muizen waar te nemen. Wij konden aantonen dat 
ontsteking leidt tot depressief gedrag, dat afhankelijk is van de activatie van IDO, zoals 
wordt bewezen in een groep van muizen behandeld met een remmer van het enzyme IDO. 
Belangwekkend is verder dat IDO is toegenomen in de hersenstam van de dieren, en met 
name in de belangrijkste serotonine producerende gebieden van de hersen.  
Zoals eerder aangegeven, worden interferon therapieën vaak geassocieerd met depressieve-
symptomen. Daarom zijn de mechanismen achter de effecten van interferon een belangrijk 
focus van huidig onderzoek. Interferonen zijn immuun modulatoren en krachtige activatoren 
van IDO, die derhalve verantwoordelijk voor depressie kunnen zijn. Inderdaad hebben  
recente studies aangetoond dat er een positieve correlatie bestaat tussen de activiteit van 
IDO, de hoeveelheid tryptofaan katabolieten en de ernst van de depressieve symptomen. Uit 
een samenwerking met de duitse onderzoekers Marco Prinz en Thomas Blank zijn een nieuw 
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ontwikkelde interferon ơ/Ƣ-receptor knock-out muislijn voor onderzoek beschikbaar 
gekomen voor de ontrafeling. Deze samenwerking is met name gericht op ontrafeling van 
interferon Ƣ (IFNƢ) bij in de behandeling van neuropsychiatrische stoornissen. In hoofdstuk 
5 hebben we vastgesteld dat 7 IFNƢ injectie in opeenvolgende dagen voldoende is om 
depressief gedrag en cognitieve stoornissen bij muizen te veroorzaken. Door gebruik te 
maken van de IFN ơ/Ƣ receptor knockout-stam konden we aantonen dat IFNƢ rechtstreeks 
werkt via de IFN a/Ƣ receptoren en op die wijze resulteert in voornoemde 
gedragsveranderingen. In overeenstemming met eerdere studies en de bevindingen van 
hoofdstuk 4, hebben we verhoogde IDO-expressie in de hersenstam in wildtype dieren 
behandeld met IFNƢ gevonden, zodat we veronderstellen dat IFNƢ geïnduceerde IDO 
activering is verantwoordelijk voor de ontwikkeling van depressief gedrag en cognitieve 
stoornissen. 
Samengenomen ondersteunen de nieuwe bevindingen van dit proefschrift de cytokine-
hypothese, en leveren meer bewijs voor de betrokkenheid van de kynurenine route en de 
upregulatie van IDO bij depressie. Zoals verder werd verondersteld en besproken in 
hoofdstuk 6, zou de karakterisering van de onderliggende signalerings mechanismen van de 
regulering en activering van de kynurenine route een nieuwe weg in de ontwikkeling van 
nieuwe antidepressant-behandelingen kunnen openen. 
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CHAPTER 9 
Magyar nyelvť összefoglaló 
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Egyre több bizonyíték támasztja alá azt a megfigyelést, miszerint mind periferiális, mind 
központi immunrendszeri folyamatok is vezethetnek major depresszióhoz (MD).Krónikus 
gyulladásos megbetegedések, mint a Crohn betegség, a rheumatoid arthritis, a krónikus 
obstruktív tüdŋbetegség vagy immunterápiák, mint pl. rákos betegek esetében az interferon 
alfa vagy az interleukin-2 kezelés gyakran járnak együtt az MD elŋfordulásával. Bizonyos 
neurodegeneratív kórképek pedig, mint az Alzheimer-kór vagy a Szklerózis multiplex, melyek 
egyfajta gyulladásos betegségeknek tekinthetŋek, szintén társulhatnak depresszióval. 
Az elmúlt néhány évtizedben, a depressziós megbetegedések kutatása egyre nagyobb 
méreteket öltött, melyhez az is hozzájárult, hogy a major depresszió a munkaképtelenség 
egyik vezetŋ oka, mely több, mint 350 millió embert érint világszerte. Ráadásul, a csökkent 
termelŋképesség és a major depresszióban szenvedŋ betegek egészségügyi ellátásának egyre 
növekvŋ költségei súlyos gazdasági problémákat okoznak. Az ismert és esetenként 
hatékonynak tekinthetŋ antidepresszáns terápiák mellett a betegek számottevŋ része mégis 
rezisztens ezekkel a kezelésekkel szemben, ezért a depresszió neurobiológiájának pontosabb 
ismeretei elengedhetetlenek az új terápiás stratégiák kifejlesztéséhez.  
Ezért disszertációm céljául azt tťztük ki, hogy megvizsgáljuk hogy a különbözŋ gyulladásos 
folyamatok milyen szerepet tölthetnek be a major depresszió kialakulásában. Kutatásaink 
alapjául a makrofág hipotézis szolgált, mely a citokinek jelentŋségét hangsúlyozza a betegség 
hátterében állható neurobiológiai tényezŋként. 
Számos gyulladásos folyamat játszik szerepet mind a MD, mind a neurodegenratív 
betegségek kialakulásában. Jóllehet, korábban az agy immunprivilégiuma 
megcáfolhatatlannak tťnt, ez a felfogás mára már megdŋlt. Az immunsejtek folyamatos 
vándorlása a vér-agy-gáton keresztül nagyban hozzájárul a perifériás és a központi 
homeosztázis fenntartásához. A központi idegrendszer rezidens immunsejtjei, a mikrogliák 
aktiválódása egyenes velejárója az agyi gyulladásoknak. Immunaktiváció hatására az aktivált 
mikrogliák többek között gyulladásos citokineket, pl. tumor nekrózis faktor alfát (TNFơ) és 
interferon gammát kezdenek el termelni és környezetükbe üríteni, ezáltal egy gyulladásos 
kaszkádot iniciálva. A neuroinflammáció követése kísérleti körülmények között, in vitro és ex 
vivo is igen elterjedt. Habár az in vivo technikák is gyors ütemben fejlŋdtek az elmúlt idŋben, a 
strukturális és funkcionális módszerek finomításához, optimalizációjához és 
szinkronizációjához további vizsgálatok szükségesek. Az idegi gyulladás megfigyelésének 
egyik konvencionális módszere az aktivált mikrogliák vizualizációja. A jelen tézis második 
fejezete alapvetŋ neuroinflammációs mechanizmusokkal foglalkozik, illetve részletesen a 
TNFơ szerepével a neuroprotekcióban és neurodegenerációban, valamint neurológiai 
képalkotó eljárásokat ismertet. 
Az immunmoduláló citokin-terápiák és a specifikus citokin-receptorok, mint cél molekulák 
kutatását egyre nagyobb érdeklŋdés kíséri. Példaként, a TNFơ és a két fŋ receptora, a tumor 
nekrózis faktor receptor 1 (TNFR1) és tumor nekrózis faktor receptor 2 (TNFR2) 
szerepének neuropszichiátriai kutatása egyre elterjedtebb. Jóllehet számos ígéretes eredmény 
áll rendelkezésünkre a receptor agonisták és antagonisták használatával kapcsolatban, a 
receptor crosstalk és a TNFơ alapvetŋ fiziológiai funkciójának komplexitása miatt további 
vizsgálatok szükségesek. Ráadásul, az öregedés hatása a citokin signaling illetve a receptor 
funkciókban sem elhanyagolható. Épp ezért, a harmadik fejezetben kutatásaink célja az volt, 
hogy megvizsgáljuk a TNFR1 és TNFR2 fiziológiai szerepét a kognitív, viselkedésbeli és 
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neuromuszkuláris funkciókban fiatal és idŋs, vad típusú, TNFR1 és TNFR2 knock out 
egereken. Kísérleteink egyik legfontosabb eredményeként elmondhatjuk, hogy a TNFR2 
elengedhetetlen szerepet játszik a hippokampuszhoz kötött tanulási és 
memóriafolyamatokban, valamint az izomrendszer mťködésében. 
A neuroinflammáció és a gyulladásos citokinek képesek egy enzimet, az indolamin 2,3 
dioxigenázt (IDO) aktiválni, mely a triptofán katabolizmus elsŋ és egyben sebesség 
meghatározó lépését szabályozza a kinurenin útvonalon keresztül. A depresszió monoamin 
hipotézise alapján részben a szerotonin rendszer zavara felelŋs a depresszív tünetek 
kialakulásáért. A legújabb ismereteink szerint azonban a depresszió neurobiológiai alapjait 
nem lehet kizárólagosan ezzel a hipotézissel leírni, sokkal inkább egyesíteni kell más 
elméletekkel is, mint pl. a citokin-hipotézissel, ezáltal a betegség megközelítéséhez egy 
összetettebb koncepcióra kell összpontosítani. Ebben a vonatkozásban, mivel a szerotonin 
szintézisében kulcsfontosságú a triptofán, és az IDO immunaktiváció hatására aktiválódik, a 
kérdés szinte magától értetŋdŋ: részt vesz-e az IDO a depresszió patofiziológiájában, és ha 
igen, vajon hogyan. 
A negyedik fejezetben kísérletes állatmodellünkben azt vizsgáltuk, hogy a központi 
idegrendszeri gyulladás hogyan járul hozzá az IDO expressziójához és aktivációjához, és 
vajon az IDO aktivációja felelŋs-e a depresszív tünetekért. A neuroinflammációt kisállat 
pozitron emissziós tomográfiával követtük nyomon, egy mikroglia marker segítségével, mely 
szelektíven jelöli az aktivált mikrogliákat. Az állatok viselkedését viselkedéstesztekkel 
vizsgáltuk. Kimutattuk, hogy a gyulladás okozta depressziós tünetek az IDO aktivációjához 
kötöttek, melyet egy kompetitív IDO-gátló használatával bizonyítottunk be. Eredményeink 
alapján elmondhatjuk továbbá azt is, hogy az IDO a fŋ szerotonin termelésért felelŋs 
agyterületen, az agytörzsben upregulálódik.. 
A már említett interferon kezeléseknek is gyakori velejárója a depresszió. Ezért az 
interferonok hatásmechanizmusának vizsgálata kulcsfontosságú. Az interferonok 
immunmodulátorok és potenciális IDO aktivátorok, így ezzel együtt felelŋsek lehetnek a 
depresszió kialakulásáért. Mint ahogy azt több vizsgálat is bebizonyította, pozitív korreláció 
van az IDO aktivitása és a triptofán katabolitok mennyisége, valamint a depressziós tünetek 
súlyossága között. Kutatásaink során lehetŋségünk nyílt egy interferon ơ/Ƣ receptor knock 
out egér törzs tesztelésére, melyet Prof. Dr. Marco Prinz és Dr. Thomas Blank 
laboratóriumában fejlesztettek ki. A kollaboráció célja az interferon Ƣ neuropszichiátriai 
viselkedésre gyakorolt hatásának feltérképezése volt. Az ötödik fejezet vizsgálataival 
kimutattuk, hogy már egy 7 napos interferon Ƣ kezelés is elegendŋ ahhoz, hogy depressziós 
tünetekhez és kognitív diszfunkcióhoz vezessen. Interferon ơ/Ƣ receptor knock out egér 
törzs használatával azt is bebizonyítottuk, hogy az interferon Ƣ közvetlenül az interferon ơ/Ƣ 
receptoron keresztül fejti ki a viselkedésbeli hatásait. Korábbi saját, és a szakirodalmi 
ismeretekkel azonosan, a vad típusú, interferon Ƣ-val kezelt egerekben az IDO expressziója 
az agytörzsben emelkedett volt, mely szintén arra enged következtetni, hogy az interferon Ƣ 
indukált IDO aktiváció felelŋs a depresszív tünetekért és kognitív károsodásért. 
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Összegezve, a jelen tézis eredményei új bizonyítékokkal támasztják alá a citokin-hipotézist, és 
bebizonyítják a kinurenin-útvonal jelentŋségét és az IDO upregulációját major 
depresszióban. Továbbá, a hatodik fejezetben feltételezzük és részletesen megvitatjuk az 
IDO regulációjáért és aktivációjáért felelŋs szignalizációs mechanizmusokat, melyek pontos 
leírása új utakat nyithat meg az antidepresszáns terápia fejlesztésében.  
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